🧬 Biotech Catalyst Calendar

Updated daily · catalystalert.io + dansfera.com Admin
1285
Upcoming
26
This Month
1235
Trial Readouts
46
PDUFA Dates
4
AdCom Votes
Type: All 🔬 Trial 💊 PDUFA 🏛️ AdCom 📊 Earnings
Mkt Size: All ≥$1B ≥$5B ≥$10B ≥$50B
Date Ticker Company Drug Type Phase PoA Mkt Size Notes
2026-04-28
Today 		INSM Insmed Incorporated Arikayce™ PDUFA Phase 2 — $6B For NTM lung disease. sNDA filing. Extracted from SEC filing: 8-K
2026-04-28
Today 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-10374 Trial Phase 2 — $8B Primary completion for HS-10374 trial (NCT06176508) in Psoriatic Arthritis
2026-04-29
in 1 days 		AZN AstraZeneca PLC Cisplatin + Gemcitabine Trial Phase 3 — $2B Primary completion for Cisplatin + Gemcitabine trial (NCT03682068) in Unresectable Locally
2026-04-29
in 1 days 		VRNA VERONA PHARMA Glycopyrrolate 21.25 mcg Trial Phase 2 — $15B Primary completion for Glycopyrrolate 21.25 mcg trial (NCT07016412) in Chronic Obstructive
2026-04-29
in 1 days 		VRNA VERONA PHARMA Ensifentrine 3 mg Trial Phase 2 — $15B Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon
2026-04-30
in 2 days 		AZN AstraZeneca PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) Truqap (capivasertib (Truqap) + abir AdCom — 92% $8B APR 30 2026 2 days 🏛️ AdCom Truqap (capivasertib (Truqap) + abir...) $AZN AstraZeneca PTEN
2026-04-30
in 2 days 		AXSM Axsome Therapeutics · sNDA Alzheimer's disease agitation Auvelity (supplemental) (dextromethorphan HBr / bupro PDUFA — 92% $4B APR 30 2026 2 days 💊 PDUFA Auvelity (supplemental) (dextromethorphan HBr / bupro...) $AXSM
2026-04-30
in 2 days 		AZN AstraZeneca HR+/HER2- advanced breast cancer — first-line with emergent ESR1 mutation camizestrant (NDA 220359 AdCom — 85% $12B APR 30 2026 2 days 🏛️ AdCom (camizestrant (NDA 220359)) $AZN AstraZeneca HR+/HER2- advance
2026-04-30
in 2 days 		AZN AstraZeneca PLC Enfortumab Vedotin Trial Phase 3 — $2B Primary completion for Enfortumab Vedotin trial (NCT04960709) in Muscle Invasive Bladder C
2026-04-30
in 2 days 		NVS Novartis AG Remibrutinib Trial Phase 3 — $12B Primary completion for Remibrutinib trial (NCT05156281) in Relapsing Multiple Sclerosis
2026-04-30
in 2 days 		VRTX Vertex Pharmaceuticals Incorporated IVA Trial Phase 3 — $6B Primary completion for IVA trial (NCT05153317) in Cystic Fibrosis
2026-04-30
in 2 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 — $25B Primary completion for Rituximab trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
2026-04-30
in 2 days 		RHHBY Roche Holding AG Prednisone Trial Phase 3 — $15B Primary completion for Prednisone trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
2026-04-30
in 2 days 		RHHBY Roche Holding AG Polatuzumab Vedotin Trial Phase 3 — $9B Primary completion for Polatuzumab Vedotin trial (NCT03274492) in Diffuse Large B-Cell Lym
2026-04-30
in 2 days 		RHHBY Roche Holding AG Cyclophosphamide Trial Phase 3 — $18B Primary completion for Cyclophosphamide trial (NCT03274492) in Diffuse Large B-Cell Lympho
2026-04-30
in 2 days 		OTSKF OTSUKA Centanafadine Hydrochloride Trial Phase 3 — $6B Primary completion for Centanafadine Hydrochloride trial (NCT05279313) in Attention Defici
2026-04-30
in 2 days 		DNLI Denali Therapeutics Inc. BIIB122 225 mg Trial Phase 2 — $12B Primary completion for BIIB122 225 mg trial (NCT06602193) in Parkinson Disease
2026-04-30
in 2 days 		ANRO Alto Neuroscience, Inc. DR30206 Trial Phase 2 — $15B Primary completion for DR30206 trial (NCT07056777) in Gastrointestinal Cancer
2026-04-30
in 2 days 		AZNCF ASTRAZENECA PLC Tozorakimab Trial Phase 3 — $20B Primary completion for Tozorakimab trial (NCT06897748) in Chronic Obstructive Pulmonary Di
2026-04-30
in 2 days 		CNTA Centessa Pharmaceuticals plc ORX750 Trial Phase 2 — $2B Primary completion for ORX750 trial (NCT07096674) in Narcolepsy Type 1
2026-04-30
in 2 days 		MRK MERCK Tulisokibart Trial Phase 3 — $1B Primary completion for Tulisokibart trial (NCT05270668) in Diffuse Cutaneous Systemic Scle
2026-04-30
in 2 days 		VRTX Vertex Pharmaceuticals Incorporated VX-548 Trial Phase 2 — $6B Primary completion for Placebo (matched to pregabalin) trial (NCT06619860) in Diabetic Per
2026-04-30
in 2 days 		PFE PFIZER vepdegestrant Trial Phase 2 — $18B Primary completion for vepdegestrant trial (NCT06125522) in Breast Cancer
2026-04-30
in 2 days 		PFE PFIZER Samuraciclib Trial Phase 2 — $18B Primary completion for Samuraciclib trial (NCT06125522) in Breast Cancer
2026-04-30
in 2 days 		GSK GSK plc Zanamivir Trial Phase 2 — $6B Primary completion for Zanamivir trial (NCT04494412) in Influenza, Human
2026-04-30
in 2 days 		TLSA Tiziana Life Sciences Ltd Foralumab TZLS-401 100 µg Trial Phase 2 — $2B Primary completion for Foralumab TZLS-401 100 µg trial (NCT06890923) in Non-Active Seconda
2026-05-01
in 73 days 		CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ-201-DDT Trial Phase 2 — $6B Primary completion for CELZ-201-DDT trial (NCT06053242) in Chronic Low-back Pain
2026-05-01
in 73 days 		AZNCF ASTRAZENECA PLC AZD7798 Trial Phase 2 — $8B Primary completion for AZD7798 trial (NCT06450197) in Moderate to Severe Crohn's Disease
2026-05-04
in 76 days 		AZN AstraZeneca PLC AZD7798 Trial Phase 2 — $8B Primary completion for AZD7798 trial (NCT06681324) in Crohn's Disease
2026-05-05
in 77 days 		BNTX BioNTech SE BNT162b2 (Omi LP.8.1) Trial Phase 3 — $15B Primary completion for BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) trial (NCT070693
2026-05-07
in 79 days 		OTSKF OTSUKA Sibeprenlimab 400 mg Trial Phase 3 — $2B Primary completion for Sibeprenlimab 400 mg trial (NCT05248646) in Immunoglobulin A Nephro
2026-05-08
in 80 days 		INCY Incyte Corporation INCB177054 Trial Phase 2 — $3B Primary completion for INCB177054 trial (NCT06873789) in Solid Tumors
2026-05-08
in 80 days 		AZN AstraZeneca PLC AZD3470 Trial Phase 2 — $15B Primary completion for AZD3470 trial (NCT06137144) in Lymphoma
2026-05-09
in 81 days 		OTSKF OTSUKA JNT-517 Tablet Trial Phase 3 — $1B Primary completion for JNT-517 Tablet trial (NCT06637514) in Phenylketonuria (PKU)
2026-05-11
in 83 days 		ALPMY Astellas Pharma enfortumab vedotin (EV) Trial Phase 2 — $3B Primary completion for enfortumab vedotin (EV) trial (NCT03288545) in Carcinoma, Transitio
2026-05-12
in 84 days 		SVA SINOVAC BIOTECH LTD Sinovac PCV13 Trial Phase 3 — $8B Primary completion for Sinovac PCV13 trial (NCT06617715) in Pneumococcal Infectious Diseas
2026-05-12
in 84 days 		HCM Hutchmed HMPL-760 planned dose 1 Trial Phase 2 — $6B Primary completion for HMPL-760 planned dose 1 trial (NCT06601504) in Relapsed/Refractory
2026-05-13
in 85 days 		REGN Regeneron Pharmaceuticals, Inc. Pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT06161441) in Resectable Non-small Cell Lung Ca
2026-05-13
in 85 days 		REGN Regeneron Pharmaceuticals, Inc. cemiplimab Trial Phase 3 — $1B Primary completion for Cemiplimab trial (NCT06161441) in Resectable Non-small Cell Lung Ca
2026-05-13
in 85 days 		REGN Regeneron Pharmaceuticals, Inc. Dupilumab Trial Phase 3 — $8B Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cance
2026-05-13
in 85 days 		REGN Regeneron Pharmaceuticals, Inc. Fianlimab Trial Phase 3 — $8B Primary completion for Fianlimab trial (NCT06161441) in Resectable Non-small Cell Lung Can
2026-05-14
in 86 days 		AZNCF ASTRAZENECA PLC AZD0901 Trial Phase 3 — $3B Primary completion for AZD0901 trial (NCT06346392) in Gastric Cancer
2026-05-14
in 86 days 		AZNCF ASTRAZENECA PLC Ramucirumab+ paclitaxel Trial Phase 3 — $3B Primary completion for Ramucirumab+ paclitaxel trial (NCT06346392) in Gastric Cancer
2026-05-14
in 86 days 		AZN AstraZeneca PLC Eplontersen Trial Phase 3 — $2B Primary completion for Eplontersen trial (NCT06194825) in Transthyretin Amyloid Cardiomyop
2026-05-14
in 86 days 		BIIB Biogen Inc. BIIB080 Trial Phase 2 — $15B Primary completion for BIIB080 trial (NCT05399888) in Mild Cognitive Impairment Due to Alz
2026-05-14
in 86 days 		RHHBY Roche Holding AG Entrectinib Trial Phase 3 — $6B Primary completion for Entrectinib trial (NCT02568267) in Breast Cancer
2026-05-15
in 87 days 		VRDN Viridian Therapeutics Active thyroid eye disease (TED) — subcutaneous anti-FcRn antibody elegrobart (VRDN-003 Trial Readout 3 — $2B MAY 15 2026 17 days 🔬 Trial Readout (elegrobart (VRDN-003)) $VRDN Viridian Therapeutics Ac
2026-05-15
in 87 days 		RLAY Relay Therapeutics PIK3CA-mutant HR+/HER2- metastatic breast cancer zovegalisib (RLY-2608 Trial Readout 2 — $6B MAY 15 2026 17 days 🔬 Trial Readout (zovegalisib (RLY-2608)) $RLAY Relay Therapeutics PIK3
2026-05-15
in 87 days 		NMRA Neumora Therapeutics, Inc. NMRA-335140 Trial Phase 3 — $15B Primary completion for NMRA-335140 trial (NCT06058013) in Major Depressive Disorder
2026-05-15
in 87 days 		ARWR Arrowhead Pharmaceuticals, Inc. Plozasiran Injection Trial Phase 3 — $3B Primary completion for Plozasiran Injection trial (NCT06347133) in Hypertriglyceridemia
2026-05-15
in 87 days 		ALC Alcon Research AR-17043 Ophthalmic Solution Trial Phase 2 — $4B Primary completion for Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution trial (NCT0
2026-05-15
in 87 days 		SNY Sanofi Venglustat (GZ402671) Trial Phase 3 — $1B Primary completion for Venglustat (GZ402671) trial (NCT05280548) in Fabry Disease
2026-05-15
in 87 days 		CODX Co-Diagnostics, Inc. ELIXCYTE Trial Phase 3 — $6B Primary completion for ELIXCYTE trial (NCT05526001) in Knee Osteoarthritis
2026-05-15
in 87 days 		EXEL Exelixis, Inc. XL092 Trial Phase 3 — $1B Primary completion for XL092 trial (NCT05425940) in Colorectal Cancer
2026-05-15
in 87 days 		ALC Alcon Research Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution Trial Phase 3 — $2B Primary completion for Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution trial (NCT0
2026-05-15
in 87 days 		MNMD Mind Medicine (MindMed) Inc. MM120 (LSD D-Tartrate) Trial Phase 3 — $8B Primary completion for MM120 (LSD D-Tartrate) trial (NCT06741228) in Generalized Anxiety D
2026-05-15
in 87 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 — $15B Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Eribulin Trial Phase 3 — $18B Primary completion for Eribulin trial (NCT06343948) in HR+HER2- Breast Cancer
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR BL-M07D1 Trial Phase 3 — $2B Primary completion for BL-M07D1 trial (NCT06316531) in HER2-positive Breast Cancer
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Irinotecan Trial Phase 3 — $2B Primary completion for Irinotecan trial (NCT06304974) in Esophageal Squamous Cell Carcinom
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Pemetrexed+Cisplatin or Carboplatin Trial Phase 3 — $15B Primary completion for Pemetrexed+Cisplatin or Carboplatin trial (NCT06382116) in Non-smal
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR T-DM1 Trial Phase 3 — $15B Primary completion for T-DM1 trial (NCT06316531) in HER2-positive Breast Cancer
2026-05-15
in 87 days 		BHVN Biohaven Pharmaceutical Holding Company Ltd. BHV-7000 Trial Phase 3 — $5B Primary completion for BHV-7000 trial (NCT06309966) in Focal Epilepsy
2026-05-15
in 87 days 		EXEL Exelixis, Inc. Regorafenib Trial Phase 3 — $8B Primary completion for Regorafenib trial (NCT05425940) in Colorectal Cancer
2026-05-15
in 87 days 		GRFS Grifols SA Xembify Trial Phase 3 — $2B Primary completion for Xembify trial (NCT05645107) in Hypogammaglobulinemia
2026-05-15
in 87 days 		ABBV AbbVie Inc. Ubrogepant Trial Phase 3 — $8B Primary completion for Ubrogepant trial (NCT05125302) in Migraine
2026-05-15
in 87 days 		TNGX Tango Therapeutics, Inc. TNG462 Trial Phase 2 — $4B Primary completion for TNG462 trial (NCT05732831) in Locally Advanced Solid Tumor
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR PD-1 Trial Phase 2 — $5B Primary completion for PD-1 trial (NCT06405425) in Urothelial Carcinoma
2026-05-15
in 87 days 		GILD Gilead Sciences, Inc. Lenacapavir Injection Trial Phase 3 — $2B Primary completion for Lenacapavir Injection trial (NCT06513312) in Pre-Exposure Prophylax
2026-05-15
in 87 days 		ALT Altimmune, Inc. Pemvidutide Trial Phase 2 — $8B Primary completion for Pemvidutide trial (NCT06987513) in Alcohol Use Disorder (AUD)
2026-05-15
in 87 days 		EVMN Evommune, Inc. EVO756 Trial Phase 2 — $3B Primary completion for EVO756 trial (NCT06873516) in Chronic Spontaneous Urticaria
2026-05-15
in 87 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-INHBE Trial Phase 2 — $25B Primary completion for ARO-INHBE trial (NCT06700538) in Obesity
2026-05-15
in 87 days 		GILD Gilead Sciences, Inc. Sacituzumab Govitecan-hziy Trial Phase 3 — $5B Primary completion for Sacituzumab Govitecan-hziy trial (NCT05101096) in Advanced Solid Tu
2026-05-15
in 87 days 		SBFM Sunshine Biopharma Inc. Clifutinib Besylate Trial Phase 2 — $8B Primary completion for Clifutinib Besylate trial (NCT05133882) in Acute Myeloid Leukemia,
2026-05-15
in 87 days 		LLY Eli Lilly and Company Mevidalen Trial Phase 2 — $15B Primary completion for Mevidalen trial (NCT06538116) in Alzheimer Disease
2026-05-15
in 87 days 		BLCO Bausch & Lomb BL1107 Low dose Trial Phase 2 — $6B Primary completion for BL1107 Low dose trial (NCT07168902) in Glaucoma
2026-05-15
in 87 days 		AGIO Agios Pharmaceuticals, Inc. Tebapivat Trial Phase 2 — $4B Primary completion for Tebapivat trial (NCT06924970) in Sickle Cell Disease
2026-05-15
in 87 days 		WST WEST PHARMACEUTICAL SERVICES INC RVU120 (SEL120) Trial Phase 2 — $1B Primary completion for RVU120 (SEL120) trial (NCT06243458) in Low Risk Myelodysplastic Syn
2026-05-15
in 87 days 		GILD Gilead Sciences, Inc. Emtricitabine/tenofovir disoproxil fumarate (F/TDF) Trial Phase 2 — $2B Primary completion for Emtricitabine/tenofovir disoproxil fumarate (F/TDF) trial (NCT06513
2026-05-15
in 87 days 		GLUE Monte Rosa Therapeutics, Inc. Oral MRT-2359 Trial Phase 2 — $18B Primary completion for Oral MRT-2359 trial (NCT05546268) in NSCLC
2026-05-18
in 90 days 		REGN Regeneron Pharmaceuticals, Inc. Trevogrumab-Part A Trial Phase 2 — $25B Primary completion for Trevogrumab-Part A trial (NCT06299098) in Obesity
2026-05-20
in 92 days 		MRK MERCK coformulation pembrolizumab/quavonlimab Trial Phase 2 — $4B Primary completion for coformulation pembrolizumab/quavonlimab trial (NCT04938817) in Smal
2026-05-21
in 93 days 		PBM PSYENCE BIOMEDICAL LTD. Psilocybin therapy Trial Phase 2 — $2B Primary completion for Psilocybin therapy trial (NCT07072728) in Adjustment Disorder
2026-05-23
in 95 days 		PFE PFIZER Multivalent Pneumococcal Vaccine - Formulation 1 Trial Phase 2 — $8B Primary completion for Multivalent Pneumococcal Vaccine - Formulation 1 trial (NCT06182124
2026-05-25
in 97 days 		SNY Sanofi Topical corticosteroids Trial Phase 3 — $8B Primary completion for Topical corticosteroids trial (NCT06241118) in Dermatitis Atopic
2026-05-25
in 97 days 		SNY Sanofi Amlitelimab Trial Phase 3 — $8B Primary completion for Amlitelimab trial (NCT06241118) in Dermatitis Atopic
2026-05-25
in 97 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for Bimekizumab trial (NCT04009499) in Psoriatic Arthritis
2026-05-25
in 97 days 		SNY Sanofi Topical tacrolimus or pimecrolimus Trial Phase 3 — $8B Primary completion for Topical tacrolimus or pimecrolimus trial (NCT06241118) in Dermatiti
2026-05-25
in 97 days 		AZNCF ASTRAZENECA PLC AZD9550 Trial Phase 2 — $50B Primary completion for AZD6234 trial (NCT06862791) in Obesity or Overweight
2026-05-25
in 97 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 — $25B Primary completion for AZD9550 trial (NCT06862791) in Obesity or Overweight
2026-05-27
in 99 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Botulinum toxin type A Trial Phase 3 — $3B Primary completion for Placebo trial (NCT04336722) in Biliary Atresia
2026-05-27
in 99 days 		SNY Sanofi RSVt vaccine Trial Phase 3 — $5B Primary completion for RSVt Vaccine trial (NCT06252285) in RSV Immunisation
2026-05-27
in 99 days 		MRNA Moderna, Inc. mRNA-1345 Trial Phase 3 — $4B Primary completion for mRNA-1345 trial (NCT06143046) in Respiratory Syncytial Virus
2026-05-27
in 99 days 		AZNCF ASTRAZENECA PLC AZD6234 Trial Phase 2 — $8B Primary completion for AZD6234 trial (NCT06851858) in Endocrinology
2026-05-28
in 100 days 		SNY Sanofi Pandemic flu H5 HA mRNA SD2 vaccine Trial Phase 2 — $5B Primary completion for Pandemic flu H5 HA mRNA SD2 vaccine trial (NCT06907511) in Pandemic
2026-05-29
in 101 days 		NVS Novartis AG Ribociclib Trial Phase 3 — $11B Primary completion for Ribociclib trial (NCT03701334) in Early Breast Cancer
2026-05-29
in 101 days 		AZNCF ASTRAZENECA PLC Benralizumab Trial Phase 3 — $20B Primary completion for Benralizumab trial (NCT06465485) in Severe Eosinophilic Asthma
2026-05-29
in 101 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 — $15B Primary completion for Durvalumab trial (NCT03682068) in Unresectable Locally Advanced Uro
2026-05-29
in 101 days 		VRTX Vertex Pharmaceuticals Incorporated VX-264 Trial Phase 2 — $15B Primary completion for VX-264 trial (NCT05791201) in Type 1 Diabetes
2026-05-30
in 102 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 — $15B Primary completion for Alectinib trial (NCT03194893) in Neoplasms
2026-05-30
in 102 days 		ANRO Alto Neuroscience, Inc. DR10624 Injection Trial Phase 2 — $8B Primary completion for DR10624 Injection trial (NCT07024212) in MASLD
2026-05-31
in 103 days 		TEVA Teva Pharmaceutical Industries Limited Fp/ABS Trial Phase 3 — $20B Primary completion for Fp/ABS trial (NCT06664619) in Asthma
2026-05-31
in 103 days 		RHHBY Roche Holding AG Lenalidomide Trial Phase 3 — $7B Primary completion for Lenalidomide trial (NCT04712097) in Relapsed or Refractory Follicul
2026-05-31
in 103 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 — $25B Primary completion for Rituximab trial (NCT04712097) in Relapsed or Refractory Follicular
2026-05-31
in 103 days 		RHHBY Roche Holding AG Mosunetuzumab Trial Phase 3 — $9B Primary completion for Mosunetuzumab trial (NCT04712097) in Relapsed or Refractory Follicu
2026-05-31
in 103 days 		RHHBY Roche Holding AG Tociluzumab Trial Phase 3 — $4B Primary completion for Tociluzumab trial (NCT04712097) in Relapsed or Refractory Follicula
2026-05-31
in 103 days 		STA Starton Holdings, Inc. Lenalidomide Trial Phase 2 — $15B Primary completion for Lenalidomide trial (NCT06087653) in Multiple Myeloma
2026-05-31
in 103 days 		PFE PFIZER disitamab vedotin Trial Phase 3 — $5B Primary completion for disitamab vedotin trial (NCT06003231) in Carcinoma, Non-Small-Cell
2026-05-31
in 103 days 		MRK MERCK Belzutifan Trial Phase 3 — $8B Primary completion for Belzutifan trial (NCT04626479) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK MK-4830 Trial Phase 2 — $15B Primary completion for MK-4830 trial (NCT04626518) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK Pembrolizumab/Quavonlimab Trial Phase 3 — $8B Primary completion for Pembrolizumab/Quavonlimab trial (NCT04626479) in Carcinoma, Renal C
2026-05-31
in 103 days 		MRK MERCK Lenvatinib Trial Phase 3 — $15B Primary completion for Lenvatinib trial (NCT04626479) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK favezelimab/pembrolizumab Trial Phase 3 — $7B Primary completion for Favezelimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal C
2026-05-31
in 103 days 		MRK MERCK Vibostolimab/Pembrolizumab Trial Phase 2 — $6B Primary completion for Vibostolimab/Pembrolizumab trial (NCT04626479) in Carcinoma, Renal
2026-05-31
in 103 days 		RHHBY Roche Holding AG Tominersen Trial Phase 2 — $1B Primary completion for Tominersen trial (NCT05686551) in Huntington Disease
2026-05-31
in 103 days 		AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL APG-115 Trial Phase 2 — $8B Primary completion for APG-115 trial (NCT04496349) in T-Prolymphocytic Leukemia
2026-05-31
in 103 days 		OTSKF OTSUKA IV Decitabine Trial Phase 2 — $4B Primary completion for IV Decitabine trial (NCT06091267) in Myelodysplastic Syndromes
2026-05-31
in 103 days 		SVA SINOVAC BIOTECH LTD Low-dose experimental vaccine Trial Phase 2 — $2B Primary completion for Low-dose experimental vaccine trial (NCT07400003) in Herpes Zoster
2026-06-01
in 173 days 		MRUS Merus NV NRG1 fusion-positive NSCLC and pancreatic cancer zenocutuzumab Trial Readout 2 — $3B JUN 1 2026 34 days 🔬 Trial Readout (zenocutuzumab) $MRUS Merus NV NRG1 fusion-positive NSC
2026-06-01
in 173 days 		RHHBY Roche / Genentech ER+/HER2- first-line advanced breast cancer (1L) giredestrant + everolimus Trial Readout 3 — $9B JUN 1 2026 34 days 🔬 Trial Readout (giredestrant + everolimus — ...) $RHHBY Roche / Genent
2026-06-01
in 173 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR7280 tablets Trial Phase 3 — $2B Primary completion for SHR7280 tablets trial (NCT05442827) in Uterine Fibroids With Menorr
2026-06-01
in 173 days 		ARDX Ardelyx Tenapanor 50 MG Trial Phase 3 — $4B Primary completion for Tenapanor 50 MG trial (NCT05643534) in Irritable Bowel Syndrome Wit
2026-06-01
in 173 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-20117 Trial Phase 3 — $10B Primary completion for HS-20117 trial (NCT06417008) in Non-Squamous Non-Small Cell Lung Ca
2026-06-01
in 173 days 		OTSKF OTSUKA Centanafadine Trial Phase 3 — $15B Primary completion for Centanafadine trial (NCT06973577) in ADHD
2026-06-01
in 173 days 		PFE PFIZER Cetuximab Trial Phase 3 — $4B Primary completion for Cetuximab trial (NCT05217446) in Metastatic Colorectal Cancer
2026-06-01
in 173 days 		REGN Regeneron Pharmaceuticals, Inc. REGN7508 Trial Phase 3 — $8B Primary completion for REGN7508 trial (NCT06299111) in Venous Thromboembolism
2026-06-01
in 173 days 		REGN Regeneron Pharmaceuticals, Inc. REGN9933 Trial Phase 2 — $8B Primary completion for REGN9933 trial (NCT06299111) in Venous Thromboembolism
2026-06-01
in 173 days 		MRTX Mirati Therapeutics, Inc. Adagrasib oral dose of 400 mg twice daily tablets Trial Phase 2 — $15B Primary completion for Adagrasib oral dose of 400 mg twice daily tablets trial (NCT0560957
2026-06-01
in 173 days 		CASI CASI Pharmaceuticals, Inc. CID-103 Trial Phase 2 — $2B Primary completion for CID-103 trial (NCT07017725) in Chronic Immune Thrombocytopenia
2026-06-02
in 174 days 		NVO Novo Nordisk A/S Tirzepatide Trial Phase 3 — $35B Primary completion for Tirzepatide trial (NCT06534411) in Diabetes Mellitus, Type 2
2026-06-02
in 174 days 		UCBJY UCB zilucoplan (RA101495) Trial Phase 3 — $1B Primary completion for zilucoplan (RA101495) trial (NCT04225871) in Generalized Myasthenia
2026-06-02
in 174 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 — $15B Primary completion for Durvalumab trial (NCT04550260) in Esophageal Squamous Cell Carcinom
2026-06-02
in 174 days 		AZN AstraZeneca PLC cisplatin + fluorouracil Trial Phase 3 — $2B Primary completion for cisplatin + fluorouracil trial (NCT04550260) in Esophageal Squamous
2026-06-03
in 175 days 		CYTK Cytokinetics Obstructive hypertrophic cardiomyopathy (oHCM) MYQORZO (aficamten AdCom — 85% $4B JUN 3 2026 36 days 🏛️ AdCom MYQORZO (aficamten) $CYTK Cytokinetics Obstructive hypertrophi
2026-06-05
in 177 days 		ARVN Arvinas / Pfizer · NDA ESR1-mutated ER+/HER2- advanced or metastatic breast cancer (2L+) vepdegestrant (ARV-471 PDUFA — 85% $10B JUN 5 2026 38 days 💊 PDUFA (vepdegestrant (ARV-471)) $ARVN Arvinas / Pfizer · NDA ESR1-mut
2026-06-05
in 177 days 		TAK TAKEDA PHARMACEUTICAL CO LTD Zasocitinib Trial Phase 3 — $8B Primary completion for Zasocitinib trial (NCT06973291) in Plaque Psoriasis
2026-06-05
in 177 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Botulinum toxin type A Trial Phase 3 — $3B Primary completion for Botulinum toxin type A trial (NCT06047457) in Episodic Migraine
2026-06-08
in 180 days 		ABBV AbbVie / Arena Pharma · NDA Eosinophilic esophagitis (EoE) cendakimab PDUFA — 90% $6B JUN 8 2026 41 days 💊 PDUFA (cendakimab) $ABBV AbbVie / Arena Pharma · NDA Eosinophilic eso
2026-06-08
in 180 days 		UCBJY UCB Rozanolixizumab Trial Phase 3 — $1B Primary completion for rozanolixizumab trial (NCT06149559) in Generalized Myasthenia Gravi
2026-06-08
in 180 days 		REGN Regeneron Pharmaceuticals, Inc. Alirocumab Trial Phase 3 — $2B Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cance
2026-06-09
in 181 days 		NVO Novo Nordisk A/S Ziltivekimab B Trial Phase 3 — $45B Primary completion for Ziltivekimab B trial (NCT05021835) in Cardiovascular Risk
2026-06-09
in 181 days 		NVS Novartis AG KAE609 (Cipargamin) Trial Phase 2 — $2B Primary completion for KAE609 (Cipargamin) trial (NCT05750628) in Uncomplicated Plasmodium
2026-06-09
in 181 days 		NVS Novartis AG INE963 Trial Phase 2 — $2B Primary completion for INE963 trial (NCT05750628) in Uncomplicated Plasmodium Falciparum M
2026-06-11
in 183 days 		GSK GSK plc BLU-5937 Trial Phase 3 — $2B Primary completion for BLU-5937 trial (NCT05600777) in Cough
2026-06-11
in 183 days 		TKPHF TAKEDA PHARMACEUTICAL CO LTD TAK-755 Trial Phase 2 — $2B Primary completion for TAK-755 trial (NCT05714969) in Thrombotic Thrombocytopenic Purpura
2026-06-12
in 184 days 		AZN AstraZeneca PLC AZD7798 Trial Phase 2 — $8B Primary completion for AZD7798 trial (NCT06450197) in Moderate to Severe Crohn's Disease
2026-06-14
in 186 days 		GMAB Genmab A/S Lenalidomide Trial Phase 3 — $5B Primary completion for Epcoritamab trial (NCT05660967) in Diffuse Large B-Cell Lymphoma
2026-06-15
in 187 days 		CYTK Cytokinetics Non-obstructive hypertrophic cardiomyopathy (nHCM) MYQORZO (aficamten — ACACIA-HCM Trial Readout 3 — $4B JUN 15 2026 48 days 🔬 Trial Readout MYQORZO (aficamten — ACACIA-HCM) $CYTK Cytokinetics No
2026-06-15
in 187 days 		COGT Cogent Biosciences Advanced systemic mastocytosis (AdvSM) bezuclastinib Trial Readout 2 — $4B JUN 15 2026 48 days 🔬 Trial Readout (bezuclastinib) $COGT Cogent Biosciences Advanced syst
2026-06-15
in 187 days 		AKBA Akebia Therapeutics, Inc. Erythropoiesis-Stimulating Agent (ESA) Trial Phase 3 — $4B Primary completion for Erythropoiesis-Stimulating Agent (ESA) trial (NCT06901505) in Anemi
2026-06-15
in 187 days 		TLX Telix Pharmaceuticals Ltd 68Ga-PSMA-11 Trial Phase 3 — $2B Primary completion for 68Ga-PSMA-11 trial (NCT07052214) in PCA
2026-06-15
in 187 days 		IONS Ionis Pharmaceuticals, Inc. ION363 Trial Phase 3 — $2B Primary completion for ION363 trial (NCT04768972) in Amyotrophic Lateral Sclerosis
2026-06-15
in 187 days 		AKBA Akebia Therapeutics, Inc. Vadadustat Trial Phase 3 — $12B Primary completion for Vadadustat trial (NCT06901505) in Anemia of Chronic Kidney Disease
2026-06-15
in 187 days 		GNLX GENELUX Corp olvimulogene nanivacirepvec Trial Phase 3 — $4B Primary completion for olvimulogene nanivacirepvec trial (NCT05281471) in Platinum-resista
2026-06-15
in 187 days 		VNDA Vanda Pharmaceuticals Inc. Tasimelteon Trial Phase 3 — $8B Primary completion for Tasimelteon trial (NCT04652882) in Sleep Wake Disorders
2026-06-15
in 187 days 		CYTK Cytokinetics, Incorporated Aficamten Trial Phase 3 — $4B Primary completion for Aficamten trial (NCT06081894) in Symptomatic Non-Obstructive Hypert
2026-06-15
in 187 days 		POCI PRECISION OPTICS CORPORATION, INC. 1mg elsunersen Trial Phase 3 — $2B Primary completion for 1mg elsunersen trial (NCT07019922) in Epileptic Encephalopathy
2026-06-15
in 187 days 		ARWR Arrowhead Pharmaceuticals, Inc. Plozasiran Injection Trial Phase 3 — $3B Primary completion for Plozasiran Injection trial (NCT06347016) in Severe Hypertriglycerid
2026-06-15
in 187 days 		RNXT RenovoRx, Inc. Gemcitabine Trial Phase 3 — $2B Primary completion for nab-paclitaxel trial (NCT03257033) in Locally Advanced Pancreatic C
2026-06-15
in 187 days 		CGON CG Oncology, Inc. Cretostimogene Grenadenorepvec Trial Phase 3 — $4B Primary completion for Cretostimogene Grenadenorepvec trial (NCT06111235) in Non Muscle In
2026-06-15
in 187 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Eribulin Trial Phase 3 — $18B Primary completion for Eribulin trial (NCT06382142) in Triple-Negative Breast Cancer
2026-06-15
in 187 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Vinorelbine Trial Phase 3 — $5B Primary completion for Vinorelbine trial (NCT06382142) in Triple-Negative Breast Cancer
2026-06-15
in 187 days 		ALKS Alkermes plc ALKS 2680 Trial Phase 2 — $2B Primary completion for ALKS 2680 trial (NCT06843590) in Idiopathic Hypersomnia
2026-06-15
in 187 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR PD-1 monoclonal antibody Trial Phase 2 — $4B Primary completion for PD-1 monoclonal antibody trial (NCT06437509) in Extensive-stage Sma
2026-06-15
in 187 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-DIMERPA Trial Phase 2 — $18B Primary completion for ARO-DIMERPA trial (NCT07223658) in Hyperlipidemia; Mixed
2026-06-15
in 187 days 		JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-9190 Trial Phase 2 — $2B Primary completion for HRS-9190 trial (NCT07404579) in Neuromuscular Blockade
2026-06-15
in 187 days 		BIVI BIOVIE INC. NE3107 Trial Phase 3 — $12B Primary completion for NE3107 trial (NCT06847191) in Long COVID
2026-06-15
in 187 days 		INCY Incyte Corporation Povorcitinib Trial Phase 3 — $2B Primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma
2026-06-15
in 187 days 		SPRY ARS Pharmaceuticals, Inc. 0.5 mg epinephrine Trial Phase 2 — $2B Primary completion for 0.5 mg epinephrine trial (NCT06927999) in Urticaria Chronic
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-5041 tablets Trial Phase 2 — $15B Primary completion for HRS-5041 tablets trial (NCT06568094) in Prostate Cancer
2026-06-15
in 187 days 		FDMT 4D Molecular Therapeutics, Inc. 4D-310 Trial Phase 2 — $1B Primary completion for 4D-310 trial (NCT05629559) in Fabry Disease
2026-06-15
in 187 days 		ALKS Alkermes plc ALKS 5461 Trial Phase 3 — $15B Primary completion for Placebo trial (NCT06843590) in Idiopathic Hypersomnia
2026-06-15
in 187 days 		SGIOY Shionogi Naldemedine Trial Phase 3 — $3B Primary completion for Naldemedine trial (NCT05588323) in Opioid-Induced Constipation (OIC
2026-06-15
in 187 days 		GRFS Grifols SA GRF312 5% Trial Phase 2 — $6B Primary completion for GRF312 5% trial (NCT07264517) in Dry Eye Disease
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR- A1811 Trial Phase 2 — $8B Primary completion for SHR- A1811 trial (NCT05896020) in Gynaecological Malignancies
2026-06-15
in 187 days 		SYRE Spyre Therapeutics, Inc. SPY001 Trial Phase 2 — $8B Primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis
2026-06-15
in 187 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 — $15B Primary completion for Tirzepatide trial (NCT06143956) in Obesity
2026-06-15
in 187 days 		ARQT Arcutis Biotherapeutics, Inc. ARQ-151 cream 0.05% Trial Phase 2 — $8B Primary completion for ARQ-151 cream 0.05% trial (NCT06998056) in Atopic Dermatitis (Eczem
2026-06-15
in 187 days 		ADVB Advanced Biomed Inc. ABD-3001 Trial Phase 2 — $8B Primary completion for ABD-3001 trial (NCT05601726) in Acute Myeloid Leukemia, Adult
2026-06-15
in 187 days 		INCY Incyte Corporation ICS-LABA Trial Phase 2 — $12B Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma
2026-06-15
in 187 days 		IMRX Immuneering Corp IMM-1-104 Monotherapy (Treatment Group A) Trial Phase 2 — $2B Primary completion for IMM-1-104 Monotherapy (Treatment Group A) trial (NCT05585320) in Ad
2026-06-15
in 187 days 		CADL Candel Therapeutics, Inc. Aglatimagene besadenovec + valacyclovir Trial Phase 3 — $15B Primary completion for aglatimagene besadenovec + valacyclovir trial (NCT07332000) in Pros
2026-06-15
in 187 days 		LLY Eli Lilly and Company LY3841136 Trial Phase 2 — $25B Primary completion for LY3841136 trial (NCT06603571) in Obesity
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR STSA-1301 subcutaneous injection Trial Phase 2 — $2B Primary completion for STSA-1301 subcutaneous injection trial (NCT06929299) in Primary Imm
2026-06-15
in 187 days 		SVA SINOVAC BIOTECH LTD Oral hexavalent reassortant rotavirus attenuated live vaccine Trial Phase 2 — $2B Primary completion for Oral hexavalent reassortant rotavirus attenuated live vaccine trial
2026-06-15
in 187 days 		CODX Co-Diagnostics, Inc. BL-M07D1 Trial Phase 2 — $15B Primary completion for BL-M07D1 trial (NCT06445400) in HER2-positive Breast Cancer
2026-06-15
in 187 days 		LLY Eli Lilly and Company LY3305677 Trial Phase 2 — $25B Primary completion for LY3305677 trial (NCT06143956) in Obesity
2026-06-15
in 187 days 		EWTX Edgewise Therapeutics, Inc. EDG-7500 Trial Phase 2 — $4B Primary completion for EDG-7500 trial (NCT06347159) in Hypertrophic Cardiomyopathy
2026-06-15
in 187 days 		ARDX Ardelyx Tenapanor Trial Phase 3 — $2B Primary completion for Tenapanor trial (NCT06553547) in Irritable Bowel Syndrome with Cons
2026-06-15
in 187 days 		BIOE Bio Essence Corp TCMCB07 Trial Phase 2 — $2B Primary completion for TCMCB07 trial (NCT06937177) in Cancer Weight Loss
2026-06-15
in 187 days 		MIRM Mirum Pharmaceuticals, Inc. Volixibat Trial Phase 2 — $1B Primary completion for Volixibat trial (NCT04663308) in Primary Sclerosing Cholangitis
2026-06-15
in 187 days 		ABBV AbbVie Inc. Mirvetuximab Soravtansine Trial Phase 3 — $4B Primary completion for Mirvetuximab Soravtansine trial (NCT06365853) in Recurrent Ovarian
2026-06-15
in 187 days 		VSTM Verastem, Inc. avutometinib and sotorasib Trial Phase 2 — $15B Primary completion for avutometinib and sotorasib trial (NCT05074810) in Non Small Cell Lu
2026-06-15
in 187 days 		CLNN Clene Inc. CNMAu8 Trial Phase 2 — $2B Primary completion for CNMAu8 trial (NCT05299658) in Amyotrophic Lateral Sclerosis
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-1167 tablets Trial Phase 2 — $15B Primary completion for HRS-1167 tablets trial (NCT06568094) in Prostate Cancer
2026-06-16
in 188 days 		SNY Sanofi Fitusiran PDUFA Phase 3 — $8B For hemophilia. BLA filing. Extracted from SEC filing: 6-K
2026-06-16
in 188 days 		BNTX BioNTech SE Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Trial Phase 3 — $15B Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri
2026-06-16
in 188 days 		NVS Novartis AG Pertuzumab Trial Phase 3 — $8B Primary completion for Pertuzumab trial (NCT04208178) in Advanced HER2+Breast Cancer
2026-06-17
in 189 days 		GSK GSK plc Azathioprine Trial Phase 3 — $2B Primary completion for Placebo trial (NCT05600777) in Cough
2026-06-17
in 189 days 		NVS Novartis AG 68Ga-PSMA-11 Trial Phase 2 — $6B Primary completion for 68Ga-PSMA-11 trial (NCT06004661) in Metastatic Castration-Resistant
2026-06-17
in 189 days 		AZN AstraZeneca PLC AZD8421 Trial Phase 2 — $12B Primary completion for AZD8421 trial (NCT06188520) in ER+ HER2- Advanced Breast Cancer
2026-06-17
in 189 days 		NVS Novartis AG AAA617 Trial Phase 3 — $2B Primary completion for AAA617 trial (NCT06004661) in Metastatic Castration-Resistant Prost
2026-06-18
in 190 days 		IMCR Immunocore Holdings plc Tebentafusp PDUFA Phase 3 — $8B For unresectable or metastatic uveal melanoma. BLA filing. Extracted from SEC filing: 8-K
2026-06-19
in 191 days 		AZN AstraZeneca PLC Tozorakimab Trial Phase 3 — $15B Primary completion for Tozorakimab trial (NCT05624450) in Viral Lung Infection and Acute R
2026-06-22
in 194 days 		INCY Incyte Corporation Itacitinib Trial Phase 3 — $5B Primary completion for itacitinib trial (NCT04640025) in Myelofibrosis
2026-06-22
in 194 days 		CLRB Cellectar Biosciences, Inc. Iopofosine I 131 single dose Trial Phase 2 — $1B Primary completion for Iopofosine I 131 single dose trial (NCT02952508) in Waldenstrom Mac
2026-06-26
in 198 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Elafibranor Trial Phase 3 — $1B Primary completion for Elafibranor trial (NCT06383403) in Primary Biliary Cholangitis
2026-06-27
in 199 days 		WVE Wave Life Sciences Ltd. WVE-N531 Trial Phase 2 — $1B Primary completion for WVE-N531 trial (NCT04906460) in Duchenne Muscular Dystrophy
2026-06-28
in 200 days 		MNKD MannKind Corporation Afrezza PDUFA Phase 3 — $8B For Type 1 diabetes. NDA filing. Extracted from SEC filing: 8-K
2026-06-29
in 201 days 		SNY Sanofi Amlitelimab Trial Phase 3 — $8B Primary completion for Amlitelimab trial (NCT06407934) in Dermatitis Atopic
2026-06-29
in 201 days 		AZN AstraZeneca PLC Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level Trial Phase 3 — $2B Primary completion for Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level trial (NCT0
2026-06-29
in 201 days 		TVRD Tvardi Therapeutics, Inc. TTI-101 Trial Phase 2 — $4B Primary completion for TTI-101 trial (NCT05440708) in Hepatocellular Carcinoma
2026-06-30
in 202 days 		AZN AstraZeneca · NDA HR+/HER2- advanced breast cancer — 1L with emergent ESR1 mutation (with CDK4/6 inh camizestrant (AZD9833 PDUFA — 85% $12B JUN 30 2026 63 days 💊 PDUFA (camizestrant (AZD9833)) $AZN AstraZeneca · NDA HR+/HER2- adva
2026-06-30
in 202 days 		AZN AstraZeneca · sNDA PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) — wit Truqap (supplemental) (capivasertib (Truqap) + abir PDUFA — 92% $8B JUN 30 2026 63 days 💊 PDUFA Truqap (supplemental) (capivasertib (Truqap) + abir...) $AZN A
2026-06-30
in 202 days 		MBRX Moleculin Biotech Relapsed/refractory AML — MIRACLE annamycin + cytarabine (AnnA Trial Readout 2B/3 — $2B JUN 30 2026 63 days 🔬 Trial Readout (annamycin + cytarabine (AnnA...) $MBRX Moleculin Biot
2026-06-30
in 202 days 		VRDN Viridian Therapeutics · BLA Thyroid eye disease (TED) — chronic, active veligrotug PDUFA — 88% $2B JUN 30 2026 63 days 💊 PDUFA (veligrotug) $VRDN Viridian Therapeutics · BLA Thyroid eye dis
2026-06-30
in 202 days 		WVE Wave Life Sciences Ltd. — Trial 1 — $25B Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT)
2026-06-30
in 202 days 		CGEM Cullinan Therapeutics, Inc. — Trial 1 — $8B Initial data from Phase 1 study of CLN-978 (OUTRACE)
2026-06-30
in 202 days 		KOD Kodiak Sciences Inc. — Trial 3 — $6B Topline data from Phase 3 trial of KSI-501(DAYBREAK)
2026-06-30
in 202 days 		LPCN Curasight A/S — Trial 1 — $6B Topline data from Phase 1 trial of uTREAT
2026-06-30
in 202 days 		RNA Lipocine Inc — Trial 3 — $2B Topline safety and efficacy results from Phase 3 trial of LPCN 1154 (oral brexanolone)
2026-06-30
in 202 days 		AQST NextCure Inc — Trial 1 — $5B Data from Phase 1 open-label dose escalation study of SIM0505 (CDH6 ADC)
2026-06-30
in 202 days 		CADL Aquestive Therapeutics Inc. — Trial 1 — $1B Data readout from second Phase 1 trial of AQST-108
2026-06-30
in 202 days 		RAPP Candel Therapeutics, Inc. — Trial 3 — $15B Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409)
2026-06-30
in 202 days 		CHRS Rapport Therapeutics, Inc. — Trial 2a — $3B 8-week follow-up results from Phase 2a trial of RAP-219
2026-06-30
in 202 days 		OCS Coherus Oncology, Inc. — Trial 1b — $3B Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripali
2026-06-30
in 202 days 		MIRM Oculis Holding AG — Trial 3 — $4B Top-line data readout from Phase 3 trial of OCS-01 (DIAMOND)
2026-06-30
in 202 days 		RHHBY Roche Holding AG Enzalutamide Trial Phase 3 — $8B Primary completion for Enzalutamide trial (NCT05112965) in Neoplasms
2026-06-30
in 202 days 		PFE PFIZER Carboplatin Trial Phase 3 — $15B Primary completion for carboplatin trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		PFE PFIZER Gemcitabine Trial Phase 3 — $8B Primary completion for gemcitabine trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		TLX Telix Pharmaceuticals Ltd 89Zr-TLX250 PET/CT Trial Phase 3 — $4B Primary completion for 89Zr-TLX250 PET/CT trial (NCT06750419) in Clear Cell Renal Cell Car
2026-06-30
in 202 days 		RHHBY Roche Holding AG Paclitaxel Trial Phase 3 — $5B Primary completion for Paclitaxel trial (NCT05112965) in Neoplasms
2026-06-30
in 202 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT05112965) in Neoplasms
2026-06-30
in 202 days 		RHHBY Roche Holding AG Bevacizumab Trial Phase 3 — $6B Primary completion for Bevacizumab trial (NCT05112965) in Neoplasms
2026-06-30
in 202 days 		RHHBY Roche Holding AG Atezolizumab Trial Phase 3 — $6B Primary completion for Atezolizumab trial (NCT05047250) in Non-Small Cell Lung Cancer
2026-06-30
in 202 days 		RHHBY Roche Holding AG Lenvatinib Trial Phase 3 — $6B Primary completion for Lenvatinib trial (NCT04770896) in Unresectable Hepatocellular Carci
2026-06-30
in 202 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 — $15B Primary completion for Durvalumab trial (NCT05221840) in Non-Small Cell Lung Cancer
2026-06-30
in 202 days 		RHHBY Roche Holding AG Inavolisib Trial Phase 3 — $18B Primary completion for Inavolisib trial (NCT05646862) in Breast Cancer
2026-06-30
in 202 days 		PFE PFIZER cisplatin Trial Phase 3 — $15B Primary completion for cisplatin trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		SBFM Sunshine Biopharma Inc. 611 300 mg Q2W Trial Phase 2 — $15B Primary completion for Matching placebo trial (NCT07042126) in Dermatitis, Atopic
2026-06-30
in 202 days 		LRVIY Laboratorios Farmaceuticos Rovi, S.A./ADR Moxifloxacin / Dexamethasone Ophthalmic Solution Trial Phase 3 — $2B Primary completion for Moxifloxacin / Dexamethasone Ophthalmic Solution trial (NCT07305987
2026-06-30
in 202 days 		CELC Celcuity Inc. (CELC) Palbociclib Trial Phase 3 — $18B Primary completion for Palbociclib trial (NCT05501886) in Breast Cancer
2026-06-30
in 202 days 		JNJ Johnson & Johnson JNJ-90301900 (NBTXR3) Trial Phase 3 — $2B Primary completion for JNJ-90301900 (NBTXR3) trial (NCT04892173) in Locally Advanced Head
2026-06-30
in 202 days 		SBFM Sunshine Biopharma Inc. 611 Trial Phase 3 — $15B Primary completion for 611 trial (NCT07042126) in Dermatitis, Atopic
2026-06-30
in 202 days 		OLMA Olema Pharmaceuticals, Inc. Palazestrant Trial Phase 3 — $18B Primary completion for Palazestrant trial (NCT06016738) in Breast Cancer
2026-06-30
in 202 days 		KALV KalVista Pharmaceuticals, Inc. KVD900 600 mg Trial Phase 3 — $2B Primary completion for KVD900 600 mg trial (NCT05511922) in Hereditary Angioedema
2026-06-30
in 202 days 		KALV KalVista Pharmaceuticals, Inc. KVD900 300 mg Trial Phase 3 — $2B Primary completion for KVD900 300 mg trial (NCT05505916) in Hereditary Angioedema
2026-06-30
in 202 days 		BGNE BeiGene, Ltd. Pamiparib capsule Trial Phase 3 — $5B Primary completion for Pamiparib capsule trial (NCT03519230) in Ovarian Cancer
2026-06-30
in 202 days 		PFE PFIZER disitamab vedotin Trial Phase 3 — $5B Primary completion for disitamab vedotin trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		RHHBY Roche Holding AG Entrectinib Trial Phase 3 — $7B Primary completion for Entrectinib trial (NCT02650401) in Solid Tumors
2026-06-30
in 202 days 		MRK MERCK Sacituzumab tirumotecan Trial Phase 3 — $8B Primary completion for Sacituzumab tirumotecan trial (NCT06637423) in Non-Muscle Invasive
2026-06-30
in 202 days 		AZNCF ASTRAZENECA PLC Oleclumab Trial Phase 2 — $15B Primary completion for Oleclumab trial (NCT06606847) in Non-Small Cell Lung Cancer
2026-06-30
in 202 days 		NVS Novartis AG 68Ga-FAP-2286 Trial Phase 2 — $5B Primary completion for 68Ga-FAP-2286 trial (NCT04939610) in Solid Tumor
2026-06-30
in 202 days 		MDNAF Medicenna Therapeutics Corp. MDNA11 Trial Phase 2 — $4B Primary completion for MDNA11 trial (NCT05086692) in Advanced Solid Tumor
2026-06-30
in 202 days 		GNTA Genenta Science S.p.A. Temferon Trial Phase 2 — $2B Primary completion for Temferon trial (NCT03866109) in Glioblastoma Multiforme
2026-06-30
in 202 days 		MRTX Mirati Therapeutics, Inc. MRTX0902 Trial Phase 2 — $3B Primary completion for MRTX0902 trial (NCT05578092) in Solid Tumor
2026-06-30
in 202 days 		RHHBY Roche Holding AG RO7247669 Trial Phase 2 — $8B Primary completion for RO7247669 trial (NCT04140500) in Solid Tumors
2026-06-30
in 202 days 		RHHBY Roche Holding AG Giredestrant Trial Phase 3 — $4B Primary completion for Giredestrant trial (NCT05634499) in Endometrial Cancer
2026-06-30
in 202 days 		MRK MERCK Rescue medication Trial Phase 3 — $3B Primary completion for Rescue medication trial (NCT06637423) in Non-Muscle Invasive Bladde
2026-06-30
in 202 days 		MAIA MAIA Biotechnology, Inc. 6-Thio-2'-Deoxyguanosine Trial Phase 3 — $15B Primary completion for 6-Thio-2'-Deoxyguanosine trial (NCT05208944) in Carcinoma, Non-Smal
2026-06-30
in 202 days 		ENGN enGene Holdings Inc. EG-70 (phase 1) Trial Phase 2 — $2B Primary completion for EG-70 (phase 1) trial (NCT04752722) in Superficial Bladder Cancer
2026-06-30
in 202 days 		CGTX COGNITION THERAPEUTICS INC golexanolone Trial Phase 2 — $1B Primary completion for golexanolone trial (NCT07304843) in Primary Biliary Cholangitis (PB
2026-06-30
in 202 days 		NVS Novartis AG Asciminib Pediatric formulation group Trial Phase 2 — $3B Primary completion for Asciminib Pediatric formulation group trial (NCT04925479) in Myeloi
2026-06-30
in 202 days 		MRNA Moderna, Inc. mRNA-1468 Trial Phase 2 — $2B Primary completion for mRNA-1468 trial (NCT05701800) in Herpes Zoster
2026-06-30
in 202 days 		MRTX Mirati Therapeutics, Inc. MRTX849 Trial Phase 3 — $13B Primary completion for MRTX849 trial (NCT05578092) in Solid Tumor
2026-06-30
in 202 days 		DNTH Dianthus Therapeutics, Inc. /DE/ DNTH103 Trial Phase 3 — $2B Primary completion for DNTH103 trial (NCT06537999) in Multifocal Motor Neuropathy
2026-06-30
in 202 days 		MRK MERCK Olaparib Trial Phase 3 — $5B Primary completion for Olaparib trial (NCT04123366) in Solid Tumors
2026-07-01
in 273 days 		MBRX Moleculin Biotech Relapsed/refractory AML (R/R AML) — annamycin (AnnAraC Trial Readout 2B/3 — $1B JUL 1 2026 64 days 🔬 Trial Readout (annamycin (AnnAraC)) $MBRX Moleculin Biotech Relapsed/
2026-07-01
in 273 days 		ALMS ALUMIS INC. ESK-001 Trial Phase 3 — $12B Primary completion for ESK-001 trial (NCT05966480) in SLE
2026-07-01
in 273 days 		ANRO Alto Neuroscience, Inc. LM-302 Trial Phase 3 — $22B Primary completion for LM-302 trial (NCT05934331) in Malignant Neoplasms of Digestive Orga
2026-07-01
in 273 days 		AZNCF ASTRAZENECA PLC Durvalumab Trial Phase 3 — $4B Primary completion for Durvalumab trial (NCT06040099) in Hepatocellular Carcinoma (HCC)
2026-07-02
in 274 days 		AMGN Amgen Inc. Docetaxel Trial Phase 2 — $2B Primary completion for Docetaxel trial (NCT05094336) in Advanced MTAP-null Solid Tumors
2026-07-02
in 274 days 		AMGN Amgen Inc. AMG 193 Trial Phase 2 — $3B Primary completion for AMG 193 trial (NCT05094336) in Advanced MTAP-null Solid Tumors
2026-07-06
in 278 days 		MRK MERCK Cisplatin Trial Phase 3 — $8B Primary completion for Cisplatin trial (NCT04380636) in Lung Neoplasms
2026-07-06
in 278 days 		MRK MERCK Olaparib Trial Phase 3 — $5B Primary completion for Olaparib trial (NCT04380636) in Lung Neoplasms
2026-07-06
in 278 days 		MRK MERCK Paclitaxel Trial Phase 3 — $12B Primary completion for Paclitaxel trial (NCT04380636) in Lung Neoplasms
2026-07-06
in 278 days 		MRK MERCK Carboplatin Trial Phase 3 — $4B Primary completion for Carboplatin trial (NCT04380636) in Lung Neoplasms
2026-07-06
in 278 days 		AZNCF ASTRAZENECA PLC Taxane Trial Phase 3 — $6B Primary completion for Taxane trial (NCT04784715) in Breast Cancer; HER2-positive; Metasta
2026-07-06
in 278 days 		REGN Regeneron Pharmaceuticals, Inc. Odronextamab Trial Phase 3 — $8B Primary completion for Odronextamab trial (NCT03888105) in B-cell Non-Hodgkin Lymphoma (B-
2026-07-06
in 278 days 		MRK MERCK Raludotatug Deruxtecan (R-DXd) Trial Phase 2 — $15B Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti
2026-07-07
in 279 days 		VERA Vera Therapeutics · BLA IgA nephropathy (IgAN) atacicept PDUFA — 88% $8B JUL 7 2026 70 days 💊 PDUFA (atacicept) $VERA Vera Therapeutics · BLA IgA nephropathy (IgAN
2026-07-07
in 279 days 		AZN AstraZeneca PLC Osimertinib Trial Phase 3 — $12B Primary completion for Osimertinib trial (NCT06194448) in Lung Cancer
2026-07-08
in 280 days 		AZNCF ASTRAZENECA PLC AZD6234 Trial Phase 2 — $8B Primary completion for AZD6234 trial (NCT06851858) in Endocrinology
2026-07-09
in 281 days 		NVS Novartis AG Iptacopan Trial Phase 3 — $2B Primary completion for Iptacopan trial (NCT04889430) in Atypical Hemolytic Uremic Syndrome
2026-07-10
in 282 days 		SWTX SpringWorks Therapeutics · NDA NF1-associated plexiform neurofibromas (NF1-PN) mirdametinib PDUFA — 93% $2B JUL 10 2026 73 days 💊 PDUFA (mirdametinib) $SWTX SpringWorks Therapeutics · NDA NF1-associ
2026-07-10
in 282 days 		SNY Sanofi SAR441344 IV Trial Phase 2 — $8B Primary completion for SAR441344 IV trial (NCT05039840) in Systemic Lupus Erythematosus
2026-07-13
in 285 days 		PFE PFIZER PF-06821497 Trial Phase 3 — $6B Primary completion for PF-06821497 trial (NCT06551324) in Metastatic Castrate Resistant Pr
2026-07-13
in 285 days 		INCY Incyte Corporation Ruxolitinib Trial Phase 3 — $5B Primary completion for Ruxolitinib trial (NCT06832618) in Atopic Dermatitis
2026-07-13
in 285 days 		RHHBY Roche Holding AG peginterferon alfa-2a [Pegasys] Trial Phase 3 — $2B Primary completion for Placebo trial (NCT06863961) in Atopic Dermatitis
2026-07-13
in 285 days 		RHHBY Roche Holding AG Afimkibart Trial Phase 3 — $8B Primary completion for Afimkibart trial (NCT06863961) in Atopic Dermatitis
2026-07-15
in 287 days 		SNGX Soligenix, Inc. Hypericin Trial Phase 3 — $2B Primary completion for Hypericin trial (NCT06470451) in CTCL/ Mycosis Fungoides
2026-07-15
in 287 days 		SVA SINOVAC BIOTECH LTD PROVARIX Trial Phase 3 — $1B Primary completion for PROVARIX trial (NCT07475000) in Varicella (Chickenpox)
2026-07-15
in 287 days 		VRDN Viridian Therapeutics, Inc. VRDN-003 Trial Phase 3 — $2B Primary completion for VRDN-003 trial (NCT07155668) in Thyroid Eye Disease
2026-07-15
in 287 days 		BHVN Biohaven Pharmaceutical Holding Company Ltd. BHV-7000 Trial Phase 3 — $5B Primary completion for BHV-7000 trial (NCT06425159) in Generalized Epilepsy
2026-07-15
in 287 days 		LXRX LEXICON PHARMACEUTICALS, INC. Sotagliflozin Trial Phase 3 — $55B Primary completion for Sotagliflozin trial (NCT06481891) in Obstructive Cardiomyopathy, Hy
2026-07-15
in 287 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Nab-paclitaxel Trial Phase 3 — $5B Primary completion for Nab-paclitaxel trial (NCT06279364) in Triple Negative Breast Cancer
2026-07-15
in 287 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Paclitaxel Trial Phase 3 — $6B Primary completion for Paclitaxel trial (NCT06279364) in Triple Negative Breast Cancer
2026-07-15
in 287 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SI-B001 Trial Phase 3 — $8B Primary completion for SI-B001 trial (NCT05943795) in Non-small Cell Lung Adenocarcinoma
2026-07-15
in 287 days 		SNGX Soligenix, Inc. SGX942 Trial Phase 3 — $1B Primary completion for Placebo trial (NCT06470451) in CTCL/ Mycosis Fungoides
2026-07-15
in 287 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 — $15B Primary completion for SKB264 trial (NCT06279364) in Triple Negative Breast Cancer
2026-07-15
in 287 days 		CHHE China Health Industries Holdings, Inc. IAH0968 Trial Phase 3 — $6B Primary completion for IAH0968 trial (NCT06504732) in Stomach Neoplasms
2026-07-15
in 287 days 		ABBV AbbVie Inc. Upadacitinib Trial Phase 3 — $8B Primary completion for Upadacitinib trial (NCT05814627) in Rheumatoid Arthritis
2026-07-15
in 287 days 		ONC BeOne Medicines Ltd. Tislelizumab Trial Phase 3 — $19B Primary completion for Tislelizumab trial (NCT04164199) in Advanced Malignancies
2026-07-15
in 287 days 		ABBV AbbVie Inc. Bimatoprost SR Trial Phase 3 — $4B Primary completion for Bimatoprost SR trial (NCT03891446) in Open-Angle Glaucoma
2026-07-15
in 287 days 		GSK GSK plc GSK5784283 Trial Phase 2 — $20B Primary completion for GSK5784283 trial (NCT06748053) in Asthma
2026-07-15
in 287 days 		GILD Gilead Sciences, Inc. Lenacapavir Tablet Trial Phase 3 — $5B Primary completion for Lenacapavir Tablet trial (NCT06101329) in Pre-Exposure Prophylaxis
2026-07-15
in 287 days 		GILD Gilead Sciences, Inc. Lenacapavir Injection Trial Phase 3 — $2B Primary completion for Lenacapavir Injection trial (NCT06101329) in Pre-Exposure Prophylax
2026-07-15
in 287 days 		GSK GSK plc Paclitaxel Trial Phase 3 — $31B Primary completion for Paclitaxel trial (NCT06317311) in Carcinoma
2026-07-15
in 287 days 		GSK GSK plc Dostarlimab Trial Phase 3 — $4B Primary completion for Dostarlimab trial (NCT06317311) in Carcinoma
2026-07-15
in 287 days 		SION Sionna Therapeutics, Inc. SION-719 Trial Phase 2 — $6B Primary completion for SION-719 trial (NCT07108153) in Cystic Fibrosis (CF)
2026-07-15
in 287 days 		DWTX Dogwood Therapeutics, Inc. Halneuron Trial Phase 2 — $1B Primary completion for Halneuron trial (NCT06848348) in Chemotherapy Induced Neuropathic P
2026-07-15
in 287 days 		EVMN Evommune, Inc. EVO756 Trial Phase 2 — $3B Primary completion for EVO756 trial (NCT07150845) in Atoptic Dermatitis
2026-07-15
in 287 days 		ABBV AbbVie Inc. Telisotuzumab vedotin Trial Phase 3 — $15B Primary completion for Telisotuzumab vedotin trial (NCT03539536) in Non-small Cell Lung Ca
2026-07-15
in 287 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-ALK7 Trial Phase 2 — $25B Primary completion for ARO-ALK7 trial (NCT06937203) in Obesity
2026-07-15
in 287 days 		BIO BIO-RAD LABORATORIES, INC. VRB-101 Trial Phase 2 — $25B Primary completion for VRB-101 trial (NCT07281937) in Obesity
2026-07-15
in 287 days 		GILD Gilead Sciences, Inc. Emtricitabine/tenofovir disoproxil fumarate (F/TDF) Trial Phase 2 — $2B Primary completion for Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) trial (NCT06101
2026-07-15
in 287 days 		CODX Co-Diagnostics, Inc. PD-1 Monoclonal Antibody Trial Phase 2 — $15B Primary completion for PD-1 Monoclonal Antibody trial (NCT06475300) in Non-small Cell Lung
2026-07-15
in 287 days 		CODX Co-Diagnostics, Inc. BL-B01D1 Trial Phase 3 — $4B Primary completion for BL-B01D1 trial (NCT06475300) in Non-small Cell Lung Cancer
2026-07-15
in 287 days 		DCPH Deciphera Pharmaceuticals, Inc. Vimseltinib Trial Phase 3 — $2B Primary completion for Vimseltinib trial (NCT03069469) in Advanced Malignant Neoplasm
2026-07-15
in 287 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 — $50B Primary completion for Aleniglipron trial (NCT06693843) in Obesity, Overweight, or Chronic
2026-07-17
in 289 days 		CELC Celcuity · NDA HR+/HER2-/PIK3CA wild-type advanced breast cancer (2nd-line post CDK4/6i) gedatolisib PDUFA — 90% $1B JUL 17 2026 80 days 💊 PDUFA (gedatolisib) $CELC Celcuity · NDA HR+/HER2-/PIK3CA wild-type
2026-07-17
in 289 days 		TEVA Teva Pharmaceutical Industries Limited TEV-56248 Trial Phase 3 — $20B Primary completion for TEV-56248 trial (NCT06052267) in Asthma
2026-07-21
in 293 days 		MRK MERCK Palbociclib Trial Phase 3 — $8B Primary completion for Palbociclib trial (NCT05468697) in Renal Cell Carcinoma
2026-07-21
in 293 days 		MRK MERCK Belzutifan Trial Phase 3 — $8B Primary completion for Belzutifan trial (NCT05468697) in Renal Cell Carcinoma
2026-07-22
in 294 days 		INCY Incyte Corporation INCB099280 Trial Phase 2 — $5B Primary completion for INCB099280 trial (NCT05879822) in Advanced Solid Tumor
2026-07-23
in 295 days 		BNTX BioNTech SE Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Trial Phase 3 — $15B Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri
2026-07-23
in 295 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04123366) in Solid Tumors
2026-07-23
in 295 days 		REGN Regeneron Pharmaceuticals, Inc. PB Trial Phase 2 — $2B Primary completion for PB trial (NCT06608901) in Sepsis-Induced Hypotension
2026-07-24
in 296 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 — $55B Primary completion for Placebo trial (NCT06151964) in Overweight and Obesity
2026-07-24
in 296 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 — $25B Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity
2026-07-25
in 297 days 		BIIB Eisai / Biogen · sNDA Subcutaneous formulation — early Alzheimer's disease Leqembi (lecanemab PDUFA — 92% $15B JUL 25 2026 88 days 💊 PDUFA Leqembi (lecanemab) $BIIB Eisai / Biogen · sNDA Subcutaneous f
2026-07-26
in 298 days 		NVAX Novavax, Inc. CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant Trial Phase 3 — $15B Primary completion for CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvan
2026-07-27
in 299 days 		AZN AstraZeneca PLC Olaparib Trial Phase 3 — $12B Primary completion for Olaparib trial (NCT04884360) in Ovarian Cancer
2026-07-28
in 300 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for Bimekizumab trial (NCT04436640) in Axial Spondyloarthritis
2026-07-29
in 301 days 		NVO Novo Nordisk · BLA Hemophilia A (with or without inhibitors) — monthly/biweekly/weekly subcutaneous denecimig (Mim8 PDUFA — 80% $1B JUL 29 2026 92 days 💊 PDUFA (denecimig (Mim8)) $NVO Novo Nordisk · BLA Hemophilia A (with
2026-07-29
in 301 days 		NVS Novartis AG cetuximab Trial Phase 2 — $5B Primary completion for JDQ443 trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-07-30
in 302 days 		PFE PFIZER ritonavir Trial Phase 3 — $15B Primary completion for ritonavir trial (NCT05261139) in COVID-19
2026-07-30
in 302 days 		PFE PFIZER Nirmatrelvir Trial Phase 3 — $15B Primary completion for nirmatrelvir trial (NCT05261139) in COVID-19
2026-07-30
in 302 days 		SBFM Sunshine Biopharma Inc. SSGJ-707 Trial Phase 3 — $2B Primary completion for SSGJ-707 trial (NCT06980272) in Advanced Non-Small Cell Lung Cancer
2026-07-30
in 302 days 		SBFM Sunshine Biopharma Inc. Pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT06980272) in Advanced Non-Small Cell Lung C
2026-07-30
in 302 days 		MRNA Moderna, Inc. mRNA-1345 Trial Phase 3 — $4B Primary completion for mRNA-1345 trial (NCT06067230) in Respiratory Syncytial Virus
2026-07-30
in 302 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR TACE+Camrelizumab+Apatinib mesylate Trial Phase 3 — $4B Primary completion for TACE+Camrelizumab+Apatinib mesylate trial (NCT05320692) in Hepatoce
2026-07-30
in 302 days 		BIO BIO-RAD LABORATORIES, INC. Recombinant Human Proteoglycan 4 Trial Phase 2 — $2B Primary completion for Recombinant Human Proteoglycan 4 trial (NCT07118241) in Sjögren's S
2026-07-30
in 302 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR JSKN003 Trial Phase 3 — $3B Primary completion for JSKN003 trial (NCT05744427) in Advanced Solid Tumor
2026-07-30
in 302 days 		MRTX Mirati Therapeutics, Inc. Adagrasib Trial Phase 3 — $15B Primary completion for Adagrasib trial (NCT05853575) in Advanced Cancer
2026-07-31
in 303 days 		BNTX BioNTech SE BNT162b2 Vaccine Trial Phase 3 — $15B Primary completion for BNT162b2 Vaccine trial (NCT07300839) in COVID-19
2026-07-31
in 303 days 		BNTX BioNTech SE Influenza and COVID-19 Combination A Trial Phase 3 — $6B Primary completion for Placebo trial (NCT07300839) in COVID-19
2026-07-31
in 303 days 		BNTX BioNTech SE BNT162b2 (2025/2026 formulation) Trial Phase 3 — $15B Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19
2026-07-31
in 303 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT06698042) in Lung Cancer
2026-07-31
in 303 days 		MRK MERCK BCG Trial Phase 3 — $4B Primary completion for BCG trial (NCT03711032) in High-risk Non-muscle Invasive Bladder Ca
2026-07-31
in 303 days 		JAZZ Jazz Pharmaceuticals plc Capecitabine Trial Phase 3 — $8B Primary completion for Tislelizumab trial (NCT05152147) in Gastric Neoplasms
2026-07-31
in 303 days 		BIIB Biogen Inc. Nusinersen Trial Phase 3 — $1B Primary completion for Nusinersen trial (NCT04729907) in Muscular Atrophy, Spinal
2026-07-31
in 303 days 		WXI WUXI Semaglutide Trial Phase 3 — $55B Primary completion for Semaglutide trial (NCT07064486) in Type 2 Diabetes (T2DM)
2026-07-31
in 303 days 		WXI WUXI BGM0504 Trial Phase 3 — $25B Primary completion for BGM0504 trial (NCT07064486) in Type 2 Diabetes (T2DM)
2026-07-31
in 303 days 		JAZZ Jazz Pharmaceuticals plc Zanidatamab Trial Phase 3 — $15B Primary completion for Zanidatamab trial (NCT05152147) in Gastric Neoplasms
2026-07-31
in 303 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Rivoceranib (Apatinib) Trial Phase 3 — $4B Primary completion for Rivoceranib (Apatinib) trial (NCT04639180) in Hepatocellular Carcin
2026-07-31
in 303 days 		JAZZ Jazz Pharmaceuticals plc ZW25 (Zanidatamab) Trial Phase 2 — $8B Primary completion for Capecitabine trial (NCT05152147) in Gastric Neoplasms
2026-07-31
in 303 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Camrelizumab Trial Phase 3 — $6B Primary completion for Camrelizumab trial (NCT04639180) in Hepatocellular Carcinoma (HCC)
2026-07-31
in 303 days 		BIOE Bio Essence Corp JMT202 injection Trial Phase 2 — $12B Primary completion for JMT202 injection trial (NCT07140809) in Hypertriglyceridemia
2026-07-31
in 303 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-20093 Trial Phase 3 — $2B Primary completion for HS-20093 trial (NCT06112704) in Advanced Solid Tumor
2026-07-31
in 303 days 		AZN AstraZeneca PLC Dapagliflozin Trial Phase 3 — $15B Primary completion for Dapagliflozin trial (NCT06942910) in Chronic Kidney Disease With Hi
2026-07-31
in 303 days 		RHHBY Roche Holding AG ZN-A-1041 Trial Phase 2 — $8B Primary completion for ZN-A-1041 trial (NCT05593094) in Advanced Solid Tumors
2026-07-31
in 303 days 		RHHBY Roche Holding AG Axitinib Trial Phase 2 — $8B Primary completion for Axitinib trial (NCT05805501) in Renal Cell Carcinoma
2026-07-31
in 303 days 		AZN AstraZeneca PLC Zibotentan/Dapagliflozin Trial Phase 3 — $5B Primary completion for Zibotentan/Dapagliflozin trial (NCT06942910) in Chronic Kidney Dise
2026-07-31
in 303 days 		BCYC BICYCLE THERAPEUTICS PLC BT5528 Trial Phase 2 — $6B Primary completion for BT5528 trial (NCT04180371) in Advanced Solid Tumor Historically Kno
2026-07-31
in 303 days 		BIOE Bio Essence Corp NECVAX-NEO1 Trial Phase 2 — $8B Primary completion for NECVAX-NEO1 trial (NCT06631079) in Solid Tumor
2026-07-31
in 303 days 		RHHBY Roche Holding AG Tiragolumab Trial Phase 3 — $4B Primary completion for Tiragolumab trial (NCT05805501) in Renal Cell Carcinoma
2026-07-31
in 303 days 		RHHBY Roche Holding AG Tobemstomig Trial Phase 2 — $5B Primary completion for Tobemstomig trial (NCT05805501) in Renal Cell Carcinoma
2026-07-31
in 303 days 		ALPMY Astellas Pharma zolbetuximab Trial Phase 3 — $2B Primary completion for zolbetuximab trial (NCT03505320) in Pharmacokinetics of Zolbetuxima
2026-08-01
in 373 days 		MRK MERCK SC Tulisokibart Trial Phase 3 — $8B Primary completion for SC Tulisokibart trial (NCT06052059) in Ulcerative Colitis
2026-08-01
in 373 days 		MRK MERCK IV Tulisokibart Trial Phase 3 — $8B Primary completion for IV Tulisokibart trial (NCT06052059) in Ulcerative Colitis
2026-08-01
in 373 days 		RHHBY Roche Holding AG Zifibancimig Trial Phase 2 — $10B Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration
2026-08-01
in 373 days 		BBOT BridgeBio Oncology Therapeutics, Inc. BBT-207 Trial Phase 2 — $7B Primary completion for BBT-207 trial (NCT05920135) in EGFR Mutant Advanced Non-Small Cell
2026-08-01
in 373 days 		MRNA Moderna, Inc. mRNA-1010 PDUFA Phase 3 — $8B For Influenza vaccine. FDA reversed its Refusal-to-File decision on Moderna's mRNA-1010 fl
2026-08-03
in 375 days 		DSKYF Daiichi Sankyo T-DXd Trial Phase 3 — $16B Primary completion for T-DXd trial (NCT06174987) in Advanced Cancer
2026-08-04
in 376 days 		SNY Sanofi Amlitelimab Trial Phase 3 — $8B Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease
2026-08-05
in 377 days 		SNYNF Sanofi Amlitelimab Trial Phase 3 — $20B Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease
2026-08-05
in 377 days 		MRNA Moderna, Inc. Influenza Vaccine PDUFA Phase 3 — $15B For influenza. The FDA reversed its earlier Refusal-to-File decision and agreed to review
2026-08-05
in 377 days 		VRNA VERONA PHARMA Glycopyrrolate 21.25 mcg Trial Phase 2 — $15B Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon
2026-08-06
in 378 days 		AZN AstraZeneca PLC AZD6234 Trial Phase 2 — $50B Primary completion for AZD6234 trial (NCT07017179) in Obesity/Overweight
2026-08-07
in 379 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for Bimekizumab trial (NCT04436640) in Axial Spondyloarthritis
2026-08-07
in 379 days 		SNY Sanofi Mometasone furoate nasal spray (MFNS) Trial Phase 3 — $2B Primary completion for Mometasone furoate nasal spray (MFNS) trial (NCT06691113) in Chroni
2026-08-07
in 379 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 — $15B Primary completion for Itepekimab (SAR440340) trial (NCT06691113) in Chronic Rhinosinusiti
2026-08-13
in 385 days 		ZEAL Zealand Pharma A/S Petrelintide Trial Phase 2 — $25B Primary completion for Petrelintide trial (NCT06926842) in Overweight
2026-08-13
in 385 days 		JSPR Jasper Therapeutics, Inc. Briquilimab Trial Phase 2 — $3B Primary completion for Briquilimab trial (NCT06736262) in Urticaria Chronic
2026-08-14
in 386 days 		AZN AstraZeneca PLC Nexium 20mg Trial Phase 3 — $2B Primary completion for Nexium 20mg trial (NCT05267613) in Erosive Esophagitis
2026-08-15
in 387 days 		IMVT Immunovant Thyroid eye disease (TED) batoclimab Trial Readout 3 — $2B AUG 15 2026 109 days 🔬 Trial Readout (batoclimab) $IMVT Immunovant Thyroid eye disease (TE
2026-08-15
in 387 days 		HELP CYBIN INC. CYB003 Trial Phase 3 — $15B Primary completion for CYB003 trial (NCT06564818) in Major Depressive Disorder
2026-08-15
in 387 days 		SNYNF Sanofi Fitusiran Trial Phase 3 — $8B Primary completion for Fitusiran trial (NCT03974113) in Hemophilia
2026-08-15
in 387 days 		PHVS Pharvaris N.V. Deucrictibant Trial Phase 3 — $2B Primary completion for Deucrictibant trial (NCT06669754) in Hereditary Angioedema (HAE)
2026-08-15
in 387 days 		ENSCW Ensysce Biosciences, Inc. PF614 capsule Trial Phase 3 — $3B Primary completion for PF614 capsule trial (NCT06602271) in Postoperative Pain, Acute
2026-08-15
in 387 days 		GRFS Grifols SA Alpha-1 MP Trial Phase 3 — $2B Primary completion for Alpha-1 MP trial (NCT01983241) in Pulmonary Emphysema in Alpha-1 PI
2026-08-15
in 387 days 		ENSCW Ensysce Biosciences, Inc. PF614 Trial Phase 2 — $6B Primary completion for Placebo trial (NCT06602271) in Postoperative Pain, Acute
2026-08-15
in 387 days 		ABBV AbbVie Inc. Upadacitinib 15mg Dose Trial Phase 3 — $8B Primary completion for Upadacitinib 15mg Dose trial (NCT06389136) in Atopic Dermatitis
2026-08-15
in 387 days 		SBFM Sunshine Biopharma Inc. Lerotinib Trial Phase 3 — $2B Primary completion for Lerotinib trial (NCT04415853) in Esophageal Cancer
2026-08-15
in 387 days 		ABBV AbbVie Inc. Venetoclax Trial Phase 3 — $8B Primary completion for Venetoclax trial (NCT03539744) in Multiple Myeloma
2026-08-15
in 387 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 — $25B Primary completion for Retatrutide trial (NCT06260722) in Diabetes Mellitus, Type 2
2026-08-15
in 387 days 		KOD Kodiak Sciences Inc Aflibercept Trial Phase 3 — $6B Primary completion for Aflibercept trial (NCT06556368) in Wet Age-related Macular Degenera
2026-08-15
in 387 days 		LLY Eli Lilly and Company Semaglutide Trial Phase 3 — $55B Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2
2026-08-15
in 387 days 		IMVT Immunovant, Inc. Batoclimab Trial Phase 3 — $2B Primary completion for Batoclimab trial (NCT05517447) in Thyroid Eye Disease
2026-08-15
in 387 days 		ABBV AbbVie Inc. Pomalidomide Trial Phase 3 — $15B Primary completion for Pomalidomide trial (NCT03539744) in Multiple Myeloma
2026-08-15
in 387 days 		KPTI Karyopharm Therapeutics Inc. Selinexor Trial Phase 3 — $8B Primary completion for Selinexor trial (NCT05611931) in Endometrial Cancer
2026-08-15
in 387 days 		EYPT EyePoint Pharmaceuticals, Inc. Aflibercept (2.0 mg) Trial Phase 3 — $6B Primary completion for Aflibercept (2.0 mg) trial (NCT06668064) in Wet Age Related Macular
2026-08-15
in 387 days 		XENE Xenon Pharmaceuticals Inc. Azetukalner Trial Phase 3 — $15B Primary completion for Azetukalner trial (NCT06775379) in Major Depressive Disorder
2026-08-15
in 387 days 		PCRX Pacira BioSciences, Inc. ZILRETTA Trial Phase 3 — $2B Primary completion for ZILRETTA trial (NCT06269705) in Glenohumeral Osteoarthritis
2026-08-15
in 387 days 		EYPT EyePoint Pharmaceuticals, Inc. EYP-1901 Trial Phase 3 — $4B Primary completion for EYP-1901 trial (NCT06668064) in Wet Age Related Macular Degeneratio
2026-08-15
in 387 days 		KOD Kodiak Sciences Inc Tarcocimab tedromer Trial Phase 3 — $6B Primary completion for Tarcocimab tedromer trial (NCT06556368) in Wet Age-related Macular
2026-08-15
in 387 days 		ACRS Aclaris Therapeutics, Inc. ATI-045 Trial Phase 2 — $8B Primary completion for ATI-045 trial (NCT07011706) in Atopic Dermatitis
2026-08-15
in 387 days 		ARGX argenx SE ARGX-119 Trial Phase 2 — $2B Primary completion for ARGX-119 trial (NCT06441682) in Amyotrophic Lateral Sclerosis
2026-08-15
in 387 days 		GILD Gilead Sciences, Inc. Zimberelimab Trial Phase 3 — $6B Primary completion for Zimberelimab trial (NCT06727565) in Head and Neck Squamous Cell Car
2026-08-15
in 387 days 		CRIS CURIS INC Ibrutinib Trial Phase 2 — $8B Primary completion for Ibrutinib trial (NCT03328078) in Relapsed Hematologic Malignancy
2026-08-15
in 387 days 		LLY Eli Lilly and Company Mazdutide Trial Phase 2 — $8B Primary completion for Mazdutide trial (NCT06817356) in Alcohol Use Disorder
2026-08-15
in 387 days 		ACRS Aclaris Therapeutics, Inc. ATI-501 400mg BID (Low dose) Trial Phase 2 — $3B Primary completion for Placebo trial (NCT07011706) in Atopic Dermatitis
2026-08-15
in 387 days 		MANE Veradermics, Inc VDPHL01 Trial Phase 3 — $3B Primary completion for VDPHL01 trial (NCT06527365) in Androgenetic Alopecia
2026-08-15
in 387 days 		ABBV AbbVie Inc. Ranibizumab Trial Phase 2 — $8B Primary completion for Ranibizumab trial (NCT04514653) in Neovascular Age-Related Macular
2026-08-15
in 387 days 		MPLT MapLight Therapeutics, Inc. ML-007C-MA BID Trial Phase 2 — $12B Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia
2026-08-15
in 387 days 		RIGL RIGEL PHARMACEUTICALS INC R906289 Monosodium (R289 Na) Trial Phase 2 — $1B Primary completion for R906289 Monosodium (R289 Na) trial (NCT05308264) in Low Risk Myelod
2026-08-15
in 387 days 		CORT Corcept Therapeutics Incorporated Relacorilant 150 mg once daily (QD) Trial Phase 3 — $5B Primary completion for Relacorilant 150 mg once daily (QD) trial (NCT06906341) in Ovarian
2026-08-15
in 387 days 		PMVP PMV Pharmaceuticals, Inc. rezatapopt Trial Phase 2 — $6B Primary completion for rezatapopt trial (NCT04585750) in Advanced Solid Tumor
2026-08-15
in 387 days 		GILD Gilead Sciences, Inc. Domvanalimab Trial Phase 3 — $15B Primary completion for Domvanalimab trial (NCT06727565) in Head and Neck Squamous Cell Car
2026-08-15
in 387 days 		CPHI CHINA PHARMA HOLDINGS, INC. ASC30 tablets Trial Phase 2 — $45B Primary completion for ASC30 tablets trial (NCT07321678) in T2DM (Type 2 Diabetes Mellitus
2026-08-15
in 387 days 		SBFM Sunshine Biopharma Inc. Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) Trial Phase 2 — $8B Primary completion for Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody I
2026-08-15
in 387 days 		CORT Corcept Therapeutics Incorporated Nab-paclitaxel 100 mg/m^2 Trial Phase 3 — $4B Primary completion for Nab-paclitaxel 80 mg/m^2 trial (NCT06906341) in Ovarian Cancer
2026-08-15
in 387 days 		DCPH Deciphera Pharmaceuticals, Inc. DCC-3084 Trial Phase 2 — $4B Primary completion for DCC-3084 trial (NCT06287463) in Advanced Solid Tumor
2026-08-15
in 387 days 		BCYC BICYCLE THERAPEUTICS PLC BT7480 Trial Phase 2 — $6B Primary completion for Nivolumab trial (NCT04180371) in Advanced Solid Tumor Historically
2026-08-15
in 387 days 		ANRO Alto Neuroscience, Inc. ALTO-203 25 μg Trial Phase 2 — $15B Primary completion for Placebo trial (NCT06656416) in Bipolar Disorder I or II With a Majo
2026-08-15
in 387 days 		ANRO Alto Neuroscience, Inc. ALTO-100 Trial Phase 2 — $10B Primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Maj
2026-08-15
in 387 days 		IPIX Innovation Pharmaceuticals Inc. S095029 Trial Phase 2 — $2B Primary completion for S095029 trial (NCT06116136) in MSI-H/dMMR Gastroesophageal-junction
2026-08-15
in 387 days 		CRIS CURIS INC Emavusertib Trial Phase 2 — $8B Primary completion for Emavusertib trial (NCT03328078) in Relapsed Hematologic Malignancy
2026-08-15
in 387 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Osimertinib Mesylate Tablets Trial Phase 2 — $15B Primary completion for Osimertinib Mesylate Tablets trial (NCT06498986) in Non-small Cell
2026-08-15
in 387 days 		IGC IGC Pharma, Inc. IGC-AD1-Active Trial Phase 2 — $15B Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
2026-08-17
in 389 days 		PRAX Praxis Precision Medicines · NDA Essential tremor (ET) — first therapy specifically designed for ET ulixacaltamide (PRAX-944 PDUFA — 90% $1B AUG 17 2026 111 days 💊 PDUFA (ulixacaltamide (PRAX-944)) $PRAX Praxis Precision Medicines
2026-08-17
in 389 days 		PFE PFIZER BAT Trial Phase 2 — $12B Primary completion for BAT trial (NCT05639647) in Gram-negative Bacterial Infections
2026-08-17
in 389 days 		PFE PFIZER ATM-AVI Trial Phase 3 — $1B Primary completion for ATM-AVI trial (NCT05639647) in Gram-negative Bacterial Infections
2026-08-18
in 390 days 		BIO BIO-RAD LABORATORIES, INC. FDA018-ADC Trial Phase 3 — $5B Primary completion for FDA018-ADC trial (NCT06519370) in Triple Negative Breast Cancer
2026-08-18
in 390 days 		MRK MERCK Raludotatug Deruxtecan (R-DXd) Trial Phase 2 — $15B Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti
2026-08-19
in 391 days 		MRK MERCK etoposide Trial Phase 3 — $15B Primary completion for etoposide trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
2026-08-19
in 391 days 		MRK MERCK Pemetrexed Trial Phase 3 — $8B Primary completion for pemetrexed trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
2026-08-19
in 391 days 		MRK MERCK Pembrolizumab/Vibostolimab Trial Phase 3 — $12B Primary completion for pembrolizumab/vibostolimab trial (NCT05298423) in Carcinoma, Non-Sm
2026-08-19
in 391 days 		MRK MERCK Cisplatin Trial Phase 3 — $8B Primary completion for Cisplatin trial (NCT04634877) in Endometrial Neoplasms
2026-08-19
in 391 days 		AZN AstraZeneca PLC 5-fluorouracil Trial Phase 3 — $8B Primary completion for 5-Fluorouracil trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Carboplatin Trial Phase 3 — $8B Primary completion for Carboplatin trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Leucovorin LV Trial Phase 2 — $4B Primary completion for Leucovorin LV trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 — $15B Primary completion for Volrustomig trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 — $12B Primary completion for Capecitabine trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Datopotamab deruxtecan (Dato-DXd) Trial Phase 3 — $15B Primary completion for Datopotamab deruxtecan (Dato-DXd) trial (NCT05489211) in Endometria
2026-08-19
in 391 days 		REGN Regeneron Pharmaceuticals, Inc. REGN7075 Trial Phase 2 — $6B Primary completion for REGN7075 trial (NCT04626635) in Advanced Solid Tumors
2026-08-20
in 392 days 		KALV KalVista Pharmaceuticals Hereditary angioedema (HAE) — on-demand oral treatment donidalorsen AdCom — 85% $1B AUG 20 2026 114 days 🏛️ AdCom (donidalorsen) $KALV KalVista Pharmaceuticals Hereditary ang
2026-08-20
in 392 days 		ARGX argenx SE Efgartigimod IV PDUFA Phase 3 — $1B For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K
2026-08-20
in 392 days 		AZNCF ASTRAZENECA PLC AZD7798 Trial Phase 2 — $8B Primary completion for AZD7798 trial (NCT06681324) in Crohn's Disease
2026-08-21
in 393 days 		NVO Novo Nordisk A/S Oral semaglutide Trial Phase 3 — $35B Primary completion for Oral semaglutide trial (NCT07271251) in Type 2 Diabetes
2026-08-21
in 393 days 		NVO Novo Nordisk A/S CagriSema (Cagrilintide B and Semaglutide I) Trial Phase 3 — $25B Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in
2026-08-22
in 394 days 		CAPR Capricor Therapeutics · BLA Duchenne muscular dystrophy (DMD) cardiomyopathy deramiocel PDUFA — 67% $1B AUG 22 2026 116 days 💊 PDUFA (deramiocel) $CAPR Capricor Therapeutics · BLA Duchenne muscu
2026-08-23
in 395 days 		PFE PFIZER PF-07220060 + PF-07104091 combination dose escalation Trial Phase 2 — $18B Primary completion for PF-07220060 + PF-07104091 combination dose escalation trial (NCT052
2026-08-24
in 396 days 		AZN AstraZeneca PLC AZD9833 Trial Phase 3 — $15B Primary completion for AZD9833 trial (NCT04711252) in ER-Positive HER2-Negative Breast Can
2026-08-24
in 396 days 		UCBJY UCB Brivaracetam Trial Phase 3 — $15B Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy
2026-08-24
in 396 days 		RHHBY Roche Holding AG RO7204239 Trial Phase 3 — $25B Primary completion for RO7204239 trial (NCT06965413) in Obesity
2026-08-25
in 397 days 		RHHBY Roche Holding AG Iberdomide PDUFA Phase 2 — $15B NDA filing. AI-extracted from news: FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdom
2026-08-25
in 397 days 		SNY Sanofi Rilzabrutinib dose 1 Trial Phase 2 — $2B Primary completion for Rilzabrutinib dose 1 trial (NCT06984627) in Graves' Disease
2026-08-27
in 399 days 		CLTS EARTH LIFE SCIENCES INC Lutetium (177Lu) rhPSMA-10.1 Injection Trial Phase 2 — $15B Primary completion for Lutetium (177Lu) rhPSMA-10.1 Injection trial (NCT05413850) in Prost
2026-08-28
in 400 days 		AZN AstraZeneca PLC AZD2936 Trial Phase 2 — $15B Primary completion for AZD2936 trial (NCT04995523) in Non-Small-Cell Lung Carcinoma
2026-08-28
in 400 days 		RHHBY Roche Holding AG Carboplatin Trial Phase 3 — $18B Primary completion for Carboplatin trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-28
in 400 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-28
in 400 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 — $15B Primary completion for Alectinib trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-28
in 400 days 		RHHBY Roche Holding AG Cisplatin Trial Phase 3 — $1B Primary completion for Cisplatin trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-30
in 402 days 		TAK TAKEDA PHARMACEUTICAL CO LTD Tetravalent Dengue Vaccine (TDV) Trial Phase 3 — $2B Primary completion for Tetravalent Dengue Vaccine (TDV) trial (NCT07047521) in Dengue Feve
2026-08-30
in 402 days 		PFE PFIZER Elranatamab Trial Phase 3 — $15B Primary completion for Elranatamab trial (NCT06152575) in Multiple Myeloma
2026-08-30
in 402 days 		PFE PFIZER Elotuzumab Trial Phase 3 — $15B Primary completion for Elotuzumab trial (NCT06152575) in Multiple Myeloma
2026-08-30
in 402 days 		IMNN Imunon, Inc. Paclitaxel Trial Phase 2 — $5B Primary completion for Paclitaxel trial (NCT05739981) in Ovarian Cancer
2026-08-31
in 403 days 		BAYRY BAYER BAY3723113 Trial Phase 3 — $2B Primary completion for BAY3723113 trial (NCT07023341) in Obstructive Hypertrophic Cardiomy
2026-08-31
in 403 days 		DSKYF Daiichi Sankyo Ramucirumab Trial Phase 3 — $3B Primary completion for Ramucirumab trial (NCT04704934) in Gastric Cancer, Adenocarcinoma
2026-08-31
in 403 days 		ALPMY Astellas Pharma Tamoxifen Trial Phase 3 — $3B Primary completion for Tamoxifen trial (NCT06440967) in Hot Flashes
2026-08-31
in 403 days 		ALPMY Astellas Pharma Fezolinetant Trial Phase 3 — $3B Primary completion for Fezolinetant trial (NCT06440967) in Hot Flashes
2026-08-31
in 403 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Wujia Yizhi granules Trial Phase 3 — $15B Primary completion for Wujia Yizhi granules trial (NCT06534723) in Alzheimer's Dementia
2026-08-31
in 403 days 		HNPHY Hansoh Pharmaceutical Group Co Limited/ADR HS-20093 Trial Phase 3 — $6B Primary completion for HS-20093 trial (NCT06935409) in Osteosarcoma
2026-08-31
in 403 days 		ALPMY Astellas Pharma nab-paclitaxel Trial Phase 2 — $8B Primary completion for nab-paclitaxel trial (NCT03816163) in Pancreatic Cancer
2026-08-31
in 403 days 		VSTM Verastem, Inc. avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel Trial Phase 2 — $8B Primary completion for avutometinib (VS-6766) and defactinib in combination with gemcitabi
2026-08-31
in 403 days 		IPSEY Ipsen Biopharmaceuticals, Inc. IPN10200 Trial Phase 3 — $2B Primary completion for IPN10200 trial (NCT04821089) in Moderate to Severe Upper Facial Lin
2026-08-31
in 403 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Dysport Trial Phase 2 — $3B Primary completion for Dysport trial (NCT04821089) in Moderate to Severe Upper Facial Line
2026-08-31
in 403 days 		4151.T Kyowa Kirin Co., Ltd. Aflibercept Injection Trial Phase 2 — $4B Primary completion for Aflibercept Injection trial (NCT06116916) in Diabetic Macular Edema
2026-08-31
in 403 days 		SNY Sanofi Belumosudil Trial Phase 3 — $2B Primary completion for Belumosudil trial (NCT05567406) in Chronic Graft Versus Host Diseas
2026-08-31
in 403 days 		4151.T Kyowa Kirin Co., Ltd. KHK4951 Trial Phase 2 — $8B Primary completion for KHK4951 trial (NCT06116890) in Neovascular Age-Related Macular Dege
2026-08-31
in 403 days 		ALPMY Astellas Pharma zolbetuximab Trial Phase 3 — $2B Primary completion for zolbetuximab trial (NCT03816163) in Pancreatic Cancer
2026-08-31
in 403 days 		SBFM Sunshine Biopharma Inc. SSGJ-706 Trial Phase 2 — $8B Primary completion for SSGJ-706 trial (NCT07171606) in First-line Advanced NSCLC Patients
2026-09-01
in 473 days 		BCYC Bicycle Therapeutics Metastatic urothelial carcinoma (Nectin-4 targeted) BT8009 Trial Readout 2 — $1B SEP 1 2026 126 days 🔬 Trial Readout (BT8009) $BCYC Bicycle Therapeutics Metastatic urothel
2026-09-01
in 473 days 		AZN AstraZeneca HR+/HER2- advanced breast cancer — first-line (frontline, traditional design) camizestrant — SERENA-4 Trial Readout 3 — $8B SEP 1 2026 126 days 🔬 Trial Readout (camizestrant — SERENA-4) $AZN AstraZeneca HR+/HER2- a
2026-09-01
in 473 days 		INCY Incyte Corporation Tafasitamab Trial Phase 3 — $5B Primary completion for Tafasitamab trial (NCT04824092) in Diffuse Large B-cell Lymphoma
2026-09-01
in 473 days 		INCY Incyte Corporation Prednisone Trial Phase 3 — $3B Primary completion for Prednisone trial (NCT04824092) in Diffuse Large B-cell Lymphoma
2026-09-01
in 473 days 		INCY Incyte Corporation Cyclophosphamide Trial Phase 3 — $5B Primary completion for Cyclophosphamide trial (NCT04824092) in Diffuse Large B-cell Lympho
2026-09-01
in 473 days 		INCY Incyte Corporation Lenalidomide Trial Phase 3 — $4B Primary completion for Lenalidomide trial (NCT04824092) in Diffuse Large B-cell Lymphoma
2026-09-01
in 473 days 		TGTX TG Therapeutics, Inc. Ublituximab Trial Phase 3 — $9B Primary completion for Ublituximab trial (NCT05877963) in Relapsing Multiple Sclerosis
2026-09-01
in 473 days 		NVO Novo Nordisk A/S NNC0519-0130 Trial Phase 2 — $35B Primary completion for NNC0519-0130 trial (NCT06717698) in Chronic Kidney Disease
2026-09-01
in 473 days 		NVO Novo Nordisk A/S Semaglutide Trial Phase 3 — $25B Primary completion for Semaglutide trial (NCT06717698) in Chronic Kidney Disease
2026-09-01
in 473 days 		PFE PFIZER Abemaciclib Trial Phase 3 — $18B Primary completion for ARV-471 trial (NCT05548127) in Breast Cancer
2026-09-02
in 474 days 		CFOO China Foods Holdings Ltd. Zurletrectinib PDUFA NDA — $3B For pediatric solid tumors. NDA filing. AI-extracted from news: InnoCare’s next-generation
2026-09-02
in 474 days 		AMGN Amgen Inc. Dazodalibep Trial Phase 3 — $2B Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)
2026-09-02
in 474 days 		TAK TAKEDA PHARMACEUTICAL CO LTD Rusfertide PDUFA NDA — $2B For Polycythemia Vera. NDA filing. AI-extracted from news: Takeda and Protagonist Announce
2026-09-02
in 474 days 		PFE PFIZER PF-07868489 Trial Phase 2 — $3B Primary completion for PF-07868489 trial (NCT06137742) in Pulmonary Arterial Hypertension
2026-09-03
in 475 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 — $25B Primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk
2026-09-06
in 478 days 		ICPT Intercept Pharmaceuticals, Inc. INT-787 Trial Phase 2 — $2B Primary completion for INT-787 trial (NCT05639543) in Alcohol Associated Hepatitis
2026-09-06
in 478 days 		ICPT Intercept Pharmaceuticals, Inc. Obeticholic acid (10 mg) Trial Phase 3 — $3B Primary completion for Placebo trial (NCT05639543) in Alcohol Associated Hepatitis
2026-09-07
in 479 days 		NVS Novartis AG EYU688 Trial Phase 2 — $1B Primary completion for EYU688 trial (NCT06006559) in Dengue
2026-09-09
in 481 days 		NVSEF NOVARTIS AG YTB323 Trial Phase 2 — $8B Primary completion for YTB323 trial (NCT05798117) in Systemic Lupus Erythematosus
2026-09-15
in 487 days 		GERN Geron Corporation Myelofibrosis (MF) — overall survival analysis Rytelo (imetelstat (Rytelo) — IMpact Trial Readout 3 — $2B SEP 15 2026 140 days 🔬 Trial Readout Rytelo (imetelstat (Rytelo) — IMpact...) $GERN Geron
2026-09-15
in 487 days 		ALNY Alnylam Pharmaceuticals · NDA Hypertension (RNA interference — twice-yearly injection) zilebesiran PDUFA — 90% $4B SEP 15 2026 140 days 💊 PDUFA (zilebesiran) $ALNY Alnylam Pharmaceuticals · NDA Hypertensio
2026-09-15
in 487 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 — $15B Primary completion for Lumateperone trial (NCT05850689) in Major Depressive Disorder
2026-09-15
in 487 days 		MRK MERCK Paclitaxel Trial Phase 3 — $12B Primary completion for Paclitaxel trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		MRK MERCK Carboplatin Trial Phase 3 — $4B Primary completion for Carboplatin trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		MRK MERCK docetaxel Trial Phase 3 — $4B Primary completion for Docetaxel trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		AVIR Atea Pharmaceuticals, Inc. Bemnifosbuvir-Ruzasvir (BEM/RZR) Trial Phase 3 — $8B Primary completion for Bemnifosbuvir-Ruzasvir (BEM/RZR) trial (NCT06868264) in HEPATITIS C
2026-09-15
in 487 days 		BIOE Bio Essence Corp Recombinant humanized anti-PD-1 monoclonal antibody injection Trial Phase 3 — $2B Primary completion for Recombinant humanized anti-PD-1 monoclonal antibody injection trial
2026-09-15
in 487 days 		ALKS Alkermes plc OLZ/SAM Trial Phase 3 — $12B Primary completion for OLZ/SAM trial (NCT05303064) in Schizophrenia
2026-09-15
in 487 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR STSP-0601 for Injection Trial Phase 3 — $8B Primary completion for STSP-0601 for Injection trial (NCT06922045) in Hemophilia
2026-09-15
in 487 days 		ARGX argenx SE empasiprubart Trial Phase 3 — $1B Primary completion for Empasiprubart trial (NCT06742190) in Multifocal Motor Neuropathy (M
2026-09-15
in 487 days 		SUPN SUPERNUS PHARMACEUTICALS, INC. SPN-812 Trial Phase 3 — $6B Primary completion for SPN-812 trial (NCT02736656) in Attention-Deficit/Hyperactivity Diso
2026-09-15
in 487 days 		LLY Eli Lilly and Company LY3650150 Trial Phase 3 — $3B Primary completion for LY3650150 trial (NCT06339008) in Perennial Allergic Rhinitis (PAR)
2026-09-15
in 487 days 		ABBV AbbVie Inc. Risankizumab Trial Phase 3 — $8B Primary completion for Risankizumab trial (NCT06100744) in Juvenile Psoriatic Arthritis
2026-09-15
in 487 days 		NVS Novartis AG Alpelisib Trial Phase 3 — $12B Primary completion for Alpelisib trial (NCT05038735) in Breast Cancer
2026-09-15
in 487 days 		NVS Novartis AG Fulvestrant Trial Phase 3 — $18B Primary completion for Fulvestrant trial (NCT05038735) in Breast Cancer
2026-09-15
in 487 days 		ALKS Alkermes plc ALKS 3831 Trial Phase 3 — $12B Primary completion for Olanzapine trial (NCT05303064) in Schizophrenia
2026-09-15
in 487 days 		MRK MERCK Cisplatin (as radiosensitizer) Trial Phase 3 — $4B Primary completion for Cisplatin (as radiosensitizer) trial (NCT04634877) in Endometrial N
2026-09-15
in 487 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 — $15B Primary completion for Tirzepatide trial (NCT05536804) in Overweight
2026-09-15
in 487 days 		CORT Corcept Therapeutics Incorporated Nenocorilant 200 mg Trial Phase 2 — $3B Primary completion for Nenocorilant 200 mg trial (NCT07276373) in Neoplasms
2026-09-15
in 487 days 		ZURA Zura Bio Ltd Tibulizumab Dose A Trial Phase 2 — $1B Primary completion for Tibulizumab Dose A trial (NCT06993610) in Hidradenitis Suppurativa
2026-09-15
in 487 days 		AGMB Agomab Therapeutics NV AGMB-129 Trial Phase 2 — $3B Primary completion for AGMB-129 trial (NCT05843578) in Fibrostenotic Crohn's Disease
2026-09-15
in 487 days 		SNDX Syndax Pharmaceuticals, Inc. Axatilimab Trial Phase 2 — $2B Primary completion for Axatilimab trial (NCT06132256) in Idiopathic Pulmonary Fibrosis
2026-09-15
in 487 days 		GILD Gilead Sciences, Inc. Seladelpar 10 mg Trial Phase 3 — $1B Primary completion for Placebo trial (NCT02932150) in Chronic Hepatitis B
2026-09-15
in 487 days 		VRNA VERONA PHARMA Nebulized Ensifentrine Suspension; 3 mg Trial Phase 2 — $2B Primary completion for Nebulized Ensifentrine Suspension; 3 mg trial (NCT06559150) in Non-
2026-09-15
in 487 days 		GILD Gilead Sciences, Inc. TAF Trial Phase 3 — $4B Primary completion for TAF trial (NCT02932150) in Chronic Hepatitis B
2026-09-15
in 487 days 		VNDA Vanda Pharmaceuticals Inc. VSJ-110 Trial Phase 2 — $6B Primary completion for VSJ-110 trial (NCT07179055) in Dry Eye
2026-09-15
in 487 days 		SLN Silence Therapeutics plc SLN360 Trial Phase 2 — $1B Primary completion for Placebo trial (NCT05499013) in Polycythemia Vera
2026-09-15
in 487 days 		ORIC Oric Pharmaceuticals, Inc. ORIC-114 Trial Phase 2 — $5B Primary completion for ORIC-114 trial (NCT05315700) in Solid Tumors
2026-09-15
in 487 days 		MOLN MOLECULAR PARTNERS AG PMD-026 Trial Phase 2 — $15B Primary completion for PMD-026 trial (NCT04115306) in Metastatic Breast Cancer
2026-09-15
in 487 days 		ORKA Oruka Therapeutics, Inc. ORKA-001 Induction Dose Trial Phase 2 — $12B Primary completion for ORKA-001 Induction Dose trial (NCT07090330) in Plaque Psoriasis
2026-09-15
in 487 days 		LLY Eli Lilly and Company LY3537021 Trial Phase 2 — $3B Primary completion for LY3537021 trial (NCT07169851) in Nausea
2026-09-15
in 487 days 		SLN Silence Therapeutics plc SLN124 Trial Phase 2 — $2B Primary completion for SLN124 trial (NCT05499013) in Polycythemia Vera
2026-09-15
in 487 days 		MGNX MacroGenics, Inc. lorigerlimab Trial Phase 2 — $8B Primary completion for lorigerlimab trial (NCT05848011) in Androgen-Independent Prostatic
2026-09-15
in 487 days 		VERA Vera Therapeutics, Inc. Atacicept Trial Phase 3 — $2B Primary completion for Atacicept trial (NCT07020923) in IgA Nephropathy (IgAN)
2026-09-15
in 487 days 		MAZE Maze Therapeutics, Inc. MZE829 Trial Phase 2 — $2B Primary completion for MZE829 trial (NCT06830629) in Proteinuric Kidney Disease
2026-09-15
in 487 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR PRT-064040 nasal spray Trial Phase 2 — $8B Primary completion for PRT-064040 nasal spray trial (NCT07304518) in Migraine
2026-09-15
in 487 days 		SBFM Sunshine Biopharma Inc. 610 Trial Phase 3 — $20B Primary completion for 610 trial (NCT06680947) in Asthma
2026-09-15
in 487 days 		VNDA Vanda Pharmaceuticals Inc. Trichostatin A Trial Phase 2 — $1B Primary completion for Trichostatin A trial (NCT07065773) in Onychomycosis of Toenail
2026-09-15
in 487 days 		BIO BIO-RAD LABORATORIES, INC. TOUR006 - 20 MG Trial Phase 2 — $2B Primary completion for TOUR006 - 20 MG trial (NCT06088979) in Thyroid Eye Disease
2026-09-15
in 487 days 		PCSA Processa Pharmaceuticals, Inc. PCS6422 and capecitabine Trial Phase 2 — $18B Primary completion for PCS6422 and capecitabine trial (NCT06568692) in Breast Cancer
2026-09-15
in 487 days 		SVA SINOVAC BIOTECH LTD Sinovac PCV24 Trial Phase 2 — $8B Primary completion for Sinovac PCV24 trial (NCT07300644) in Pneumococcal Infectious Diseas
2026-09-15
in 487 days 		GILD Gilead Sciences, Inc. Pembrolizumab Trial Phase 2 — $15B Primary completion for Sacituzumab Govitecan-hziy (SG) trial (NCT05186974) in Non-small Ce
2026-09-15
in 487 days 		KPTI Karyopharm Therapeutics Inc. Selinexor Trial Phase 3 — $8B Primary completion for Selinexor trial (NCT04562870) in Myelofibrosis
2026-09-15
in 487 days 		BHVN Biohaven Pharmaceutical Holding Company Ltd. Taldefgrobep Alfa Trial Phase 3 — $25B Primary completion for Taldefgrobep Alfa trial (NCT07281495) in Obesity
2026-09-15
in 487 days 		CORT Corcept Therapeutics Incorporated Dazucorilant 300 mg Trial Phase 2 — $2B Primary completion for Dazucorilant 300 mg trial (NCT05407324) in Amyotrophic Lateral Scle
2026-09-15
in 487 days 		CORT Corcept Therapeutics Incorporated Miricorilant (Cohort A) Trial Phase 2 — $8B Primary completion for Miricorilant (Cohort A) trial (NCT06108219) in Nonalcoholic Steatoh
2026-09-15
in 487 days 		CYTK Cytokinetics, Incorporated CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Trial Phase 2 — $15B Primary completion for CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) trial (NCT06793371)
2026-09-15
in 487 days 		IRON Disc Medicine, Inc. DISC-0974 Trial Phase 2 — $2B Primary completion for DISC-0974 trial (NCT05320198) in Myelofibrosis; Anemia
2026-09-15
in 487 days 		TEVA Teva Pharmaceutical Industries Limited TEV-53408 Trial Phase 2 — $2B Primary completion for TEV-53408 trial (NCT06807463) in Celiac Disease
2026-09-17
in 489 days 		SNY Sanofi Belumosudil Trial Phase 3 — $2B Primary completion for Belumosudil trial (NCT06082037) in Lung Transplant Rejection
2026-09-17
in 489 days 		VRTX Vertex Pharmaceuticals Incorporated Biological/Vaccine Trial Phase 3 — $15B Primary completion for Biological/Vaccine trial (NCT06832410) in Type 1 Diabetes
2026-09-17
in 489 days 		GSK GSK plc Flu mRNA (Formulation B1) Trial Phase 2 — $6B Primary completion for Flu mRNA (Formulation B1) trial (NCT07204964) in Influenza, Human
2026-09-18
in 490 days 		MRK MERCK Nemtabrutinib Trial Phase 3 — $4B Primary completion for Nemtabrutinib trial (NCT03162536) in Lymphoma, B-Cell
2026-09-18
in 490 days 		TKPHF TAKEDA PHARMACEUTICAL CO LTD TAK-279 Trial Phase 3 — $8B Primary completion for TAK-279 trial (NCT06233461) in Crohn's Disease
2026-09-21
in 493 days 		CRDL Cardiol Therapeutics Inc. CardiolRx Trial Phase 3 — $1B Primary completion for CardiolRx trial (NCT06708299) in Recurrent Pericarditis
2026-09-21
in 493 days 		NVS Novartis AG VHB937 Trial Phase 2 — $2B Primary completion for VHB937 trial (NCT06643481) in Amyotrophic Lateral Sclerosis (ALS)
2026-09-21
in 493 days 		PFE PFIZER PF-07275315 Trial Phase 2 — $20B Primary completion for PF-07275315 trial (NCT05995964) in Atopic Dermatitis
2026-09-22
in 494 days 		ONC BeOne Medicines Ltd. Sonrotoclax Trial Phase 3 — $2B Primary completion for Sonrotoclax trial (NCT05952037) in Waldenstrom Macroglobulinemia
2026-09-27
in 499 days 		PRAX Praxis Precision Medicines · NDA SCN2A- and SCN8A-related developmental and epileptic encephalopathi relutrigine PDUFA — 93% $1B SEP 27 2026 152 days 💊 PDUFA (relutrigine) $PRAX Praxis Precision Medicines · NDA SCN2A- a
2026-09-28
in 500 days 		RHHBY Roche Holding AG Inavolisib Trial Phase 3 — $18B Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer
2026-09-28
in 500 days 		RHHBY Roche Holding AG Phesgo Trial Phase 3 — $15B Primary completion for Phesgo trial (NCT05894239) in Metastatic Breast Cancer
2026-09-28
in 500 days 		RHHBY Roche Holding AG Optional Endocrine Therapy of Investigator's Choice Trial Phase 3 — $15B Primary completion for Optional Endocrine Therapy of Investigator's Choice trial (NCT05894
2026-09-28
in 500 days 		RHHBY Roche Holding AG Taxane-based chemotherapy Trial Phase 3 — $18B Primary completion for Taxane-based Chemotherapy trial (NCT05894239) in Metastatic Breast
2026-09-28
in 500 days 		RHHBY Roche Holding AG peginterferon alfa-2a [Pegasys] Trial Phase 3 — $2B Primary completion for Placebo trial (NCT05894239) in Metastatic Breast Cancer
2026-09-28
in 500 days 		INCY Incyte Corporation INCB099280 Trial Phase 2 — $2B Primary completion for INCB099280 trial (NCT05888844) in Cutaneous Squamous Cell Carcinoma
2026-09-28
in 500 days 		AZN AstraZeneca PLC AZD0901 Trial Phase 2 — $3B Primary completion for AZD0901 trial (NCT07143604) in Gastric Cancer
2026-09-30
in 502 days 		ROIV Priovant Therapeutics / Roivant Sciences · NDA Dermatomyositis (DM) — inflammatory myopathy brepocitinib PDUFA — 93% $2B SEP 30 2026 155 days 💊 PDUFA (brepocitinib) $ROIV Priovant Therapeutics / Roivant Sciences
2026-09-30
in 502 days 		AZN AstraZeneca PLC Pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT06417814) in Metastatic Non-small Cell Lung Ca
2026-09-30
in 502 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR Topotecan Trial Phase 3 — $4B Primary completion for Topotecan trial (NCT06498479) in Small Cell Lung Cancer
2026-09-30
in 502 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-20093 Trial Phase 3 — $8B Primary completion for HS-20093 trial (NCT06498479) in Small Cell Lung Cancer
2026-09-30
in 502 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 — $15B Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity
2026-09-30
in 502 days 		BIO BIO-RAD LABORATORIES, INC. JMT101 Trial Phase 3 — $6B Primary completion for JMT101 trial (NCT06735391) in Locally Advanced or Metastatic Non-sq
2026-09-30
in 502 days 		BIIB Biogen Inc. Litifilimab Trial Phase 3 — $4B Primary completion for Litifilimab trial (NCT05531565) in Subacute Cutaneous Lupus Erythem
2026-09-30
in 502 days 		ISCO International Stem Cell CORP NaBen® Trial Phase 3 — $2B Primary completion for NaBen® trial (NCT03094429) in Refractory Schizophrenia
2026-09-30
in 502 days 		AZN AstraZeneca PLC Cisplatin Trial Phase 3 — $2B Primary completion for Cisplatin trial (NCT06417814) in Metastatic Non-small Cell Lung Can
2026-09-30
in 502 days 		AZN AstraZeneca PLC Carboplatin Trial Phase 3 — $8B Primary completion for Carboplatin trial (NCT06417814) in Metastatic Non-small Cell Lung C
2026-09-30
in 502 days 		AZN AstraZeneca PLC Dato-DXd Trial Phase 3 — $18B Primary completion for Dato-DXd trial (NCT06417814) in Metastatic Non-small Cell Lung Canc
2026-09-30
in 502 days 		AZN AstraZeneca PLC Osimertinib Trial Phase 3 — $12B Primary completion for Osimertinib trial (NCT06417814) in Metastatic Non-small Cell Lung C
2026-09-30
in 502 days 		GSK GSK plc GSK4527226 Trial Phase 2 — $15B Primary completion for GSK4527226 trial (NCT06079190) in Alzheimer's Disease
2026-09-30
in 502 days 		TAK TAKEDA PHARMACEUTICAL CO LTD TAK-279 Trial Phase 3 — $12B Primary completion for TAK-279 trial (NCT06254950) in Ulcerative Colitis
2026-09-30
in 502 days 		RHHBY Roche Holding AG Glofitamab Trial Phase 3 — $5B Primary completion for Glofitamab trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-09-30
in 502 days 		RHHBY Roche Holding AG Vincristine Trial Phase 3 — $9B Primary completion for Vincristine trial (NCT04980222) in Lymphoma
2026-09-30
in 502 days 		BMRN BioMarin Pharmaceutical Inc. BMN 351 Trial Phase 2 — $1B Primary completion for BMN 351 trial (NCT06280209) in Duchenne Muscular Dystrophy
2026-09-30
in 502 days 		BIO BIO-RAD LABORATORIES, INC. JIN-A02 Trial Phase 2 — $7B Primary completion for JIN-A02 trial (NCT05394831) in EGFR Mutant Advanced Non-small Cell
2026-09-30
in 502 days 		TPTX Turning Point Therapeutics, Inc. Oral repotrectinib (TPX-0005) Trial Phase 2 — $4B Primary completion for Oral repotrectinib (TPX-0005) trial (NCT04094610) in Locally Advanc
2026-09-30
in 502 days 		AZN AstraZeneca PLC Rosuvastatin Trial Phase 3 — $28B Primary completion for Rosuvastatin trial (NCT07218900) in Dyslipidaemia
2026-09-30
in 502 days 		BIOE Bio Essence Corp Fruquintinib Trial Phase 2 — $8B Primary completion for Fruquintinib trial (NCT07235293) in Colorectal Cancer
2026-09-30
in 502 days 		RHHBY Roche Holding AG Doxorubicin Trial Phase 3 — $6B Primary completion for Doxorubicin trial (NCT04980222) in Lymphoma
2026-09-30
in 502 days 		AZN AstraZeneca PLC AZD0780 Trial Phase 3 — $4B Primary completion for AZD0780 trial (NCT07218900) in Dyslipidaemia
2026-09-30
in 502 days 		GNTA Genenta Science S.p.A. Pembrolizumab Trial Phase 2 — $4B Primary completion for Pembrolizumab trial (NCT06716853) in Clear Cell RCC
2026-09-30
in 502 days 		DSKYF Daiichi Sankyo CS-1008 Trial Phase 2 — $15B Primary completion for Carboplatin trial (NCT06362252) in Extensive Stage-small Cell Lung
2026-09-30
in 502 days 		DSKYF Daiichi Sankyo Ifinatamab deruxtecan Trial Phase 3 — $2B Primary completion for Ifinatamab deruxtecan trial (NCT06362252) in Extensive Stage-small
2026-09-30
in 502 days 		RHHBY Roche Holding AG Prednisone Trial Phase 3 — $15B Primary completion for Prednisone trial (NCT04980222) in Lymphoma
2026-09-30
in 502 days 		RHHBY Roche Holding AG tocilizumab Trial Phase 3 — $25B Primary completion for Tocilizumab trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-09-30
in 502 days 		QURE uniQure N.V. AMT-162 Trial Phase 2 — $2B Primary completion for AMT-162 trial (NCT06100276) in Amyotrophic Lateral Sclerosis
2026-10-01
in 573 days 		REGN Regeneron · BLA VEXAS syndrome (complement C5 inhibitor) pozelimab PDUFA — 93% $2B OCT 1 2026 156 days 💊 PDUFA (pozelimab) $REGN Regeneron · BLA VEXAS syndrome (complement C
2026-10-01
in 573 days 		ARGX argenx SE Efgartigimod PH20 SC Trial Phase 3 — $1B Primary completion for Efgartigimod PH20 SC trial (NCT06392386) in Generalized Myasthenia
2026-10-01
in 573 days 		GSK GSK plc Belumosudil PDUFA NDA — $2B For chronic graft-versus-host disease. NDA filing. Extracted from SEC filing: 6-K
2026-10-01
in 573 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 — $25B Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure
2026-10-01
in 573 days 		NVS Novartis AG Iptacopan (LNP023) Trial Phase 3 — $2B Primary completion for Iptacopan (LNP023) trial (NCT05230537) in Age-Related Macular Degen
2026-10-02
in 574 days 		TKPHF TAKEDA PHARMACEUTICAL CO LTD TAK-861 Trial Phase 3 — $2B Primary completion for TAK-861 trial (NCT07363720) in Narcolepsy Type 1 (NT1)
2026-10-05
in 577 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 — $25B Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure
2026-10-05
in 577 days 		MRNA Moderna, Inc. mRNA-1189 Trial Phase 2 — $1B Primary completion for mRNA-1189 trial (NCT05164094) in Epstein-Barr Virus Infection
2026-10-05
in 577 days 		RHHBY Roche Holding AG Afimkibart Trial Phase 3 — $8B Primary completion for Afimkibart trial (NCT06863961) in Atopic Dermatitis
2026-10-06
in 578 days 		AZN AstraZeneca PLC Benralizumab Trial Phase 3 — $20B Primary completion for Benralizumab trial (NCT06512883) in Eosinophilic Granulomatosis Wit
2026-10-07
in 579 days 		REGN Regeneron Pharmaceuticals, Inc. Dupilumab Trial Phase 3 — $8B Primary completion for Dupilumab trial (NCT02612454) in Atopic Dermatitis
2026-10-08
in 580 days 		PFE PFIZER Rimegepant Trial Phase 3 — $4B Primary completion for Rimegepant trial (NCT06616194) in Migraine
2026-10-09
in 581 days 		AZN AstraZeneca PLC AZD7760 Trial Phase 2 — $3B Primary completion for AZD7760 trial (NCT06749457) in Staphylococcus Aureus
2026-10-09
in 581 days 		TECX Tectonic Therapeutic, Inc. TX000045- Dose A Trial Phase 2 — $4B Primary completion for TX000045- Dose A trial (NCT06616974) in Pulmonary Hypertension
2026-10-13
in 585 days 		BIOE Bio Essence Corp JSKN003 Trial Phase 3 — $12B Primary completion for JSKN003 trial (NCT06846437) in Unrespectable Locally Advanced and o
2026-10-13
in 585 days 		GSK GSK plc Cobolimab Trial Phase 2 — $8B Primary completion for Cobolimab trial (NCT06521567) in Melanoma
2026-10-14
in 586 days 		GSK GSK plc Momelotinib Trial Phase 3 — $2B Primary completion for Momelotinib trial (NCT06517875) in Primary Myelofibrosis
2026-10-14
in 586 days 		GSK GSK plc Luspatercept Trial Phase 2 — $2B Primary completion for Luspatercept trial (NCT06517875) in Primary Myelofibrosis
2026-10-15
in 587 days 		LLY Eli Lilly and Company LY3537982 Trial Phase 3 — $15B Primary completion for LY3537982 trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		XENE Xenon Pharmaceuticals Inc. XEN1101 Trial Phase 3 — $4B Primary completion for XEN1101 trial (NCT05716100) in Focal Onset Seizures
2026-10-15
in 587 days 		TENX TENAX THERAPEUTICS, INC. TNX-103 Trial Phase 3 — $4B Primary completion for TNX-103 trial (NCT05983250) in Pulmonary Hypertension
2026-10-15
in 587 days 		ABBV AbbVie Inc. Aflibercept (EYLEA®) Trial Phase 3 — $15B Primary completion for Aflibercept (EYLEA®) trial (NCT05407636) in AMD
2026-10-15
in 587 days 		EYPT EyePoint Pharmaceuticals, Inc. Aflibercept (2.0 mg) Trial Phase 3 — $6B Primary completion for Aflibercept (2.0 mg) trial (NCT06683742) in Wet Age Related Macular
2026-10-15
in 587 days 		HUMA Humacyte, Inc. Acellular Tissue Engineered Vessel (ATEV) Trial Phase 3 — $10B Primary completion for Acellular Tissue Engineered Vessel (ATEV) trial (NCT05908084) in En
2026-10-15
in 587 days 		MESO MESOBLAST LTD Rexlemestrocel-L + HA mixture Trial Phase 3 — $2B Primary completion for Rexlemestrocel-L + HA mixture trial (NCT06325566) in Degenerative D
2026-10-15
in 587 days 		EYPT EyePoint Pharmaceuticals, Inc. EYP-1901 Trial Phase 3 — $4B Primary completion for EYP-1901 trial (NCT06683742) in Wet Age Related Macular Degeneratio
2026-10-15
in 587 days 		SBFM Sunshine Biopharma Inc. Clascoterone Trial Phase 3 — $3B Primary completion for Clascoterone trial (NCT06403501) in Acne Vulgaris
2026-10-15
in 587 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 — $25B Primary completion for Retatrutide trial (NCT06297603) in Type 2 Diabetes
2026-10-15
in 587 days 		LLY Eli Lilly and Company carboplatin Trial Phase 3 — $18B Primary completion for Carboplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		CODX Co-Diagnostics, Inc. Tapinarof cream, 1% Trial Phase 3 — $12B Primary completion for tapinarof cream, 1% trial (NCT05172726) in Plaque Psoriasis
2026-10-15
in 587 days 		LLY Eli Lilly and Company pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		LLY Eli Lilly and Company cisplatin Trial Phase 3 — $15B Primary completion for Cisplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		URGN UroGen Pharma Ltd. UGN-104 Trial Phase 3 — $2B Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carci
2026-10-15
in 587 days 		LLY Eli Lilly and Company Pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		VNDA Vanda Pharmaceuticals Inc. iloperidone Trial Phase 3 — $12B Primary completion for iloperidone trial (NCT07090161) in Hypertension
2026-10-15
in 587 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR BL-B01D1 for Injection Trial Phase 2 — $2B Primary completion for BL-B01D1 for Injection trial (NCT06598787) in Recurrent Glioblastom
2026-10-15
in 587 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 — $50B Primary completion for Aleniglipron trial (NCT07400588) in Obese
2026-10-15
in 587 days 		BIO BIO-RAD LABORATORIES, INC. TRIV-509 Trial Phase 2 — $8B Primary completion for TRIV-509 trial (NCT07167758) in Atopic Dermatitis
2026-10-15
in 587 days 		SUPN SUPERNUS PHARMACEUTICALS, INC. SPN-817 Trial Phase 2 — $3B Primary completion for SPN-817 trial (NCT06798896) in Focal Onset Seizures
2026-10-15
in 587 days 		GILD Gilead Sciences, Inc. Optimized Background Regimen (OBR) Trial Phase 3 — $28B Primary completion for Optimized Background Regimen (OBR) trial (NCT06749054) in HIV-1-inf
2026-10-15
in 587 days 		GILD Gilead Sciences, Inc. Oral Lenacapavir Trial Phase 3 — $28B Primary completion for Oral Lenacapavir trial (NCT06749054) in HIV-1-infection
2026-10-15
in 587 days 		GILD Gilead Sciences, Inc. Sacituzumab Govitecan-hziy Trial Phase 3 — $5B Primary completion for Sacituzumab Govitecan-hziy trial (NCT05119907) in Solid Tumor
2026-10-15
in 587 days 		RAPP Rapport Therapeutics, Inc. RAP-219 Trial Phase 2 — $3B Primary completion for RAP-219 trial (NCT07046494) in Bipolar 1 Disorder
2026-10-15
in 587 days 		ABOS Acumen Pharmaceuticals, Inc. sabirnetug Trial Phase 2 — $15B Primary completion for sabirnetug trial (NCT06335173) in Alzheimer Disease
2026-10-15
in 587 days 		IMCR Immunocore Holdings plc Brenetafusp Trial Phase 3 — $3B Primary completion for Brenetafusp trial (NCT04262466) in Select Advanced Solid Tumors
2026-10-15
in 587 days 		IPIX Innovation Pharmaceuticals Inc. GI-101 Trial Phase 2 — $15B Primary completion for GI-101 trial (NCT04977453) in Advanced Solid Tumor
2026-10-15
in 587 days 		MPLT MapLight Therapeutics, Inc. ML-004 (IR)/(ER) tablet Trial Phase 2 — $2B Primary completion for ML-004 (IR)/(ER) tablet trial (NCT05081245) in Autism Spectrum Diso
2026-10-15
in 587 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR BL-M07D1 Trial Phase 3 — $2B Primary completion for BL-M07D1 trial (NCT06423885) in HER2-positive Gastric or Gastroesop
2026-10-15
in 587 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR PD-1 monoclonal antibody Trial Phase 2 — $4B Primary completion for PD-1 monoclonal antibody trial (NCT06423885) in HER2-positive Gastr
2026-10-16
in 588 days 		RHHBY Roche Holding AG Atezolizumab Trial Phase 3 — $6B Primary completion for Atezolizumab trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-10-16
in 588 days 		RHHBY Roche Holding AG Polatuzumab Vedotin Trial Phase 3 — $9B Primary completion for Polatuzumab Vedotin trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-10-16
in 588 days 		RHHBY Roche Holding AG Obinutuzumab Trial Phase 3 — $4B Primary completion for Obinutuzumab trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-10-16
in 588 days 		RHHBY Roche Holding AG 89Zr-Df-IAB22M2C Trial Phase 2 — $9B Primary completion for 89Zr-Df-IAB22M2C trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-10-18
in 590 days 		BGNE BeiGene, Ltd. BGB-45035 Trial Phase 2 — $25B Primary completion for BGB-45035 trial (NCT07100938) in Rheumatoid Arthritis
2026-10-19
in 591 days 		INCY Incyte Corporation Povorcitinib Trial Phase 3 — $2B Primary completion for Povorcitinib trial (NCT06516965) in Prurigo Nodularis
2026-10-19
in 591 days 		PFE PFIZER PF-07264660 Trial Phase 2 — $8B Primary completion for PF-07264660 trial (NCT05995964) in Atopic Dermatitis
2026-10-19
in 591 days 		AMGN Amgen Inc. Rocatinlimab Trial Phase 3 — $20B Primary completion for Rocatinlimab trial (NCT06376045) in Asthma
2026-10-20
in 592 days 		KALV KalVista Pharmaceuticals · NDA Hereditary angioedema (HAE) — on-demand oral treatment donidalorsen PDUFA — 93% $2B OCT 20 2026 175 days 💊 PDUFA (donidalorsen) $KALV KalVista Pharmaceuticals · NDA Hereditar
2026-10-20
in 592 days 		OTSKF OTSUKA SEP-363856 Trial Phase 3 — $12B Primary completion for SEP-363856 trial (NCT06894212) in Schizophrenia
2026-10-20
in 592 days 		BIIB Biogen Inc. SAGE-217 Trial Phase 3 — $8B Primary completion for Placebo trial (NCT05531565) in Subacute Cutaneous Lupus Erythematos
2026-10-22
in 594 days 		AMGN Amgen Inc. Dazodalibep Trial Phase 3 — $2B Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)
2026-10-23
in 595 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 — $15B Primary completion for Durvalumab trial (NCT06040099) in Hepatocellular Carcinoma (HCC)
2026-10-26
in 598 days 		NVS Novartis AG Inclisiran sodium 300 mg Trial Phase 3 — $18B Primary completion for Inclisiran sodium 300 mg trial (NCT05360446) in Coronary Artery Dis
2026-10-26
in 598 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Cabozantinib Trial Phase 2 — $4B Primary completion for Cabozantinib trial (NCT06341712) in Osteosarcoma
2026-10-27
in 599 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 — $15B Primary completion for Volrustomig trial (NCT05775159) in Hepatocellular Carcinoma
2026-10-27
in 599 days 		AZN AstraZeneca PLC Lenvatinib Trial Phase 2 — $4B Primary completion for Lenvatinib trial (NCT05775159) in Hepatocellular Carcinoma
2026-10-28
in 600 days 		MRK MERCK Belzutifan Trial Phase 3 — $8B Primary completion for Belzutifan trial (NCT05239728) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK Belzutifan Trial Phase 3 — $8B Primary completion for Belzutifan trial (NCT04736706) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK Lenvatinib Trial Phase 3 — $15B Primary completion for Lenvatinib trial (NCT04736706) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04736706) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK Pembrolizumab/Quavonlimab Trial Phase 3 — $8B Primary completion for Pembrolizumab/Quavonlimab trial (NCT04736706) in Carcinoma, Renal C
2026-10-29
in 601 days 		MRK MERCK tildrakizumab PDUFA Phase 2 — $12B For Adults with Active Psoriatic Arthritis If the sBLA is approved. sbla filing. AI-extra
2026-10-30
in 602 days 		CYTK Cytokinetics · sNDA Obstructive HCM — aficamten vs MYQORZO (supplemental) (aficamten (MAPLE-HCM sNDA PDUFA — 92% $8B OCT 30 2026 185 days 💊 PDUFA MYQORZO (supplemental) (aficamten (MAPLE-HCM sNDA)) $CYTK Cyt
2026-10-30
in 602 days 		VRTX Vertex Pharmaceuticals Incorporated VX-121/TEZ/D-IVA Trial Phase 3 — $6B Primary completion for VX-121/TEZ/D-IVA trial (NCT05444257) in Cystic Fibrosis
2026-10-30
in 602 days 		AMGN Amgen Inc. Rocatinlimab Trial Phase 3 — $20B Primary completion for Rocatinlimab trial (NCT06527404) in Prurigo Nodularis
2026-10-30
in 602 days 		BNTX BioNTech SE BNT162b2 (2025/2026 formulation) Trial Phase 3 — $15B Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19
2026-10-30
in 602 days 		SNYNF Sanofi venglustat (GZ402671) Trial Phase 2 — $2B Primary completion for venglustat (GZ402671) trial (NCT02843035) in Gaucher Disease Type 1
2026-10-30
in 602 days 		INBX Inhibrx Biosciences, Inc. INBRX-106 - Hexavalent OX40 agonist antibody Trial Phase 2 — $13B Primary completion for INBRX-106 - Hexavalent OX40 agonist antibody trial (NCT04198766) in
2026-10-31
in 603 days 		RHHBY Roche Holding AG Carboplatin Trial Phase 3 — $18B Primary completion for Carboplatin trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Gemcitabine Trial Phase 3 — $8B Primary completion for Gemcitabine trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Cisplatin Trial Phase 3 — $1B Primary completion for Cisplatin trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Docetaxel Trial Phase 3 — $15B Primary completion for Docetaxel trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		AZN AstraZeneca PLC Fulvestrant Trial Phase 3 — $18B Primary completion for Fulvestrant trial (NCT06635447) in Breast Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Bevacizumab Trial Phase 3 — $6B Primary completion for Bevacizumab trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Cobimetinib Trial Phase 3 — $8B Primary completion for Cobimetinib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Entrectinib Trial Phase 3 — $18B Primary completion for Entrectinib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Atezolizumab Trial Phase 3 — $6B Primary completion for Atezolizumab trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 — $15B Primary completion for Alectinib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Vemurafenib Trial Phase 3 — $8B Primary completion for Vemurafenib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Divarasib Trial Phase 3 — $15B Primary completion for Divarasib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		AZN AstraZeneca PLC Capivasertib Trial Phase 3 — $5B Primary completion for Capivasertib trial (NCT06635447) in Breast Cancer
2026-10-31
in 603 days 		TKPHF TAKEDA PHARMACEUTICAL CO LTD TAK-788 Trial Phase 3 — $8B Primary completion for TAK-788 trial (NCT04129502) in Advanced/Metastatic Non-Small Cell L
2026-10-31
in 603 days 		IPIX Innovation Pharmaceuticals Inc. Cenerimod Trial Phase 3 — $4B Primary completion for Cenerimod trial (NCT05648500) in Lupus Erythematosus, Systemic
2026-10-31
in 603 days 		IMMP Immutep Limited eftilagimod alpha Trial Phase 3 — $18B Primary completion for eftilagimod alpha trial (NCT05747794) in Breast Carcinoma
2026-10-31
in 603 days 		TEVA Teva Pharmaceutical Industries Limited TEV-56248 Trial Phase 3 — $20B Primary completion for TEV-56248 trial (NCT06052267) in Asthma
2026-10-31
in 603 days 		SRPT Sarepta Therapeutics, Inc. Eteplirsen Trial Phase 3 — $1B Primary completion for Eteplirsen trial (NCT03992430) in Muscular Dystrophy, Duchenne
2026-10-31
in 603 days 		ANNX Annexon, Inc. Vonaprument Trial Phase 3 — $4B Primary completion for Vonaprument trial (NCT06510816) in Geographic Atrophy
2026-10-31
in 603 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR6390 Trial Phase 3 — $12B Primary completion for SHR6390 trial (NCT04842617) in Hormone Receptor Positive,Human Epid
2026-10-31
in 603 days 		RHHBY Roche Holding AG Axitinib Trial Phase 2 — $8B Primary completion for Tiragolumab trial (NCT05805501) in Renal Cell Carcinoma
2026-10-31
in 603 days 		JSPR Jasper Therapeutics, Inc. Briquilimab Trial Phase 2 — $3B Primary completion for Briquilimab trial (NCT06162728) in Chronic Spontaneous Urticaria
2026-10-31
in 603 days 		ACRV Acrivon Therapeutics, Inc. ACR-368 Trial Phase 2 — $3B Primary completion for ACR-368 trial (NCT05548296) in Endometrial Adenocarcinoma
2026-10-31
in 603 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 — $15B Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome
2026-10-31
in 603 days 		TAK TAKEDA PHARMACEUTICAL CO LTD TAK-788 Trial Phase 2 — $15B Primary completion for TAK-788 trial (NCT02716116) in Carcinoma, Non-Small-Cell Lung
2026-10-31
in 603 days 		SYRE Spyre Therapeutics, Inc. SPY002-072 Trial Phase 2 — $25B Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis
2026-10-31
in 603 days 		RHHBY Roche Holding AG Nab-paclitaxel Trial Phase 3 — $15B Primary completion for Nab-Paclitaxel trial (NCT05852691) in Breast Cancer
2026-10-31
in 603 days 		ADAG Adagene Inc. ADG126 Trial Phase 2 — $15B Primary completion for ADG126 trial (NCT05405595) in Advanced/Metastatic Solid Tumors
2026-10-31
in 603 days 		RHHBY Roche Holding AG Tobemstomig Trial Phase 2 — $5B Primary completion for Tobemstomig trial (NCT05852691) in Breast Cancer
2026-11-01
in 673 days 		BMY Bristol-Myers Squibb Company KarXT Trial Phase 3 — $8B Primary completion for KarXT trial (NCT06951698) in Bipolar-I Disorder With Mania or Mania
2026-11-01
in 673 days 		SRRK Scholar Rock Holding Corporation Apitegromab Trial Phase 3 — $2B Primary completion for Apitegromab trial (NCT05626855) in Spinal Muscular Atrophy
2026-11-01
in 673 days 		OTSKF OTSUKA JNT-517 Tablet Trial Phase 3 — $1B Primary completion for JNT-517 Tablet trial (NCT06971731) in Phenylketonuria
2026-11-01
in 673 days 		SMMT Summit Therapeutics Inc. Drug: Ivonescimab Injection PDUFA Phase 3 — $8B Extracted from: Summit gets November PDUFA date for its PD-1xVEGF bispecific
2026-11-01
in 673 days 		CRBP Corbus Pharmaceuticals Holdings, Inc. CRB-601 monoclonal antibody Trial Phase 2 — $14B Primary completion for CRB-601 monoclonal antibody trial (NCT06603844) in Solid Tumor
2026-11-02
in 674 days 		GSK GSK plc Dostarlimab Trial Phase 3 — $4B Primary completion for Dostarlimab trial (NCT05723562) in Neoplasms, Rectal
2026-11-03
in 675 days 		REGN Regeneron Pharmaceuticals, Inc. Dupilumab Trial Phase 3 — $8B Primary completion for Placebo trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma
2026-11-03
in 675 days 		REGN Regeneron Pharmaceuticals, Inc. cemiplimab Trial Phase 3 — $1B Primary completion for Cemiplimab trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma
2026-11-03
in 675 days 		BAYRY BAYER BAY2599023 (DTX201) Trial Phase 2 — $5B Primary completion for BAY2599023 (DTX201) trial (NCT03588299) in Hemophilia A
2026-11-05
in 677 days 		SNY Sanofi Fitusiran Trial Phase 3 — $8B Primary completion for Fitusiran trial (NCT03754790) in Hemophilia
2026-11-06
in 678 days 		MRK MERCK vinblastine Trial Phase 2 — $7B Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma
2026-11-07
in 679 days 		MRK MERCK Lenvatinib Trial Phase 3 — $15B Primary completion for Lenvatinib trial (NCT05319730) in Esophageal Squamous Cell Carcinom
2026-11-07
in 679 days 		MRK MERCK Sacituzumab tirumotecan Trial Phase 3 — $8B Primary completion for Sacituzumab tirumotecan trial (NCT05319730) in Esophageal Squamous
2026-11-07
in 679 days 		MRK MERCK Paclitaxel Trial Phase 3 — $12B Primary completion for Paclitaxel trial (NCT05319730) in Esophageal Squamous Cell Carcinom
2026-11-07
in 679 days 		MRK MERCK Antihistamine Trial Phase 2 — $2B Primary completion for Antihistamine trial (NCT05319730) in Esophageal Squamous Cell Carci
2026-11-07
in 679 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT05319730) in Esophageal Squamous Cell Carci
2026-11-07
in 679 days 		MRK MERCK Supportive care measures Trial Phase 3 — $15B Primary completion for Supportive care measures trial (NCT05319730) in Esophageal Squamous
2026-11-07
in 679 days 		MRK MERCK MK-4830 Trial Phase 2 — $15B Primary completion for MK-4830 trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
2026-11-09
in 681 days 		BIO BIO-RAD LABORATORIES, INC. BAT8010 for Injection Trial Phase 2 — $14B Primary completion for BAT8010 for Injection trial (NCT06376136) in Advanced Solid Tumors
2026-11-10
in 682 days 		ALNY Alnylam / Roche · NDA Hepatitis B virus (HBV) — functional cure combination therapy elebsiran PDUFA — 90% $4B NOV 10 2026 196 days 💊 PDUFA (elebsiran) $ALNY Alnylam / Roche · NDA Hepatitis B virus (HB
2026-11-10
in 682 days 		ANRO Alto Neuroscience, Inc. Apatinib Trial Phase 3 — $4B Primary completion for Apatinib trial (NCT06351020) in Locally Advanced or Metastatic GC a
2026-11-10
in 682 days 		ANRO Alto Neuroscience, Inc. LM-302 Trial Phase 3 — $4B Primary completion for LM-302 trial (NCT06351020) in Locally Advanced or Metastatic GC and
2026-11-12
in 684 days 		RHHBY Roche Holding AG Ocrelizumab Trial Phase 3 — $28B Primary completion for Ocrelizumab trial (NCT03523858) in Progressive Multiple Sclerosis (
2026-11-13
in 685 days 		GSK GSK plc Niraparib Trial Phase 3 — $4B Primary completion for Niraparib trial (NCT04641247) in Ovarian Neoplasms
2026-11-13
in 685 days 		AZN AstraZeneca PLC AZD0486 Trial Phase 2 — $4B Primary completion for AZD0486 trial (NCT06137118) in B-cell Acute Lymphoblastic Leukemia
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Capecitabine Trial Phase 3 — $15B Primary completion for capecitabine trial (NCT06118333) in Nasopharyngeal Carcinoma
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR gemcitabine Trial Phase 3 — $1B Primary completion for gemcitabine trial (NCT06118333) in Nasopharyngeal Carcinoma
2026-11-15
in 687 days 		LLY Eli Lilly and Company Lasmiditan Trial Phase 3 — $8B Primary completion for Lasmiditan trial (NCT04396236) in Migraine
2026-11-15
in 687 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 — $15B Primary completion for Tirzepatide trial (NCT06662383) in Obesity
2026-11-15
in 687 days 		ABBV AbbVie Inc. ABBV-444 Trial Phase 3 — $6B Primary completion for ABBV-444 trial (NCT07284381) in Dry Eye Disease
2026-11-15
in 687 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 — $25B Primary completion for Orforglipron trial (NCT06649045) in OSA
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 — $15B Primary completion for SKB264 trial (NCT06448312) in Non-Small Cell Lung Cancer
2026-11-15
in 687 days 		MNMD Mind Medicine (MindMed) Inc. MM120 (LSD D-Tartrate) Trial Phase 3 — $8B Primary completion for MM120 (LSD D-Tartrate) trial (NCT06809595) in Generalized Anxiety D
2026-11-15
in 687 days 		NAMS NewAmsterdam Pharma Co N.V. Obicetrapib Trial Phase 3 — $18B Primary completion for Obicetrapib trial (NCT05202509) in Atherosclerotic Cardiovascular D
2026-11-15
in 687 days 		ONC BeOne Medicines Ltd. Sonrotoclax Trial Phase 3 — $2B Primary completion for Sonrotoclax trial (NCT04973605) in Relapsed/Refractory Multiple Mye
2026-11-15
in 687 days 		VIR Vir Biotechnology, Inc. Elebsiran Trial Phase 3 — $6B Primary completion for Elebsiran trial (NCT07142811) in Viral Hepatitis
2026-11-15
in 687 days 		ATOS ATOSSA THERAPEUTICS, INC. (Z)-endoxifen Trial Phase 2 — $18B Primary completion for (Z)-endoxifen trial (NCT05607004) in Breast Neoplasms
2026-11-15
in 687 days 		APTOF Aptose Biosciences Inc. Tuspetinib Trial Phase 2 — $2B Primary completion for Tuspetinib trial (NCT03850574) in Leukemia, Myeloid, Acute
2026-11-15
in 687 days 		APGE Apogee Therapeutics, Inc. APG777 Trial Phase 2 — $8B Primary completion for APG777 trial (NCT06395948) in Atopic Dermatitis
2026-11-15
in 687 days 		VIR Vir Biotechnology, Inc. Tobevibart Trial Phase 3 — $6B Primary completion for Tobevibart trial (NCT07142811) in Viral Hepatitis
2026-11-15
in 687 days 		BEIGF BeOne Medicines Ltd. Zanubrutinib Trial Phase 2 — $4B Primary completion for Zanubrutinib trial (NCT06637501) in Chronic Lymphocytic Leukemia
2026-11-15
in 687 days 		ZURA Zura Bio Ltd Tibulizumab Dose A Trial Phase 2 — $1B Primary completion for Tibulizumab Dose A trial (NCT06993610) in Hidradenitis Suppurativa
2026-11-15
in 687 days 		BNTX BioNTech SE RO7198457 intravenous (IV) Trial Phase 2 — $2B Primary completion for RO7198457 intravenous (IV) trial (NCT04486378) in Colorectal Cancer
2026-11-15
in 687 days 		ONC BeOne Medicines Ltd. Dexamethasone Trial Phase 2 — $6B Primary completion for Dexamethasone trial (NCT04973605) in Relapsed/Refractory Multiple M
2026-11-15
in 687 days 		VXRT Vaxart, Inc. VXA-CoV2-3.1 Trial Phase 2 — $15B Primary completion for VXA-CoV2-3.1 trial (NCT06672055) in SARS-CoV2
2026-11-15
in 687 days 		ABBV AbbVie Inc. Livmoniplimab Trial Phase 3 — $4B Primary completion for Livmoniplimab trial (NCT05822752) in Hepatocellular Carcinoma
2026-11-15
in 687 days 		ARGX argenx SE Empasiprubart IV Trial Phase 3 — $1B Primary completion for Empasiprubart IV trial (NCT06284954) in Dermatomyositis
2026-11-15
in 687 days 		ABBV AbbVie Inc. Mirvetuximab Soravtansine Trial Phase 3 — $4B Primary completion for Mirvetuximab soravtansine trial (NCT05456685) in High Grade Ovarian
2026-11-15
in 687 days 		ABBV AbbVie Inc. ABT-869 Trial Phase 2 — $8B Primary completion for Carboplatin trial (NCT05456685) in High Grade Ovarian Cancer
2026-11-15
in 687 days 		ABBV AbbVie Inc. Lenvatinib Trial Phase 2 — $4B Primary completion for Lenvatinib trial (NCT05822752) in Hepatocellular Carcinoma
2026-11-15
in 687 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR-A1811 combined with Pyrotinib. Trial Phase 2 — $9B Primary completion for SHR-A1811 combined with Pyrotinib. trial (NCT06015048) in HER2-expr
2026-11-15
in 687 days 		ABBV AbbVie Inc. Budigalimab Trial Phase 3 — $3B Primary completion for Budigalimab trial (NCT05822752) in Hepatocellular Carcinoma
2026-11-15
in 687 days 		MNKD MannKind Corporation Basal insulin Trial Phase 2 — $15B Primary completion for Basal insulin trial (NCT07224321) in Type 1 Diabetes Mellitus
2026-11-15
in 687 days 		MNKD MannKind Corporation Technosphere Insulin Trial Phase 3 — $55B Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu
2026-11-15
in 687 days 		ABBV AbbVie Inc. ABBV-932 Trial Phase 2 — $8B Primary completion for ABBV-932 trial (NCT06846320) in Generalized Anxiety Disorder (GAD)
2026-11-15
in 687 days 		VIR Vir Biotechnology, Inc. Bulevirtide Trial Phase 3 — $6B Primary completion for Bulevirtide trial (NCT07142811) in Viral Hepatitis
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SI-B001 Trial Phase 3 — $8B Primary completion for SI-B001 trial (NCT06668961) in Head and Neck Squamous Cell Carcinom
2026-11-15
in 687 days 		ABBV AbbVie Inc. Obinutuzumab Trial Phase 3 — $4B Primary completion for Obinutuzumab trial (NCT04895436) in Chronic Lymphocytic Leukemia (C
2026-11-15
in 687 days 		LLY Eli Lilly and Company LY3938577 Trial Phase 2 — $35B Primary completion for LY3938577 trial (NCT07215312) in Diabetes Mellitus, Type 2
2026-11-15
in 687 days 		BGNE BeiGene, Ltd. Tislelizumab (BGB-A317) Trial Phase 2 — $6B Primary completion for Tislelizumab (BGB-A317) trial (NCT03736889) in MSI-H/dMMR Solid Tum
2026-11-15
in 687 days 		LLY Eli Lilly and Company MORF-057 Trial Phase 2 — $18B Primary completion for MORF-057 trial (NCT06226883) in Inflammatory Bowel Diseases
2026-11-15
in 687 days 		JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Bupivacaine Liposome Injection Trial Phase 2 — $2B Primary completion for Bupivacaine Liposome Injection trial (NCT06529432) in Local Analges
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SI-B003 Trial Phase 2 — $2B Primary completion for SI-B003 trial (NCT06668961) in Head and Neck Squamous Cell Carcinom
2026-11-15
in 687 days 		ABBV AbbVie Inc. Venetoclax Trial Phase 3 — $8B Primary completion for Venetoclax trial (NCT04895436) in Chronic Lymphocytic Leukemia (CLL
2026-11-15
in 687 days 		TYRA Tyra Biosciences, Inc. TYRA-300 Trial Phase 2 — $2B Primary completion for TYRA-300 trial (NCT05544552) in Locally Advanced Urothelial Carcino
2026-11-15
in 687 days 		NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Trial Phase 2 — $18B Primary completion for obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks trial (
2026-11-15
in 687 days 		ONC BeOne Medicines Ltd. BGB-16673 Trial Phase 3 — $8B Primary completion for BGB-16673 trial (NCT05006716) in B-cell Malignancy
2026-11-15
in 687 days 		ELTX Elicio Therapeutics, Inc. ELI-002 7P Trial Phase 2 — $6B Primary completion for ELI-002 7P trial (NCT05726864) in Pancreatic Ductal Adenocarcinoma
2026-11-15
in 687 days 		CRDF Cardiff Oncology, Inc. FOLFOX Trial Phase 2 — $8B Primary completion for FOLFOX trial (NCT06106308) in Metastatic Colorectal Cancer
2026-11-15
in 687 days 		CRDF Cardiff Oncology, Inc. Onvansertib Trial Phase 2 — $8B Primary completion for Onvansertib trial (NCT06106308) in Metastatic Colorectal Cancer
2026-11-15
in 687 days 		KPRX KIORA PHARMACEUTICALS INC KIO-104 Trial Phase 2 — $4B Primary completion for KIO-104 trial (NCT06825702) in Macular Edema
2026-11-16
in 688 days 		UCBJY UCB Zilucoplan Trial Phase 3 — $1B Primary completion for Zilucoplan trial (NCT06055959) in Generalized Myasthenia Gravis
2026-11-16
in 688 days 		MRK MERCK Tulisokibart Trial Phase 3 — $1B Primary completion for Tulisokibart trial (NCT06956235) in Hidradenitis Suppurativa
2026-11-17
in 689 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 — $15B Primary completion for Volrustomig trial (NCT06079671) in Locally Advanced Cervical Cancer
2026-11-19
in 691 days 		RHHBY Roche Holding AG RO7269162 Trial Phase 2 — $15B Primary completion for RO7269162 trial (NCT06402838) in Alzheimer's Disease
2026-11-19
in 691 days 		NVS Novartis AG 225Ac-PSMA-R2 Trial Phase 2 — $15B Primary completion for 225Ac-PSMA-R2 trial (NCT05983198) in Prostate Cancer
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin aspart Trial Phase 3 — $50B Primary completion for Insulin aspart trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin glargine Trial Phase 3 — $50B Primary completion for Insulin glargine trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-23
in 695 days 		NVO Novo Nordisk A/S Insulin Icodec Trial Phase 3 — $35B Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-24
in 696 days 		AZN AstraZeneca PLC AZD0754 Trial Phase 2 — $8B Primary completion for AZD0754 trial (NCT06267729) in Metastatic Prostate Cancer
2026-11-27
in 699 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 — $55B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2026-11-29
in 701 days 		PFE PFIZER Rimegepant Trial Phase 3 — $4B Primary completion for Rimegepant trial (NCT06641466) in Menstrual Migraine
2026-11-30
in 702 days 		RNAC Cartesian Therapeutics, Inc. Decartes-08 Trial Phase 3 — $2B Primary completion for Decartes-08 trial (NCT06799247) in Myasthaenia Gravis
2026-11-30
in 702 days 		SNY Sanofi Rilzabrutinib Trial Phase 3 — $3B Primary completion for rilzabrutinib trial (NCT07216079) in Immune Thrombocytopenia
2026-11-30
in 702 days 		AZN AstraZeneca PLC Tremelimumab Trial Phase 3 — $4B Primary completion for Tremelimumab trial (NCT07081633) in Hepatocellular Carcinoma
2026-11-30
in 702 days 		BIO BIO-RAD LABORATORIES, INC. JMT108 Trial Phase 2 — $8B Primary completion for JMT108 trial (NCT07280832) in Unresectable Locally Advanced or Meta
2026-11-30
in 702 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 — $15B Primary completion for Durvalumab trial (NCT07081633) in Hepatocellular Carcinoma
2026-11-30
in 702 days 		RHHBY Roche Holding AG Risdiplam Trial Phase 3 — $1B Primary completion for Risdiplam trial (NCT05808764) in Muscular Atrophy, Spinal
2026-11-30
in 702 days 		NVSEF NOVARTIS AG JDQ443 Trial Phase 2 — $2B Primary completion for JDQ443 trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-11-30
in 702 days 		NVSEF NOVARTIS AG Trametinib Trial Phase 3 — $2B Primary completion for trametinib trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-11-30
in 702 days 		NVSEF NOVARTIS AG Ribociclib Trial Phase 3 — $18B Primary completion for Ribociclib trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-11-30
in 702 days 		NVSEF NOVARTIS AG cetuximab Trial Phase 2 — $5B Primary completion for cetuximab trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-11-30
in 702 days 		BAYRY BAYER BAY2927088_formulation A Trial Phase 2 — $15B Primary completion for BAY2927088_formulation A trial (NCT05099172) in Advanced Non-small
2026-11-30
in 702 days 		VTRS MYLAN MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Trial Phase 2 — $12B Primary completion for MR-130A-01 contraceptive transdermal patch, containing norelgestrom
2026-11-30
in 702 days 		SNY Sanofi Isatuximab intravenous (IV) Trial Phase 2 — $15B Primary completion for Isatuximab intravenous (IV) trial (NCT05669989) in Plasma Cell Myel
2026-12-01
in 773 days 		ARGX argenx SE EFG PH20 SC Trial Phase 3 — $1B Primary completion for EFG PH20 SC trial (NCT05523167) in Active Idiopathic Inflammatory M
2026-12-01
in 773 days 		SNY Sanofi PCV21 Trial Phase 3 — $8B Primary completion for PCV21 trial (NCT06838000) in Pneumococcal Infections
2026-12-01
in 773 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 — $15B Primary completion for Itepekimab (SAR440340) trial (NCT06208306) in Chronic Obstructive P
2026-12-01
in 773 days 		BIIB Biogen Inc. SAGE-217 Trial Phase 3 — $8B Primary completion for Placebo trial (NCT06685757) in Antibody-mediated Rejection
2026-12-01
in 773 days 		ZNTL Zentalis Pharmaceuticals, Inc. azenosertib Trial Phase 2 — $8B Primary completion for azenosertib trial (NCT05128825) in High-Grade Serous Ovarian, Fallo
2026-12-01
in 773 days 		RNAC Cartesian Therapeutics, Inc. Descartes-08 Trial Phase 2 — $8B Primary completion for Descartes-08 trial (NCT07089121) in Childhood-onset Systemic Lupus
2026-12-01
in 773 days 		ALMS ALUMIS INC. ESK-001 Trial Phase 3 — $12B Primary completion for ESK-001 trial (NCT05739435) in Plaque Psoriasis
2026-12-01
in 773 days 		SNY Sanofi Pandemic flu H5 HA mRNA SD2 vaccine Trial Phase 2 — $5B Primary completion for Pandemic flu H5 HA mRNA SD2 vaccine trial (NCT06907511) in Pandemic
2026-12-01
in 773 days 		NVO Novo Nordisk A/S NNC0662-0419 Trial Phase 2 — $15B Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight
2026-12-01
in 773 days 		MRK MERCK Zanzalintinib PDUFA Phase 3 — $8B For Renal cell carcinoma (RCC). Exelixis presented data on Zanzalintinib for renal cell ca
2026-12-02
in 774 days 		PFE PFIZER Enzalutamide Trial Phase 3 — $18B Primary completion for Enzalutamide trial (NCT06629779) in Metastatic Castration-Resistant
2026-12-02
in 774 days 		PFE PFIZER PF-06821497 Trial Phase 3 — $6B Primary completion for PF-06821497 trial (NCT06629779) in Metastatic Castration-Resistant
2026-12-03
in 775 days 		ESALY Eisai E2814 Trial Phase 2 — $15B Primary completion for E2814 trial (NCT06602258) in Alzheimer's Disease
2026-12-03
in 775 days 		ESALY Eisai Lecanemab Trial Phase 3 — $8B Primary completion for Lecanemab trial (NCT06602258) in Alzheimer's Disease
2026-12-05
in 777 days 		VRTX Vertex Pharmaceuticals · sNDA Moderate-to-severe chronic lower back pain (NaV1.8 blocker) Journavx (suzetrigine PDUFA — 92% $2B DEC 5 2026 221 days 💊 PDUFA Journavx (suzetrigine) $VRTX Vertex Pharmaceuticals · sNDA Mod
2026-12-06
in 778 days 		PFE PFIZER ibuzatrelvir Trial Phase 3 — $15B Primary completion for ibuzatrelvir trial (NCT07013474) in COVID-19 Infection
2026-12-09
in 781 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 — $12B Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2026-12-09
in 781 days 		AZN AstraZeneca PLC AZD0901 Trial Phase 2 — $3B Primary completion for AZD0901 trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2026-12-11
in 783 days 		PFE PFIZER disitamab vedotin Trial Phase 3 — $5B Primary completion for disitamab vedotin trial (NCT04879329) in Urothelial Carcinoma
2026-12-14
in 786 days 		AMGN Amgen Inc. ABP 234 Trial Phase 3 — $6B Primary completion for ABP 234 trial (NCT06430866) in Early-stage Non-squamous Non-small C
2026-12-15
in 787 days 		AXSM Axsome Therapeutics, Inc. Solriamfetol 150 mg Trial Phase 3 — $3B Primary completion for Solriamfetol 150 mg trial (NCT06568367) in Excessive Sleepiness
2026-12-15
in 787 days 		ABBV AbbVie Inc. Tavapadon Trial Phase 3 — $12B Primary completion for Placebo trial (NCT05843643) in Systemic Lupus Erythematosus
2026-12-15
in 787 days 		ABBV AbbVie Inc. Lutikizumab Trial Phase 3 — $1B Primary completion for Lutikizumab trial (NCT06468228) in Hidradenitis Suppurativa
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Topotecan Trial Phase 3 — $4B Primary completion for Topotecan trial (NCT06500026) in Small Cell Lung Cancer
2026-12-15
in 787 days 		ABBV AbbVie Inc. Ranibizumab (LUCENTIS®) Trial Phase 3 — $15B Primary completion for Ranibizumab (LUCENTIS®) trial (NCT04704921) in AMD
2026-12-15
in 787 days 		MDGL Madrigal Pharmaceuticals, Inc. Resmetirom Trial Phase 3 — $12B Primary completion for Resmetirom trial (NCT05500222) in NASH
2026-12-15
in 787 days 		IONS Ionis Pharmaceuticals, Inc. Donidalorsen Trial Phase 3 — $2B Primary completion for Donidalorsen trial (NCT05392114) in Hereditary Angioedema
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. SKB264 Trial Phase 3 — $15B Primary completion for SKB264 trial (NCT06711900) in Non-Small Cell Lung Cancer
2026-12-15
in 787 days 		OCS Oculis Holding AG licaminlimab Trial Phase 3 — $6B Primary completion for licaminlimab trial (NCT07548632) in Dry Eye Disease (DED)
2026-12-15
in 787 days 		AVIR Atea Pharmaceuticals, Inc. Bemnifosbuvir-Ruzasvir Trial Phase 3 — $8B Primary completion for Bemnifosbuvir-Ruzasvir trial (NCT07037277) in HEPATITIS C VIRUS CHR
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. pemetrexed Trial Phase 3 — $15B Primary completion for pemetrexed trial (NCT06711900) in Non-Small Cell Lung Cancer
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Docetaxel Trial Phase 3 — $15B Primary completion for Docetaxel trial (NCT06382129) in Non-small Cell Lung Cancer
2026-12-15
in 787 days 		VIR Vir Biotechnology, Inc. Bulevirtide Trial Phase 3 — $6B Primary completion for Bulevirtide trial (NCT07128550) in Viral Hepatitis
2026-12-15
in 787 days 		VIR Vir Biotechnology, Inc. Tobevibart Trial Phase 3 — $6B Primary completion for Tobevibart trial (NCT07128550) in Viral Hepatitis
2026-12-15
in 787 days 		IPSEY Ipsen Biopharmaceuticals, Inc. IPN10200 Trial Phase 3 — $2B Primary completion for IPN10200 trial (NCT07427797) in Moderate to Severe Glabellar Lines
2026-12-15
in 787 days 		MDWD MediWound Ltd. EscharEx (EX-03) Trial Phase 3 — $2B Primary completion for EscharEx (EX-03) trial (NCT06568627) in Venous Leg Ulcer (VLU)
2026-12-15
in 787 days 		CLCS Cell Source, Inc. Immuncell-LC Trial Phase 3 — $6B Primary completion for Immuncell-LC trial (NCT04969731) in Pancreatic Ductal Adenocarcinom
2026-12-15
in 787 days 		ABBV AbbVie Inc. Upadacitinib Trial Phase 3 — $8B Primary completion for Upadacitinib trial (NCT05843643) in Systemic Lupus Erythematosus
2026-12-15
in 787 days 		CLCS Cell Source, Inc. Gemcitabine Trial Phase 3 — $6B Primary completion for Gemcitabine trial (NCT04969731) in Pancreatic Ductal Adenocarcinoma
2026-12-15
in 787 days 		VIR Vir Biotechnology, Inc. Elebsiran Trial Phase 3 — $6B Primary completion for Elebsiran trial (NCT07128550) in Viral Hepatitis
2026-12-15
in 787 days 		BHVN Biohaven Pharmaceutical Holding Company Ltd. BHV-7000 Trial Phase 3 — $5B Primary completion for BHV-7000 trial (NCT06132893) in Focal Epilepsy
2026-12-15
in 787 days 		KOD Kodiak Sciences Inc KSI-101 Trial Phase 3 — $2B Primary completion for KSI-101 trial (NCT06996080) in Macular Edema Secondary to Inflammat
2026-12-15
in 787 days 		WXI WUXI Mesenchymal Stem Cells Trial Phase 3 — $6B Primary completion for Mesenchymal Stem Cells trial (NCT06570291) in Knee Osteoarthritis
2026-12-15
in 787 days 		MANE Veradermics, Inc VDPHL01 Trial Phase 3 — $3B Primary completion for VDPHL01 trial (NCT06972264) in Androgenetic Alopecia
2026-12-15
in 787 days 		NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + ezetimibe 10 mg FDC daily Trial Phase 3 — $15B Primary completion for obicetrapib 10 mg + ezetimibe 10 mg FDC daily trial (NCT06305559) i
2026-12-15
in 787 days 		DMAC DiaMedica Therapeutics Inc. Recombinant human tissue kallikrein Trial Phase 3 — $8B Primary completion for Recombinant human tissue kallikrein trial (NCT05065216) in Acute St
2026-12-15
in 787 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 — $25B Primary completion for Retatrutide trial (NCT06662383) in Obesity
2026-12-15
in 787 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide Trial Phase 3 — $2B Primary completion for Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide tri
2026-12-15
in 787 days 		GILD Gilead Sciences, Inc. Eribulin Mesylate Injection Trial Phase 3 — $15B Primary completion for Sacituzumab Govitecan-hziy trial (NCT04639986) in Metastatic Breast
2026-12-15
in 787 days 		AXSM Axsome Therapeutics, Inc. Solriamfetol 300 mg Trial Phase 3 — $2B Primary completion for Solriamfetol 300 mg trial (NCT06568367) in Excessive Sleepiness
2026-12-15
in 787 days 		GLSI Greenwich LifeSciences, Inc. GLSI-100 Trial Phase 3 — $18B Primary completion for GLSI-100 trial (NCT05232916) in Breast Cancer
2026-12-15
in 787 days 		VNDA Vanda Pharmaceuticals Inc. VQW-765 Trial Phase 3 — $2B Primary completion for VQW-765 trial (NCT07221578) in Social Anxiety Disorder (SAD)
2026-12-15
in 787 days 		GILD Gilead Sciences, Inc. anitocabtagene-autoleucel Trial Phase 2 — $15B Primary completion for anitocabtagene-autoleucel trial (NCT05396885) in Multiple Myeloma
2026-12-15
in 787 days 		EIKN Eikon Therapeutics, Inc. EIK1001 Trial Phase 3 — $8B Primary completion for EIK1001 trial (NCT06246110) in NSCLC
2026-12-15
in 787 days 		ABBV AbbVie Inc. ABBV-400 Trial Phase 2 — $6B Primary completion for ABBV-400 trial (NCT06107413) in Unresectable Metastatic Colorectal
2026-12-15
in 787 days 		VMAR Vision Marine Technologies Inc. Atropine Trial Phase 2 — $8B Primary completion for SHJ002 trial (NCT06579287) in Myopia, Progressive
2026-12-15
in 787 days 		VRNA VERONA PHARMA Ensifentrine Trial Phase 3 — $15B Primary completion for Ensifentrine trial (NCT05270525) in COPD
2026-12-15
in 787 days 		EXAS EXACT SCIENCES CORP Modified FOLFIRINOX Trial Phase 2 — $2B Primary completion for Modified FOLFIRINOX trial (NCT06850623) in Locally Advanced Pancrea
2026-12-15
in 787 days 		EPRX EUPRAXIA PHARMACEUTICALS INC. EP-104GI Trial Phase 2 — $2B Primary completion for EP-104GI trial (NCT05608681) in Eosinophilic Esophagitis
2026-12-15
in 787 days 		JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 Trial Phase 2 — $15B Primary completion for SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 trial (NCT05482568) in A
2026-12-15
in 787 days 		TRAW Traws Pharma, Inc. TRX-100 Trial Phase 2 — $6B Primary completion for TRX-100 trial (NCT07371650) in Influenza
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. BL-M07D1 Trial Phase 2 — $15B Primary completion for BL-M07D1 trial (NCT06131450) in Gynecological Malignancies
2026-12-15
in 787 days 		EIKN Eikon Therapeutics, Inc. Paclitaxel Trial Phase 2 — $18B Primary completion for Paclitaxel trial (NCT06246110) in NSCLC
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR GNC-035 Trial Phase 2 — $12B Primary completion for GNC-035 trial (NCT06066203) in Non-hodgkin's Lymphoma
2026-12-15
in 787 days 		AVLN Avalyn Pharma Inc. AP02 Trial Phase 2 — $8B Primary completion for AP02 trial (NCT07194382) in Idiopathic Pulmonary Fibrosis (IPF)
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Envafolimab+Lenvatinib Trial Phase 2 — $3B Primary completion for Envafolimab+Lenvatinib trial (NCT05112991) in Advanced Endometrial
2026-12-15
in 787 days 		ZLAB Zai Lab Limited ZL-1310 Trial Phase 3 — $12B Primary completion for ZL-1310 trial (NCT06885281) in Solid Tumors
2026-12-15
in 787 days 		LLY Eli Lilly and Company Pirtobrutinib Trial Phase 2 — $12B Primary completion for Pirtobrutinib trial (NCT06721013) in Immune Thrombocytopenia (ITP)
2026-12-15
in 787 days 		ABVX Abivax S.A. Obefazimod Trial Phase 2 — $8B Primary completion for Obefazimod trial (NCT06456593) in Moderately to Severely Active Cro
2026-12-15
in 787 days 		ALZN Alzamend Neuro, Inc. Lithium carbonate Trial Phase 2 — $8B Primary completion for Lithium carbonate trial (NCT07540338) in Bipolar I Disorder
2026-12-15
in 787 days 		ALZN Alzamend Neuro, Inc. AL001 Trial Phase 2 — $15B Primary completion for AL001 trial (NCT07540338) in Bipolar I Disorder
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Lenvatinib + Envafolimab Trial Phase 2 — $3B Primary completion for Lenvatinib + Envafolimab trial (NCT05024214) in Solid Tumors
2026-12-15
in 787 days 		LLY Eli Lilly and Company LY3457263 Trial Phase 2 — $55B Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes
2026-12-15
in 787 days 		OMER Omeros Corporation OMS906 study drug Trial Phase 2 — $2B Primary completion for OMS906 study drug trial (NCT06298955) in Paroxysmal Nocturnal Hemog
2026-12-15
in 787 days 		PHAT Phathom Pharmaceuticals, Inc. Vonoprazan Trial Phase 3 — $3B Primary completion for Vonoprazan trial (NCT06851559) in Eosinophilic Esophagitis
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. SI-B003 Trial Phase 2 — $5B Primary completion for SI-B003 trial (NCT05965856) in Urothelial Carcinoma
2026-12-15
in 787 days 		ANRO Alto Neuroscience, Inc. ALTO-203 25 μg Trial Phase 2 — $15B Primary completion for Placebo trial (NCT05922878) in Major Depressive Disorder
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. BL-B01D1 Trial Phase 3 — $4B Primary completion for BL-B01D1 trial (NCT05924841) in Small Cell Lung Cancer
2026-12-15
in 787 days 		SBFMW Sunshine Biopharma Inc. HEC585 dose A Trial Phase 2 — $2B Primary completion for HEC585 dose A trial (NCT05139719) in Progressive Fibrosing Intersti
2026-12-15
in 787 days 		ABBV AbbVie Inc. Eluxadoline Trial Phase 2 — $8B Primary completion for Eluxadoline trial (NCT03339128) in Irritable Bowel Syndrome
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. PD-1 Monoclonal Antibody Trial Phase 2 — $15B Primary completion for PD-1 Monoclonal Antibody trial (NCT06008054) in Esophageal Cancer
2026-12-15
in 787 days 		BEAM Beam Therapeutics Inc. BEAM-201 Trial Phase 2 — $2B Primary completion for BEAM-201 trial (NCT05885464) in Lymphoblastic Lymphoma
2026-12-15
in 787 days 		DNLI Denali Therapeutics Inc. DNL593 Trial Phase 2 — $1B Primary completion for DNL593 trial (NCT05262023) in Frontotemporal Dementia
2026-12-15
in 787 days 		FDMT 4D Molecular Therapeutics, Inc. 4D-710 Trial Phase 2 — $6B Primary completion for 4D-710 trial (NCT05248230) in Cystic Fibrosis Lung
2026-12-15
in 787 days 		ANRO Alto Neuroscience, Inc. ALTO-300 Trial Phase 2 — $15B Primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR GNC-038 Trial Phase 2 — $5B Primary completion for GNC-038 trial (NCT05623982) in Non-hodgkin's Lymphoma
2026-12-15
in 787 days 		ZURA Zura Bio Ltd Tibulizumab Trial Phase 2 — $1B Primary completion for Tibulizumab trial (NCT06843239) in Systemic Sclerosis (SSc)
2026-12-15
in 787 days 		GEHC GE HealthCare Technologies Inc. Regadenoson Trial Phase 2 — $15B Primary completion for Regadenoson trial (NCT04604782) in Myocardial Ischemia
2026-12-15
in 787 days 		ASND Ascendis Pharma A/S Navepegritide Trial Phase 2 — $2B Primary completion for Navepegritide trial (NCT06732895) in Achondroplasia
2026-12-16
in 788 days 		BIO BIO-RAD LABORATORIES, INC. KN026 Trial Phase 3 — $6B Primary completion for KN026 trial (NCT06747338) in Early or Locally Advanced HER2-positiv
2026-12-16
in 788 days 		MRK MERCK Posaconazole IV 6 mg/kg Trial Phase 2 — $4B Primary completion for Posaconazole IV 6 mg/kg trial (NCT04665037) in Invasive Fungal Infe
2026-12-17
in 789 days 		IPSEY Ipsen Biopharmaceuticals, Inc. Elafibranor Trial Phase 3 — $1B Primary completion for Elafibranor trial (NCT06730061) in Primary Biliary Cholangitis
2026-12-17
in 789 days 		SNY Sanofi SAR442970 Trial Phase 2 — $8B Primary completion for SAR442970 trial (NCT06958536) in Crohn's Disease
2026-12-18
in 790 days 		KDNY Chinook Therapeutics, Inc. Atrasentan Trial Phase 3 — $2B Primary completion for Atrasentan trial (NCT04573478) in IgA Nephropathy
2026-12-18
in 790 days 		ABBV AbbVie Inc. MEDI0618 Trial Phase 2 — $8B Primary completion for MEDI0618 trial (NCT06602479) in Migraine
2026-12-18
in 790 days 		RHHBY Roche Holding AG Tobemstomig Trial Phase 2 — $5B Primary completion for Tobemstomig trial (NCT05852691) in Breast Cancer
2026-12-18
in 790 days 		ABBV AbbVie Inc. Tavapadon Trial Phase 3 — $12B Primary completion for Placebo trial (NCT03339128) in Irritable Bowel Syndrome
2026-12-21
in 793 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for Bimekizumab trial (NCT06921850) in Hidradenitis Suppurativa
2026-12-22
in 794 days 		ADVM Adverum Biotechnologies, Inc. Aflibercept Trial Phase 3 — $8B Primary completion for Aflibercept trial (NCT06856577) in Neovascular Age-Related Macular
2026-12-23
in 795 days 		SNY Sanofi MRI contrast-enhancing agents Trial Phase 3 — $28B Primary completion for MRI contrast-enhancing agents trial (NCT06141486) in Multiple Scler
2026-12-23
in 795 days 		MRK MERCK Enfortumab vedotin (EV) Trial Phase 3 — $4B Primary completion for Enfortumab vedotin (EV) trial (NCT04700124) in Bladder Cancer
2026-12-23
in 795 days 		BIOE Bio Essence Corp JOINTSTEM Trial Phase 3 — $8B Primary completion for JOINTSTEM trial (NCT04427930) in Knee Osteoarthritis
2026-12-23
in 795 days 		SNY Sanofi Frexalimab Trial Phase 3 — $15B Primary completion for Frexalimab trial (NCT06141486) in Multiple Sclerosis
2026-12-23
in 795 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04700124) in Bladder Cancer
2026-12-23
in 795 days 		SNYNF Sanofi frexalimab Trial Phase 2 — $2B Primary completion for frexalimab trial (NCT06500702) in Focal Segmental Glomerulosclerosi
2026-12-23
in 795 days 		VRTX Vertex Pharmaceuticals Incorporated IVA Trial Phase 3 — $6B Primary completion for IVA trial (NCT05668741) in Cystic Fibrosis
2026-12-23
in 795 days 		VRTX Vertex Pharmaceuticals Incorporated VX-522 mRNA therapy Trial Phase 2 — $6B Primary completion for VX-522 mRNA therapy trial (NCT05668741) in Cystic Fibrosis
2026-12-24
in 796 days 		NVS Novartis AG Ofatumumab approved dose Trial Phase 3 — $12B Primary completion for Ofatumumab approved dose trial (NCT06869785) in Relapsing Multiple
2026-12-25
in 797 days 		IPIX Innovation Pharmaceuticals Inc. Gemcitabine hydrochloride and albumin binding paclitaxel Trial Phase 3 — $2B Primary completion for Gemcitabine hydrochloride and albumin binding paclitaxel trial (NCT
2026-12-25
in 797 days 		NVO Novo Nordisk A/S Semaglutide Trial Phase 3 — $25B Primary completion for Semaglutide trial (NCT03811561) in Diabetes Mellitus, Type 2
2026-12-25
in 797 days 		PFE PFIZER Ritlecitinib 50 mg Trial Phase 3 — $3B Primary completion for Ritlecitinib 50 mg trial (NCT07219615) in Chronic Spontaneous Urtic
2026-12-26
in 798 days 		INCY Incyte Corporation Povorcitinib Trial Phase 3 — $2B Primary completion for Povorcitinib trial (NCT06212999) in Hidradenitis Suppurativa (HS)
2026-12-27
in 799 days 		IDIA Idorsia Pharmaceuticals Ltd. BOND-003 PDUFA NDA — $1B BLA submitted. AI-extracted from: CG Oncology Conference: Credo Posts 75.5% CR in BOND-003
2026-12-27
in 799 days 		CNTA Centessa Pharmaceuticals plc epilepsy drug PDUFA NDA — $15B For epilepsy. NDA submitted. AI-extracted from: Praxis tees up another approval filing; Ge
2026-12-28
in 800 days 		NVS Novartis AG Iptacopan Trial Phase 3 — $2B Primary completion for Iptacopan trial (NCT06517758) in Generalized Myasthenia Gravis
2026-12-28
in 800 days 		MRK MERCK Ramucirumab Trial Phase 2 — $6B Primary completion for Ramucirumab trial (NCT06445972) in Gastroesophageal Junction
2026-12-30
in 802 days 		CLCS Cell Source, Inc. JointStem Trial Phase 3 — $12B Primary completion for JointStem trial (NCT04368806) in Osteoarthritis, Knee
2026-12-30
in 802 days 		IVA Inventiva S.A. IVA337 Trial Phase 3 — $12B Primary completion for IVA337 trial (NCT04849728) in NASH - Nonalcoholic Steatohepatitis
2026-12-30
in 802 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Vicagrel Trial Phase 3 — $5B Primary completion for Vicagrel trial (NCT06577519) in Acute Coronary Syndrome (ACS) Under
2026-12-30
in 802 days 		PFE PFIZER ARV-471 (PF-07850327) Trial Phase 3 — $18B Primary completion for ARV-471 (PF-07850327) trial (NCT05909397) in Breast Cancer
2026-12-30
in 802 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR VC004 Capsules Trial Phase 3 — $4B Primary completion for VC004 Capsules trial (NCT06658353) in Locally Advanced Solid Tumor
2026-12-30
in 802 days 		SAIC Science Applications International Corp MY008211A tablets Trial Phase 3 — $2B Primary completion for MY008211A tablets trial (NCT06933914) in Paroxysmal Nocturnal Hemog
2026-12-30
in 802 days 		OTSKF OTSUKA Sibeprenlimab 400 mg Trial Phase 3 — $2B Primary completion for Sibeprenlimab 400 mg trial (NCT05248646) in Immunoglobulin A Nephro
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR KN035 Trial Phase 2 — $14B Primary completion for KN035 trial (NCT03667170) in Solid Tumor
2026-12-30
in 802 days 		PBMWW PSYENCE BIOMEDICAL LTD. Psilocybin therapy Trial Phase 2 — $2B Primary completion for Psilocybin therapy trial (NCT07072728) in Adjustment Disorder
2026-12-30
in 802 days 		VRTX Vertex Pharmaceuticals Incorporated Inaxaplin Trial Phase 2 — $2B Primary completion for Inaxaplin trial (NCT06794996) in Proteinuric Kidney Disease
2026-12-30
in 802 days 		BIO BIO-RAD LABORATORIES, INC. autologous dendritic cells Trial Phase 2 — $2B Primary completion for autologous dendritic cells trial (NCT04115761) in GBM
2026-12-30
in 802 days 		BIO BIO-RAD LABORATORIES, INC. LB1410 Trial Phase 2 — $12B Primary completion for LB1410 trial (NCT06468358) in Solid Tumor
2026-12-30
in 802 days 		SGIOY Shionogi S-337395 Trial Phase 2 — $4B Primary completion for S-337395 trial (NCT07214571) in Respiratory Syncytial Virus Infecti
2026-12-30
in 802 days 		AMGN Amgen Inc. Tarlatamab Trial Phase 3 — $4B Primary completion for Tarlatamab trial (NCT05060016) in Relapsed/Refractory Small Cell Lu
2026-12-30
in 802 days 		NVS Novartis AG Iptacopan Trial Phase 3 — $2B Primary completion for Iptacopan trial (NCT06388941) in Anti-Neutrophil Cytoplasm Antibodi
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Docetaxel Trial Phase 3 — $15B Primary completion for Docetaxel trial (NCT05631262) in Selected Subjects With Advanced So
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 — $15B Primary completion for SKB264 trial (NCT05631262) in Selected Subjects With Advanced Solid
2026-12-30
in 802 days 		PFE PFIZER ARV-471 Trial Phase 3 — $12B Primary completion for ARV-471 trial (NCT05573555) in Breast Cancer
2026-12-30
in 802 days 		SUPN SUPERNUS PHARMACEUTICALS, INC. BIS-001ER Trial Phase 2 — $2B Primary completion for BIS-001ER trial (NCT03474770) in Focal Impaired Awareness Seizures
2026-12-30
in 802 days 		SLS SELLAS Life Sciences Group, Inc. SLS009 Trial Phase 2 — $12B Primary completion for SLS009 trial (NCT04588922) in Hematologic Malignancies
2026-12-30
in 802 days 		PFE PFIZER Ribociclib Trial Phase 3 — $18B Primary completion for Ribociclib trial (NCT05573555) in Breast Cancer
2026-12-31
in 803 days 		VIR Vir Biotechnology, Inc. Elebsiran Trial Phase 3 — $6B Primary completion for Elebsiran trial (NCT06903338) in Viral Hepatitis
2026-12-31
in 803 days 		PFE PFIZER Lenalidomide Trial Phase 3 — $15B Primary completion for Lenalidomide trial (NCT04404283) in Diffuse Large B-cell Lymphoma
2026-12-31
in 803 days 		FOLD Amicus Therapeutics, Inc. migalastat HCl 150 mg Trial Phase 3 — $1B Primary completion for migalastat HCl 150 mg trial (NCT04020055) in Fabry Disease
2026-12-31
in 803 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR-A1811 Trial Phase 3 — $15B Primary completion for SHR-A1811 trial (NCT05424835) in HER2-Positive, Unresectable and/or
2026-12-31
in 803 days 		LRVIY Laboratorios Farmaceuticos Rovi, S.A./ADR Etoricoxib + Betamethasone fixed dose Trial Phase 3 — $8B Primary completion for Etoricoxib + Betamethasone fixed dose trial (NCT06863701) in Gout A
2026-12-31
in 803 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Pyrotinib in combination with Capecitabine. Trial Phase 3 — $6B Primary completion for Pyrotinib in combination with Capecitabine. trial (NCT05424835) in
2026-12-31
in 803 days 		GALDY Galderma Group AG/ADR Vehicle Cream Trial Phase 3 — $3B Primary completion for Vehicle Cream trial (NCT07186413) in Acne Vulgaris
2026-12-31
in 803 days 		SGEN Seagen Inc. brentuximab vedotin Trial Phase 3 — $8B Primary completion for brentuximab vedotin trial (NCT04609566) in Melanoma
2026-12-31
in 803 days 		INSM Insmed Incorporated Treprostinil Palmitil Trial Phase 3 — $4B Primary completion for Treprostinil Palmitil trial (NCT05649748) in Pulmonary Arterial Hyp
2026-12-31
in 803 days 		ANNX Annexon, Inc. Tanruprubart Trial Phase 3 — $1B Primary completion for Tanruprubart trial (NCT07020819) in Guillain-Barre Syndrome
2026-12-31
in 803 days 		RHHBY Roche Holding AG Pertuzumab Trial Phase 3 — $18B Primary completion for Pertuzumab trial (NCT02320435) in Solid Tumors
2026-12-31
in 803 days 		RHHBY Roche Holding AG Trastuzumab Trial Phase 3 — $18B Primary completion for Trastuzumab trial (NCT02320435) in Solid Tumors
2026-12-31
in 803 days 		RHHBY Roche Holding AG Optional Endocrine Therapy of Investigator's Choice Trial Phase 3 — $15B Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer
2026-12-31
in 803 days 		RHHBY Roche Holding AG Other Combination Anti-Cancer Therapies Trial Phase 3 — $2B Primary completion for Other Combination Anti-Cancer Therapies trial (NCT02320435) in Soli
2026-12-31
in 803 days 		VIR Vir Biotechnology, Inc. Tobevibart Trial Phase 3 — $6B Primary completion for Tobevibart trial (NCT06903338) in Viral Hepatitis
2026-12-31
in 803 days 		TGTX TG Therapeutics, Inc. Ublituximab Trial Phase 3 — $9B Primary completion for Ublituximab trial (NCT07211633) in Relapsing Multiple Sclerosis
2026-12-31
in 803 days 		GALDY Galderma Group AG/ADR Trifarotene Trial Phase 3 — $3B Primary completion for Trifarotene trial (NCT07186413) in Acne Vulgaris
2026-12-31
in 803 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Fuzuloparib , Abiraterone acetate and Prednisone Trial Phase 3 — $6B Primary completion for Fuzuloparib , Abiraterone acetate and Prednisone trial (NCT04691804
2026-12-31
in 803 days 		HKPD Hong Kong Pharma Digital Technology Holdings Ltd EI-001 Trial Phase 2 — $2B Primary completion for EI-001 trial (NCT07223229) in Non-segmental Vitiligo
2026-12-31
in 803 days 		RHHBY Roche Holding AG Mosunetuzumab Trial Phase 3 — $9B Primary completion for Tocilizumab trial (NCT04524871) in Advanced Liver Cancers
2026-12-31
in 803 days 		RHHBY Roche Holding AG Tobemstomig Trial Phase 2 — $5B Primary completion for Atezolizumab trial (NCT05645692) in Urothelial Cancer
2026-12-31
in 803 days 		GSK GSK plc MMB Trial Phase 2 — $2B Primary completion for MMB trial (NCT03441113) in Neoplasms
2026-12-31
in 803 days 		RHHBY Roche Holding AG Bevacizumab 15 mg/kg Trial Phase 2 — $6B Primary completion for Bevacizumab 15 mg/kg trial (NCT04524871) in Advanced Liver Cancers
2026-12-31
in 803 days 		GOVX GeoVax Labs, Inc. COVID-19 Vaccine Trial Phase 2 — $15B Primary completion for COVID-19 Vaccine trial (NCT04977024) in COVID-19 Infection
2026-12-31
in 803 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR KL590586 Capsule Trial Phase 2 — $3B Primary completion for KL590586 Capsule trial (NCT05265091) in Advanced Solid Tumor
2026-12-31
in 803 days 		MRK MERCK MK-1167 Trial Phase 2 — $15B Primary completion for MK-1167 trial (NCT06721156) in Alzheimer Disease
2026-12-31
in 803 days 		JAZZ Jazz Pharmaceuticals plc Zanidatamab Trial Phase 3 — $15B Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer
2026-12-31
in 803 days 		MRTX Mirati Therapeutics, Inc. MRTX849 Trial Phase 3 — $5B Primary completion for MRTX849 trial (NCT03785249) in Advanced Cancer
2026-12-31
in 803 days 		PFE PFIZER Palbociclib Trial Phase 3 — $18B Primary completion for Palbociclib trial (NCT05226871) in Breast Cancer
2026-12-31
in 803 days 		BIOE Bio Essence Corp CD19-targeted chimeric antigen receptor T-cell Trial Phase 2 — $5B Primary completion for CD19-targeted chimeric antigen receptor T-cell trial (NCT05326243)
2026-12-31
in 803 days 		MRTX Mirati Therapeutics, Inc. Pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT03785249) in Advanced Cancer
2026-12-31
in 803 days 		CLCS Cell Source, Inc. Super DC Vaccine Trial Phase 2 — $1B Primary completion for Super DC Vaccine trial (NCT07146672) in Solid Tumor Cancer
2026-12-31
in 803 days 		ANRO Alto Neuroscience, Inc. STI-6129 Trial Phase 2 — $6B Primary completion for STI-6129 trial (NCT05565807) in Relapsed or Refractory Multiple Mye
2026-12-31
in 803 days 		MNOV MediciNova, Inc. MN-001 Trial Phase 2 — $8B Primary completion for MN-001 trial (NCT05464784) in Diabetes Mellitus, Type 2
2026-12-31
in 803 days 		INCY Incyte Corporation Tafasitamab Trial Phase 3 — $5B Primary completion for tafasitamab trial (NCT04661007) in Non Hodgkins Lymphoma
2026-12-31
in 803 days 		SBFM Sunshine Biopharma Inc. SSGJ-705 Trial Phase 2 — $5B Primary completion for SSGJ-705 trial (NCT07022002) in Locally Advanced, Recurrent or Meta
2026-12-31
in 803 days 		INCY Incyte Corporation Lenalidomide Trial Phase 3 — $4B Primary completion for lenalidomide trial (NCT04661007) in Non Hodgkins Lymphoma
2026-12-31
in 803 days 		INO Inovio Pharmaceuticals, Inc. INO-5401 Trial Phase 2 — $2B Primary completion for INO-5401 trial (NCT03491683) in Glioblastoma
2026-12-31
in 803 days 		SUPN SUPERNUS PHARMACEUTICALS, INC. SPN-821 2400 mg Trial Phase 2 — $15B Primary completion for SPN-821 2400 mg trial (NCT07226661) in Major Depressive Disorder (M
2026-12-31
in 803 days 		POCI PRECISION OPTICS CORPORATION, INC. CD19 and CD22 targeted prime CAR-T cells Trial Phase 2 — $4B Primary completion for CD19 and CD22 targeted prime CAR-T cells trial (NCT04781634) in B-A
2026-12-31
in 803 days 		MRTX Mirati Therapeutics, Inc. Cetuximab Trial Phase 3 — $6B Primary completion for Cetuximab trial (NCT03785249) in Advanced Cancer
2026-12-31
in 803 days 		PFE PFIZER Cetuximab Trial Phase 3 — $4B Primary completion for Cetuximab trial (NCT05226871) in Breast Cancer
2026-12-31
in 803 days 		POCI PRECISION OPTICS CORPORATION, INC. BCMA CAR-T cells Trial Phase 2 — $15B Primary completion for BCMA CAR-T cells trial (NCT04271644) in Multiple Myeloma
2026-12-31
in 803 days 		INCY Incyte Corporation R-CHOP Trial Phase 2 — $9B Primary completion for R-CHOP trial (NCT04661007) in Non Hodgkins Lymphoma
2026-12-31
in 803 days 		POCI PRECISION OPTICS CORPORATION, INC. BCMA targeted prime CAR-T cells Trial Phase 2 — $15B Primary completion for BCMA targeted prime CAR-T cells trial (NCT04776330) in Multiple Mye
2026-12-31
in 803 days 		INCY Incyte Corporation Parsaclisib Trial Phase 2 — $8B Primary completion for parsaclisib trial (NCT04661007) in Non Hodgkins Lymphoma
2026-12-31
in 803 days 		PFE PFIZER Letrozole Trial Phase 3 — $18B Primary completion for Letrozole trial (NCT05226871) in Breast Cancer
2026-12-31
in 803 days 		ESLA Estrella Immunopharma, Inc. EB103 Trial Phase 2 — $6B Primary completion for EB103 trial (NCT06343311) in B-Cell Non-Hodgkin's Lymphoma (NHL)
2026-12-31
in 803 days 		PFE PFIZER fulvestrant Trial Phase 3 — $4B Primary completion for Fulvestrant trial (NCT05226871) in Breast Cancer
2027-01-01
in 9673 days 		EXEL Exelixis, Inc. Cabozantinib PDUFA Phase 3 — $6B For advanced hepatocellular carcinoma. sNDA filing. Extracted from SEC filing: 8-K
2027-01-01
in 9673 days 		TAK TAKEDA PHARMACEUTICAL CO LTD Potential Polycythemia Vera Treatment PDUFA NDA — $2B For Polycythemia Vera. NDA filing. AI-extracted from news: Takeda, Protagonist Say FDA Acc
2027-01-01
in 9673 days 		REPL Replimune Group, Inc. RP3 Trial Phase 2 — $3B Primary completion for RP3 trial (NCT05733611) in Refractory Metastatic Colorectal Cancer
2027-01-04
in 9676 days 		MRK MERCK Paclitaxel Trial Phase 3 — $12B Primary completion for Paclitaxel trial (NCT06356311) in Gastroesophageal Cancer
2027-01-04
in 9676 days 		MRK MERCK Rescue medication Trial Phase 3 — $3B Primary completion for Rescue medication trial (NCT06356311) in Gastroesophageal Cancer
2027-01-04
in 9676 days 		MRK MERCK Sacituzumab tirumotecan Trial Phase 3 — $8B Primary completion for Sacituzumab tirumotecan trial (NCT06356311) in Gastroesophageal Can
2027-01-04
in 9676 days 		MRK MERCK Supportive care measures Trial Phase 3 — $15B Primary completion for Supportive care measures trial (NCT06356311) in Gastroesophageal Ca
2027-01-04
in 9676 days 		AZNCF ASTRAZENECA PLC AZD0780 Trial Phase 3 — $4B Primary completion for AZD0780 trial (NCT07000136) in Heterozygous Familial Hypercholester
2027-01-04
in 9676 days 		MRK MERCK Trifluridine-Tipiracil Trial Phase 3 — $8B Primary completion for Trifluridine-Tipiracil trial (NCT06356311) in Gastroesophageal Canc
2027-01-07
in 9679 days 		RHHBY Roche Holding AG Ranibizumab Trial Phase 3 — $4B Primary completion for Ranibizumab trial (NCT04657289) in Neovascular Age-related Macular
2027-01-07
in 9679 days 		SNYNF Sanofi PCV21 Trial Phase 3 — $4B Primary completion for PCV21 trial (NCT07247188) in Sickle Cell Disease
2027-01-07
in 9679 days 		NVSEF NOVARTIS AG EYU688 Trial Phase 2 — $1B Primary completion for EYU688 trial (NCT06006559) in Dengue
2027-01-07
in 9679 days 		AZN AstraZeneca PLC AZD9829 Trial Phase 2 — $12B Primary completion for AZD9829 trial (NCT06179511) in Hematological Malignancies
2027-01-08
in 9680 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 — $15B Primary completion for Itepekimab (SAR440340) trial (NCT06834347) in Chronic Rhinosinusiti
2027-01-08
in 9680 days 		OCUL Ocular Therapeutix, Inc. Aflibercept Trial Phase 3 — $8B Primary completion for Aflibercept trial (NCT06495918) in Neovascular Age-related Macular
2027-01-08
in 9680 days 		SNY Sanofi Mometasone furoate nasal spray (MFNS) Trial Phase 3 — $2B Primary completion for Mometasone furoate nasal spray (MFNS) trial (NCT06834360) in Chroni
2027-01-08
in 9680 days 		SNY Sanofi Isatuximab SC-OBDS Trial Phase 2 — $4B Primary completion for Isatuximab SC-OBDS trial (NCT06356571) in Plasma Cell Myeloma Refra
2027-01-12
in 9684 days 		MRK MERCK Sacituzumab Govitecan Trial Phase 3 — $15B Primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-C
2027-01-12
in 9684 days 		GSK GSK plc Adjuvanted RSVPreF3 vaccine Trial Phase 2 — $4B Primary completion for Adjuvanted RSVPreF3 vaccine trial (NCT07092865) in Respiratory Sync
2027-01-14
in 9686 days 		SBFM Sunshine Biopharma Inc. 608 Q2W Trial Phase 3 — $12B Primary completion for Placebo trial (NCT07261644) in Ankylosing Spondylitis
2027-01-14
in 9686 days 		SBFM Sunshine Biopharma Inc. 608 dose Trial Phase 3 — $3B Primary completion for 608 dose trial (NCT07261644) in Ankylosing Spondylitis
2027-01-14
in 9686 days 		NVO Novo Nordisk A/S UBT251 Trial Phase 2 — $15B Primary completion for UBT251 trial (NCT07395687) in Overweight
2027-01-14
in 9686 days 		REGN Regeneron Pharmaceuticals, Inc. Sarilumab Trial Phase 3 — $15B Primary completion for Sarilumab trial (NCT05125016) in Metastatic Castration-resistant Pr
2027-01-14
in 9686 days 		REGN Regeneron Pharmaceuticals, Inc. cemiplimab Trial Phase 3 — $1B Primary completion for Cemiplimab trial (NCT05125016) in Metastatic Castration-resistant P
2027-01-14
in 9686 days 		REGN Regeneron Pharmaceuticals, Inc. REGN5678 Trial Phase 2 — $6B Primary completion for REGN5678 trial (NCT05125016) in Metastatic Castration-resistant Pro
2027-01-15
in 9687 days 		GSK GSK plc FF/UMEC/VI Trial Phase 3 — $20B Primary completion for FF/UMEC/VI trial (NCT05757102) in Asthma
2027-01-15
in 9687 days 		POCI PRECISION OPTICS CORPORATION, INC. 40 mg/day vormatrogine for 12 weeks Trial Phase 3 — $4B Primary completion for 40 mg/day vormatrogine for 12 weeks trial (NCT07505004) in Focal Ep
2027-01-15
in 9687 days 		PCVX Vaxcyte, Inc. 31 valent pneumococcal conjugate vaccine Trial Phase 3 — $6B Primary completion for 31 valent pneumococcal conjugate vaccine trial (NCT07284654) in Pne
2027-01-15
in 9687 days 		SNY Sanofi efanesoctocog alfa (BIVV001) Trial Phase 3 — $5B Primary completion for efanesoctocog alfa (BIVV001) trial (NCT04644575) in Hemophilia A
2027-01-15
in 9687 days 		PCVX Vaxcyte, Inc. PCV20 Trial Phase 3 — $6B Primary completion for PCV20 trial (NCT07284654) in Pneumococcal Vaccines
2027-01-15
in 9687 days 		ABBV AbbVie Inc. Upadacitinib Trial Phase 3 — $8B Primary completion for Upadacitinib trial (NCT06701331) in Atopic Dermatitis
2027-01-15
in 9687 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 — $25B Primary completion for Orforglipron trial (NCT06972472) in Obesity
2027-01-15
in 9687 days 		MLTX MoonLake Immunotherapeutics Risankizumab Trial Phase 3 — $5B Primary completion for Risankizumab trial (NCT06641089) in Arthritis, Psoriatic
2027-01-15
in 9687 days 		AMGN Amgen Inc. Ocrelizumab (US) Trial Phase 3 — $10B Primary completion for Ocrelizumab (US) trial (NCT06700343) in Relapsing-remitting Multipl
2027-01-15
in 9687 days 		AZTR Azitra, Inc. ATR04-484 Trial Phase 2 — $2B Primary completion for ATR04-484 trial (NCT06830863) in EGFR Inhibitor-associated Rash
2027-01-15
in 9687 days 		GILD Gilead Sciences, Inc. Tilpisertib Fosmecarbil Trial Phase 2 — $8B Primary completion for Tilpisertib Fosmecarbil trial (NCT06029972) in Ulcerative Colitis
2027-01-15
in 9687 days 		COYA Coya Therapeutics, Inc. COYA 302 Trial Phase 2 — $2B Primary completion for COYA 302 trial (NCT07161999) in Amyotrophic Lateral Sclerosis (ALS)
2027-01-15
in 9687 days 		RCUS Arcus Biosciences, Inc. Domvanalimab Trial Phase 3 — $3B Primary completion for Domvanalimab trial (NCT05329766) in Gastrointestinal Tract Malignan
2027-01-15
in 9687 days 		RCUS Arcus Biosciences, Inc. Quemliclustat Trial Phase 3 — $12B Primary completion for Quemliclustat trial (NCT05329766) in Gastrointestinal Tract Maligna
2027-01-15
in 9687 days 		EWTX Edgewise Therapeutics, Inc. Sevasemten Dose 1 Trial Phase 2 — $1B Primary completion for Sevasemten Dose 1 trial (NCT05540860) in Duchenne Muscular Dystroph
2027-01-15
in 9687 days 		MPLT MapLight Therapeutics, Inc. ML-007C-MA BID Trial Phase 2 — $12B Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia
2027-01-15
in 9687 days 		RCUS Arcus Biosciences, Inc. Zimberelimab Trial Phase 3 — $15B Primary completion for Zimberelimab trial (NCT05329766) in Gastrointestinal Tract Malignan
2027-01-16
in 9688 days 		CRBP Corbus Pharmaceuticals Holdings, Inc. CRB-701 Trial Phase 2 — $2B Primary completion for CRB-701 trial (NCT06265727) in Solid Tumor, Adult
2027-01-17
in 9689 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma
2027-01-17
in 9689 days 		MRK MERCK Sacituzumab Tirumotecan (sac-TMT) Trial Phase 2 — $6B Primary completion for Sacituzumab Tirumotecan (sac-TMT) trial (NCT06469944) in Gastroesop
2027-01-18
in 9690 days 		PFE PFIZER RSVpreF Trial Phase 3 — $6B Primary completion for RSVpreF trial (NCT05035212) in Lower Respiratory Tract Illness
2027-01-18
in 9690 days 		SNY Sanofi Investigational hMPV/RSV vaccine Trial Phase 2 — $3B Primary completion for Investigational hMPV/RSV vaccine trial (NCT06686654) in Human Metap
2027-01-18
in 9690 days 		AZNCF ASTRAZENECA PLC Durvalumab Trial Phase 3 — $4B Primary completion for Durvalumab trial (NCT05374603) in Lung Cancer
2027-01-18
in 9690 days 		AZN AstraZeneca PLC Savolitinib Trial Phase 3 — $4B Primary completion for Savolitinib trial (NCT05374603) in Lung Cancer
2027-01-19
in 9691 days 		SNY Sanofi SAR445877 Trial Phase 2 — $3B Primary completion for SAR445877 trial (NCT05584670) in Solid Tumor
2027-01-20
in 9692 days 		GSK GSK plc Bepirovirsen Trial Phase 2 — $3B Primary completion for Bepirovirsen trial (NCT06497504) in Hepatitis B
2027-01-21
in 9693 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 — $80B Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mell
2027-01-25
in 9697 days 		NVO Novo Nordisk A/S Insulin icodec Trial Phase 3 — $8B Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1
2027-01-25
in 9697 days 		VRTX Vertex Pharmaceuticals Incorporated Suzetrigine Trial Phase 3 — $30B Primary completion for Suzetrigine trial (NCT06696443) in Diabetic Peripheral Neuropathic
2027-01-25
in 9697 days 		PFE PFIZER MET233 and MET097 Trial Phase 2 — $50B Primary completion for MET233 and MET097 trial (NCT06924320) in Obesity and Obesity-relate
2027-01-28
in 9700 days 		REGN Regeneron Pharmaceuticals, Inc. Ravulizumab Trial Phase 3 — $2B Primary completion for Ravulizumab trial (NCT05133531) in Paroxysmal Nocturnal Hemoglobinu
2027-01-28
in 9700 days 		REGN Regeneron Pharmaceuticals, Inc. Cemdisiran Trial Phase 3 — $2B Primary completion for Cemdisiran trial (NCT05133531) in Paroxysmal Nocturnal Hemoglobinur
2027-01-28
in 9700 days 		VNDA Vanda Pharmaceuticals Inc. Imsidolimab PDUFA Phase 2 — $3B For Rare Skin Disease. BLA filing. AI-extracted from news: Vanda Pharmaceuticals Says US F
2027-01-28
in 9700 days 		AZN AstraZeneca PLC Rilvegostomig Trial Phase 3 — $4B Primary completion for Rilvegostomig trial (NCT07069712) in Gastroesophageal Adenocarcinom
2027-01-28
in 9700 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 — $12B Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2027-01-28
in 9700 days 		AZN AstraZeneca PLC 5-Fluorouracil (5-FU) Trial Phase 2 — $6B Primary completion for 5-Fluorouracil (5-FU) trial (NCT07069712) in Gastroesophageal Adeno
2027-01-28
in 9700 days 		AZN AstraZeneca PLC AZD0901 Trial Phase 2 — $3B Primary completion for AZD0901 trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2027-01-29
in 9701 days 		NVS Novartis AG Iptacopan Trial Phase 3 — $2B Primary completion for iptacopan trial (NCT04817618) in C3G
2027-01-30
in 9702 days 		RHHBY Roche Holding AG Afimkibart Trial Phase 3 — $8B Primary completion for Afimkibart trial (NCT06588855) in Moderately to Severely Active Ulc
2027-01-31
in 9703 days 		MRK MERCK Fluorouracil (5-FU) Trial Phase 3 — $4B Primary completion for Fluorouracil (5-FU) trial (NCT04241185) in Urinary Bladder Neoplasm
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Ocrelizumab Test Formulation Trial Phase 2 — $28B Primary completion for Ocrelizumab Test Formulation trial (NCT07074886) in Multiple Sclero
2027-01-31
in 9703 days 		DSKYF Daiichi Sankyo DS-5141b Trial Phase 2 — $1B Primary completion for DS-5141b trial (NCT04433234) in Duchenne Muscular Dystrophy
2027-01-31
in 9703 days 		CHHE China Health Industries Holdings, Inc. MK-1045 Trial Phase 2 — $2B Primary completion for MK-1045 trial (NCT05579132) in Acute Lymphoblastic Leukemia
2027-01-31
in 9703 days 		CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ-201 Administration Trial Phase 2 — $15B Primary completion for CELZ-201 Administration trial (NCT05626712) in Type 1 Diabetes
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Oxaliplatin Trial Phase 3 — $8B Primary completion for Oxaliplatin trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Gemcitabine Trial Phase 3 — $8B Primary completion for Gemcitabine trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Glofitamab Trial Phase 3 — $5B Primary completion for Glofitamab trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Obinutuzumab Trial Phase 3 — $4B Primary completion for Obinutuzumab trial (NCT06806033) in B-Cell Non-Hodgkins Lymphoma
2027-02-01
in 9773 days 		MRK MERCK Cisplatin Trial Phase 3 — $8B Primary completion for Cisplatin trial (NCT04241185) in Urinary Bladder Neoplasms
2027-02-01
in 9773 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04241185) in Urinary Bladder Neoplasms
2027-02-01
in 9773 days 		MRK MERCK levoleucovorin Trial Phase 3 — $2B Primary completion for levoleucovorin trial (NCT04210115) in Esophageal Squamous Cell Carc
2027-02-01
in 9773 days 		MRK MERCK 5-FU Trial Phase 3 — $2B Primary completion for 5-FU trial (NCT04210115) in Esophageal Squamous Cell Carcinoma (ESC
2027-02-01
in 9773 days 		MRK MERCK Leucovorin Trial Phase 3 — $3B Primary completion for leucovorin trial (NCT04210115) in Esophageal Squamous Cell Carcinom
2027-02-02
in 9774 days 		NVS Novartis AG LXH254 Trial Phase 2 — $8B Primary completion for LXH254 trial (NCT04417621) in Melanoma
2027-02-03
in 9775 days 		BAYRY BAYER BAY2927088 Trial Phase 3 — $4B Primary completion for BAY2927088 trial (NCT06760819) in Advanced Solid Tumors
2027-02-04
in 9776 days 		MLTX MoonLake Immunotherapeutics Sonelokimab Trial Phase 3 — $1B Primary completion for Sonelokimab trial (NCT06641076) in Arthritis, Psoriatic
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Carboplatin Trial Phase 3 — $15B Primary completion for Carboplatin trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Ipilimumab Trial Phase 3 — $8B Primary completion for Ipilimumab trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Nivolumab Trial Phase 3 — $4B Primary completion for Nivolumab trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Paclitaxel Trial Phase 3 — $12B Primary completion for Paclitaxel trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Pemetrexed Trial Phase 2 — $15B Primary completion for Pemetrexed trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-08
in 9780 days 		RHHBY Roche Holding AG RO7795081 Trial Phase 2 — $50B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-08
in 9780 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 — $55B Primary completion for Semaglutide trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-09
in 9781 days 		REGN Regeneron Pharmaceuticals, Inc. REGN9933 Trial Phase 2 — $8B Primary completion for REGN9933 trial (NCT07175428) in Atrial Fibrillation (AF)
2027-02-09
in 9781 days 		REGN Regeneron Pharmaceuticals, Inc. REGN7508 Trial Phase 3 — $8B Primary completion for REGN7508 trial (NCT07175428) in Atrial Fibrillation (AF)
2027-02-09
in 9781 days 		REGN Regeneron Pharmaceuticals, Inc. Apixaban Trial Phase 2 — $12B Primary completion for Apixaban trial (NCT07175428) in Atrial Fibrillation (AF)
2027-02-11
in 9783 days 		RHHBY Roche Holding AG Ranibizumab Trial Phase 3 — $4B Primary completion for Ranibizumab trial (NCT04567303) in Macular Degeneration
2027-02-11
in 9783 days 		RHHBY Roche Holding AG Zifibancimig Trial Phase 2 — $10B Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration
2027-02-11
in 9783 days 		AZNCF ASTRAZENECA PLC AZD4144 Trial Phase 2 — $8B Primary completion for AZD4144 trial (NCT07215702) in Sepsis
2027-02-12
in 9784 days 		OCUL Ocular Therapeutix, Inc. AXPAXLI PDUFA NDA — $12B For wet-AMD. NDA submitted. AI-extracted from: Ocular: 'Buy' As AXPAXLI Program For Wet-AM
2027-02-13
in 9785 days 		EPZM Epizyme, Inc. Tazemetostat Trial Phase 3 — $8B Primary completion for Tazemetostat trial (NCT04224493) in Relapsed/Refractory Follicular
2027-02-13
in 9785 days 		MRK MERCK vinblastine Trial Phase 2 — $7B Primary completion for vinblastine trial (NCT03407144) in Hodgkin Lymphoma
2027-02-13
in 9785 days 		PFE PFIZER PF-07868489 Trial Phase 2 — $3B Primary completion for PF-07868489 trial (NCT06137742) in Pulmonary Arterial Hypertension
2027-02-13
in 9785 days 		MRK MERCK Doxorubicin Trial Phase 3 — $18B Primary completion for doxorubicin trial (NCT03407144) in Hodgkin Lymphoma
2027-02-13
in 9785 days 		MRK MERCK Boserolimab Trial Phase 2 — $4B Primary completion for etoposide trial (NCT03407144) in Hodgkin Lymphoma
2027-02-15
in 9787 days 		BIO BIO-RAD LABORATORIES, INC. NH002 (Perflutren Lipid Microspheres) Injectable Suspension Trial Phase 2 — $2B Primary completion for NH002 (Perflutren Lipid Microspheres) Injectable Suspension trial (
2027-02-15
in 9787 days 		GMAB Genmab A/S Paclitaxel Trial Phase 3 — $4B Primary completion for Paclitaxel trial (NCT06619236) in Platinum-resistant Ovarian Cancer
2027-02-15
in 9787 days 		GILD Gilead Sciences, Inc. Sacituzumab Govitecan-hziy Trial Phase 3 — $5B Primary completion for Sacituzumab Govitecan-hziy trial (NCT05382286) in Triple Negative B
2027-02-15
in 9787 days 		ABBV AbbVie Inc. Atogepant Trial Phase 3 — $4B Primary completion for Atogepant trial (NCT06806293) in Menstrual Migraine (MM)
2027-02-15
in 9787 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 — $25B Primary completion for Orforglipron trial (NCT06672549) in Obesity
2027-02-15
in 9787 days 		SBFM Sunshine Biopharma Inc. 610 Trial Phase 3 — $20B Primary completion for 610 trial (NCT06680947) in Asthma
2027-02-15
in 9787 days 		GMAB Genmab A/S Rina-S Trial Phase 3 — $4B Primary completion for Rina-S trial (NCT06619236) in Platinum-resistant Ovarian Cancer
2027-02-15
in 9787 days 		MRNA Moderna, Inc. mRNA-1403 Trial Phase 3 — $2B Primary completion for mRNA-1403 trial (NCT06592794) in Acute Gastroenteritis
2027-02-15
in 9787 days 		GILD Gilead Sciences, Inc. Vinflunine Trial Phase 3 — $2B Primary completion for Paclitaxel trial (NCT05382286) in Triple Negative Breast Cancer
2027-02-15
in 9787 days 		XLO Xilio Therapeutics, Inc. XTX301 Trial Phase 2 — $4B Primary completion for XTX301 trial (NCT05684965) in Advanced Solid Tumor
2027-02-15
in 9787 days 		ABBV AbbVie Inc. Venetoclax Trial Phase 3 — $8B Primary completion for Venetoclax trial (NCT04086264) in Acute Myeloid Leukemia
2027-02-15
in 9787 days 		IRON Disc Medicine, Inc. DISC-3405 Trial Phase 2 — $2B Primary completion for DISC-3405 trial (NCT06985147) in Polycythemia Vera (PV)
2027-02-15
in 9787 days 		ABCL AbCellera Biologics Inc. ABCL635 Trial Phase 2 — $2B Primary completion for ABCL635 trial (NCT07118891) in Vasomotor Symptoms Associated With M
2027-02-15
in 9787 days 		GNLX GENELUX Corp Platinum chemotherapy: carboplatin or cisplatin Trial Phase 2 — $10B Primary completion for Platinum chemotherapy: carboplatin or cisplatin trial (NCT06463665)
2027-02-15
in 9787 days 		KRYS Krystal Biotech, Inc. KB707 Trial Phase 2 — $10B Primary completion for KB707 trial (NCT06228326) in Lung Cancer, Non-small Cell
2027-02-15
in 9787 days 		ABBV AbbVie Inc. Ravagalimab Trial Phase 2 — $25B Primary completion for Ravagalimab trial (NCT06972446) in Rheumatoid Arthritis
2027-02-15
in 9787 days 		MGNX MacroGenics, Inc. lorigerlimab Trial Phase 2 — $8B Primary completion for Lorigerlimab trial (NCT06730347) in Platinum-resistant Ovarian Canc
2027-02-15
in 9787 days 		ABBV AbbVie Inc. IMGN632 Trial Phase 2 — $8B Primary completion for IMGN632 trial (NCT04086264) in Acute Myeloid Leukemia
2027-02-15
in 9787 days 		ABBV AbbVie Inc. Lutikizumab Trial Phase 3 — $1B Primary completion for Lutikizumab trial (NCT06524635) in Hidradenitis Suppurativa
2027-02-15
in 9787 days 		LLY Eli Lilly and Company Brenipatide Trial Phase 2 — $20B Primary completion for Brenipatide trial (NCT07223840) in Smoking
2027-02-15
in 9787 days 		IPIX Innovation Pharmaceuticals Inc. GI-108 Trial Phase 2 — $4B Primary completion for GI-108 trial (NCT07172802) in Advanced Solid Tumor
2027-02-15
in 9787 days 		MPLT MapLight Therapeutics, Inc. ML-007C-MA Trial Phase 2 — $2B Primary completion for ML-007C-MA trial (NCT06887192) in Psychosis Associated With Alzheim
2027-02-15
in 9787 days 		GNLX GENELUX Corp olvimulogene nanivacirepvec Trial Phase 3 — $4B Primary completion for Olvimulogene nanivacirepvec trial (NCT06463665) in Advanced Non-squ
2027-02-17
in 9789 days 		MLTX MoonLake Immunotherapeutics — PDUFA NDA — $8B For inflammatory arthritis. BLA submitted. AI-extracted from: MoonLake has 'confidence' ah
2027-02-18
in 9790 days 		AZN AstraZeneca PLC Zibotentan/Dapagliflozin Trial Phase 3 — $5B Primary completion for Zibotentan/Dapagliflozin trial (NCT06087835) in Chronic Kidney Dise
2027-02-19
in 9791 days 		RHHBY Roche Holding AG Fulvestrant Trial Phase 3 — $8B Primary completion for Fulvestrant trial (NCT06065748) in Estrogen Receptor-Positive, HER2
2027-02-19
in 9791 days 		RHHBY Roche Holding AG Giredestrant Trial Phase 3 — $4B Primary completion for Giredestrant trial (NCT06065748) in Estrogen Receptor-Positive, HER
2027-02-20
in 9792 days 		REGN Regeneron Pharmaceuticals, Inc. REGN7508 Trial Phase 3 — $8B Primary completion for REGN7508 trial (NCT07015905) in Venous Thromboembolism (VTE)
2027-02-20
in 9792 days 		REGN Regeneron Pharmaceuticals, Inc. REGN9933 Trial Phase 2 — $8B Primary completion for Enoxaparin trial (NCT07015905) in Venous Thromboembolism (VTE)
2027-02-20
in 9792 days 		REGN Regeneron Pharmaceuticals, Inc. Dupilumab Trial Phase 3 — $8B Primary completion for Placebo trial (NCT07015905) in Venous Thromboembolism (VTE)
2027-02-20
in 9792 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB518 Trial Phase 2 — $11B Primary completion for SKB518 trial (NCT07019675) in Lung Carcinoma
2027-02-22
in 9794 days 		AZNCF ASTRAZENECA PLC Osimertinib Trial Phase 3 — $15B Primary completion for Osimertinib trial (NCT05629234) in Cancer
2027-02-22
in 9794 days 		NVS Novartis AG Remibrutinib Trial Phase 3 — $12B Primary completion for Remibrutinib trial (NCT06868212) in Chronic Spontaneous Urticaria (
2027-02-22
in 9794 days 		NVS Novartis AG Dupilumab Trial Phase 3 — $3B Primary completion for Dupilumab trial (NCT06868212) in Chronic Spontaneous Urticaria (CSU
2027-02-22
in 9794 days 		AMGN Amgen Inc. AMG 732 Trial Phase 2 — $2B Primary completion for AMG 732 trial (NCT06401044) in Thyroid Eye Disease
2027-02-23
in 9795 days 		PFE PFIZER Tofacitinib Trial Phase 3 — $25B Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis
2027-02-25
in 9797 days 		UCBJY UCB Brivaracetam Trial Phase 3 — $15B Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy
2027-02-26
in 9798 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 — $55B Primary completion for Placebo trial (NCT05138133) in Lupus Nephritis
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Obinutuzumab Trial Phase 3 — $4B Primary completion for Obinutuzumab trial (NCT06084936) in Lymphoma
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 — $25B Primary completion for Rituximab trial (NCT06084936) in Lymphoma
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Glofitamab Trial Phase 3 — $5B Primary completion for Glofitamab trial (NCT06084936) in Lymphoma
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Bendamustine Trial Phase 3 — $4B Primary completion for Bendamustine trial (NCT06084936) in Lymphoma
2027-02-26
in 9798 days 		ARDX Ardelyx Tenapanor 5 mg BID Trial Phase 3 — $2B Primary completion for Tenapanor 5 mg BID trial (NCT07382167) in Chronic Idiopathic Consti
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Mosunetuzumab Trial Phase 3 — $9B Primary completion for Tocilizumab trial (NCT05535244) in Multiple Myeloma
2027-02-26
in 9798 days 		NVS Novartis AG letrozole Trial Phase 3 — $18B Primary completion for Letrozole trial (NCT01872260) in Breast Cancer
2027-02-26
in 9798 days 		NVS Novartis AG BYL719 Trial Phase 2 — $18B Primary completion for BYL719 trial (NCT01872260) in Breast Cancer
2027-02-26
in 9798 days 		NVS Novartis AG Alpelisib Trial Phase 3 — $12B Primary completion for Alpelisib trial (NCT04524000) in Advanced Breast Cancer
2027-02-26
in 9798 days 		MRK MERCK Cabozantinib Trial Phase 3 — $8B Primary completion for Cabozantinib trial (NCT03634540) in Renal Cell Carcinoma (RCC)
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Cevostamab Trial Phase 2 — $15B Primary completion for Cevostamab trial (NCT05535244) in Multiple Myeloma
2027-02-28
in 9800 days 		REGN Regeneron Pharmaceuticals, Inc. REGN5715 Trial Phase 3 — $2B Primary completion for REGN5715 trial (NCT07309432) in Allergic Conjunctivitis
2027-02-28
in 9800 days 		REGN Regeneron Pharmaceuticals, Inc. REGN5713 Trial Phase 3 — $5B Primary completion for REGN5713 trial (NCT07309432) in Allergic Conjunctivitis
2027-02-28
in 9800 days 		FBRX Forte Biosciences, Inc. FB102 Trial Phase 2 — $2B Primary completion for FB102 trial (NCT06982963) in Celiac Disease
2027-03-01
in 9873 days 		GSK GSK plc Feladilimab PDUFA Phase 2 — $15B For multiple myeloma. BLA filing. Extracted from SEC filing: 6-K
2027-03-01
in 9873 days 		NVO Novo Nordisk A/S CagriSema (Cagrilintide B and Semaglutide I) Trial Phase 3 — $25B Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT07011667) in
2027-03-01
in 9873 days 		GENK GEN Restaurant Group, Inc. SUL-238 (1500 mg t.i.d.) film-coated tablets Trial Phase 2 — $12B Primary completion for SUL-238 (1500 mg t.i.d.) film-coated tablets trial (NCT07322887) in
2027-03-04
in 9876 days 		XENE Xenon Pharmaceuticals Inc. Azetukalner PDUFA Phase 3 — $15B For epilepsy. NDA submitted. AI-extracted from: Xenon gets Phase 3 win with epilepsy drug,
2027-03-07
in 9879 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-20089 Trial Phase 3 — $5B Primary completion for HS-20089 trial (NCT06855069) in Ovarian Cancer
2027-03-08
in 9880 days 		MRK MERCK methotrexate Trial Phase 3 — $12B Primary completion for Methotrexate trial (NCT07176390) in Arthritis, Rheumatoid
2027-03-08
in 9880 days 		MRK MERCK Tulisokibart Trial Phase 3 — $1B Primary completion for Tulisokibart trial (NCT07176390) in Arthritis, Rheumatoid
2027-03-09
in 9881 days 		PFE PFIZER Ritlecitinib 50 mg Trial Phase 3 — $3B Primary completion for Ritlecitinib 50 mg trial (NCT06873945) in Alopecia Areata
2027-03-09
in 9881 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoria
2027-03-09
in 9881 days 		PFE PFIZER Ritlecitinib 100 mg Trial Phase 3 — $2B Primary completion for Ritlecitinib 100 mg trial (NCT06873945) in Alopecia Areata
2027-03-10
in 9882 days 		AZN AstraZeneca PLC Surovatamig Trial Phase 2 — $6B Primary completion for Surovatamig trial (NCT06526793) in B-cell Non-Hodgkin Lymphoma
2027-03-11
in 9883 days 		BMY Bristol-Myers Squibb Company Ipilimumab Trial Phase 3 — $8B Primary completion for Ipilimumab trial (NCT03873402) in Renal Cell Carcinoma
2027-03-11
in 9883 days 		BMY Bristol-Myers Squibb Company Nivolumab Trial Phase 3 — $4B Primary completion for Nivolumab trial (NCT03873402) in Renal Cell Carcinoma
2027-03-11
in 9883 days 		REGN Regeneron Pharmaceuticals, Inc. Fixed Dose Combination (FDC) cemiplimab+fianlimab Trial Phase 2 — $8B Primary completion for Fixed Dose Combination (FDC) cemiplimab+fianlimab trial (NCT0619095
2027-03-11
in 9883 days 		REGN Regeneron Pharmaceuticals, Inc. Dupilumab Trial Phase 3 — $8B Primary completion for Placebo trial (NCT06190951) in Melanoma
2027-03-12
in 9884 days 		TVTX Travere Therapeutics, Inc. Sparsentan Trial Phase 3 — $2B Primary completion for Sparsentan trial (NCT05003986) in Focal Segmental Glomerulosclerosi
2027-03-13
in 9885 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 — $15B Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity
2027-03-13
in 9885 days 		OTSKF OTSUKA Sibeprenlimab Trial Phase 2 — $2B Primary completion for Sibeprenlimab trial (NCT06928142) in Sjogren Disease
2027-03-14
in 9886 days 		ZLAB Zai Lab Limited ZL-1109 (VRDN-003) Trial Phase 3 — $2B Primary completion for ZL-1109 (VRDN-003) trial (NCT07211776) in Thyroid Eye Disease (TED)
2027-03-15
in 9887 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR Rezvilutamide Tablets Trial Phase 3 — $5B Primary completion for Rezvilutamide Tablets trial (NCT07241416) in Metastatic Hormone-sen
2027-03-15
in 9887 days 		PCVX Vaxcyte, Inc. PCV20 Trial Phase 3 — $6B Primary completion for PCV20 trial (NCT07425392) in Pneumococcal Vaccines
2027-03-15
in 9887 days 		ARGX argenx SE Efgartigimod IV Trial Phase 3 — $1B Primary completion for Efgartigimod IV trial (NCT04833894) in Generalized Myasthenia Gravi
2027-03-15
in 9887 days 		ADVB Advanced Biomed Inc. [18F]PSMA-1007 Trial Phase 3 — $15B Primary completion for [18F]PSMA-1007 trial (NCT06122584) in Prostate Cancer
2027-03-15
in 9887 days 		ATXS Astria Therapeutics, Inc. navenibart Trial Phase 3 — $2B Primary completion for navenibart trial (NCT06842823) in Hereditary Angioedema (HAE)
2027-03-15
in 9887 days 		OCUL Ocular Therapeutix, Inc. Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection proce Trial Phase 3 — $2B Primary completion for Single intravitreal injection of axitinib hydrogel implant followed
2027-03-15
in 9887 days 		VTRS MYLAN Transdermal system containing progestin Trial Phase 3 — $15B Primary completion for Transdermal system containing progestin trial (NCT06672016) in Fema
2027-03-15
in 9887 days 		BGNE BeiGene, Ltd. bendamustine Trial Phase 3 — $4B Primary completion for bendamustine trial (NCT04002297) in Mantle Cell Lymphoma; Non-Hodgk
2027-03-15
in 9887 days 		BGNE BeiGene, Ltd. Zanubrutinib Trial Phase 3 — $1B Primary completion for zanubrutinib trial (NCT04002297) in Mantle Cell Lymphoma; Non-Hodgk
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Cariprazine Trial Phase 3 — $15B Primary completion for Cariprazine trial (NCT04777357) in Depression
2027-03-15
in 9887 days 		PCVX Vaxcyte, Inc. 31-valent pneumococcal conjugate vaccine Trial Phase 3 — $6B Primary completion for 31-valent pneumococcal conjugate vaccine trial (NCT07365826) in Pne
2027-03-15
in 9887 days 		DCPH Deciphera Pharmaceuticals, Inc. Inlexisertib Trial Phase 2 — $15B Primary completion for Inlexisertib trial (NCT05957367) in GIST
2027-03-15
in 9887 days 		FDMT 4D Molecular Therapeutics, Inc. Aflibercept IVT Trial Phase 2 — $8B Primary completion for Aflibercept IVT trial (NCT05197270) in Neovascular (Wet) Age-Relate
2027-03-15
in 9887 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR0302 Tablets Trial Phase 2 — $2B Primary completion for SHR0302 Tablets trial (NCT07251595) in Non-segmental Vitiligo
2027-03-15
in 9887 days 		LLY Eli Lilly and Company Macupatide Trial Phase 2 — $25B Primary completion for Macupatide trial (NCT07215559) in Obesity
2027-03-15
in 9887 days 		EWTX Edgewise Therapeutics, Inc. Sevasemten Dose 1 Trial Phase 2 — $1B Primary completion for Sevasemten Dose 1 trial (NCT06100887) in Duchenne Muscular Dystroph
2027-03-15
in 9887 days 		DCPH Deciphera Pharmaceuticals, Inc. Ripretinib Trial Phase 3 — $2B Primary completion for Ripretinib trial (NCT05957367) in GIST
2027-03-15
in 9887 days 		LLY Eli Lilly and Company Solbinsiran Trial Phase 2 — $3B Primary completion for Solbinsiran trial (NCT07269210) in Severe Hypertriglyceridemia
2027-03-15
in 9887 days 		GMAB Genmab A/S Epcoritamab Trial Phase 3 — $5B Primary completion for Epcoritamab trial (NCT05451810) in Diffuse Large B-Cell Lymphoma
2027-03-15
in 9887 days 		FDMT 4D Molecular Therapeutics, Inc. 4D-150 IVT Trial Phase 2 — $4B Primary completion for 4D-150 IVT trial (NCT05197270) in Neovascular (Wet) Age-Related Mac
2027-03-15
in 9887 days 		ALLR Allarity Therapeutics, Inc. 2X-121 Trial Phase 2 — $6B Primary completion for 2X-121 trial (NCT03878849) in Advanced Ovarian Cancer
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Paclitaxel Trial Phase 3 — $15B Primary completion for Paclitaxel trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Gemcitabine Trial Phase 2 — $5B Primary completion for Gemcitabine trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Docetaxel Trial Phase 3 — $15B Primary completion for Docetaxel trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Budigalimab Trial Phase 3 — $3B Primary completion for Budigalimab trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		SPTX Seaport Therapeutics, Inc. SPT-300 Trial Phase 2 — $15B Primary completion for SPT-300 trial (NCT07065240) in Major Depressive Disorder (MDD)
2027-03-15
in 9887 days 		MNKD MannKind Corporation Basal insulin Trial Phase 2 — $15B Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Livmoniplimab Trial Phase 3 — $4B Primary completion for Livmoniplimab trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		BIOE Bio Essence Corp ROC-101 Trial Phase 2 — $3B Primary completion for ROC-101 trial (NCT07175038) in Pulmonary Arterial Hypertension (PAH
2027-03-15
in 9887 days 		CGEN Compugen Ltd. COM701 Trial Phase 2 — $5B Primary completion for COM701 trial (NCT06888921) in Ovarian Cancer
2027-03-15
in 9887 days 		ALGS Aligos Therapeutics, Inc. ALG-000184 Trial Phase 2 — $8B Primary completion for ALG-000184 trial (NCT06963710) in Chronic Hepatitis B Infection
2027-03-15
in 9887 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-4642 Trial Phase 2 — $4B Primary completion for HRS-4642 trial (NCT06520488) in Advanced Solid Tumors
2027-03-15
in 9887 days 		NUVB Nuvation Bio Inc. NUV-1511 Trial Phase 2 — $4B Primary completion for NUV-1511 trial (NCT06334432) in Advanced Solid Tumor
2027-03-15
in 9887 days 		COGT Cogent Biosciences, Inc. CGT4859 Trial Phase 2 — $1B Primary completion for CGT4859 trial (NCT06777316) in Intrahepatic Cholangiocarcinoma (Icc
2027-03-15
in 9887 days 		BIO BIO-RAD LABORATORIES, INC. BG1805 Trial Phase 2 — $2B Primary completion for BG1805 trial (NCT06118788) in Leukemia, Myeloid, Acute
2027-03-15
in 9887 days 		PCRX Pacira BioSciences, Inc. Enekinragene Inzadenovec (PCRX-201) Trial Phase 2 — $12B Primary completion for Enekinragene Inzadenovec (PCRX-201) trial (NCT06884865) in Osteoart
2027-03-15
in 9887 days 		PCRX Pacira BioSciences, Inc. SKY0402 Trial Phase 3 — $2B Primary completion for Placebo trial (NCT06884865) in Osteoarthritis (OA) of the Knee
2027-03-15
in 9887 days 		EWTX Edgewise Therapeutics, Inc. Sevasemten Dose 2 Trial Phase 2 — $1B Primary completion for Sevasemten Dose 2 trial (NCT06100887) in Duchenne Muscular Dystroph
2027-03-16
in 9888 days 		TKPHF TAKEDA PHARMACEUTICAL CO LTD TAK-755 Trial Phase 3 — $2B Primary completion for TAK-755 trial (NCT04683003) in Thrombotic Thrombocytopenic Purpura
2027-03-17
in 9889 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 — $25B Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity
2027-03-18
in 9890 days 		HELP CYBIN INC. CYB003 Trial Phase 3 — $15B Primary completion for CYB003 trial (NCT06793397) in Major Depressive Disorder (MDD)
2027-03-19
in 9891 days 		UCBJY UCB Bimekizumab Trial Phase 3 — $8B Primary completion for bimekizumab trial (NCT06506916) in Moderate to Severe Plaque Psoria
2027-03-21
in 9893 days 		AZN AstraZeneca PLC Ramucirumab Trial Phase 2 — $15B Primary completion for Ramucirumab trial (NCT07098338) in Non-Small Cell Lung Cancer
2027-03-21
in 9893 days 		AZN AstraZeneca PLC Rilvegostomig Trial Phase 3 — $4B Primary completion for Rilvegostomig trial (NCT07098338) in Non-Small Cell Lung Cancer
2027-03-22
in 9894 days 		REGN Regeneron Pharmaceuticals, Inc. Fianlimab Trial Phase 3 — $8B Primary completion for fianlimab trial (NCT06246916) in Melanoma
2027-03-22
in 9894 days 		REGN Regeneron Pharmaceuticals, Inc. cemiplimab Trial Phase 3 — $1B Primary completion for cemiplimab trial (NCT06246916) in Melanoma
2027-03-22
in 9894 days 		MRK MERCK Lenvatinib Trial Phase 3 — $15B Primary completion for Lenvatinib trial (NCT04976634) in Neoplasm Malignant
2027-03-22
in 9894 days 		MRK MERCK Belzutifan Trial Phase 3 — $8B Primary completion for Belzutifan trial (NCT03634540) in Renal Cell Carcinoma (RCC)
2027-03-22
in 9894 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04976634) in Neoplasm Malignant
2027-03-24
in 9896 days 		NVS Novartis AG Ianalumab Trial Phase 3 — $1B Primary completion for Ianalumab trial (NCT05639114) in Systemic Lupus Erythematosus
2027-03-25
in 9897 days 		SNYNF Sanofi Clotting factor concentrates (CFC) or bypassing agents (BPA) Trial Phase 3 — $8B Primary completion for Fitusiran trial (NCT05662319) in Hemophilia
2027-03-25
in 9897 days 		REGN Regeneron Pharmaceuticals, Inc. Sarilumab Trial Phase 3 — $15B Primary completion for Sarilumab trial (NCT04590326) in Ovarian Cancer
2027-03-25
in 9897 days 		REGN Regeneron Pharmaceuticals, Inc. REGN5668 Trial Phase 2 — $5B Primary completion for REGN5668 trial (NCT04590326) in Ovarian Cancer
2027-03-25
in 9897 days 		REGN Regeneron Pharmaceuticals, Inc. cemiplimab Trial Phase 3 — $1B Primary completion for Cemiplimab trial (NCT04590326) in Ovarian Cancer
2027-03-26
in 9898 days 		AZN AstraZeneca PLC AZD0780 Trial Phase 3 — $4B Primary completion for AZD0780 trial (NCT07000136) in Heterozygous Familial Hypercholester
2027-03-26
in 9898 days 		IPSEY Ipsen Biopharmaceuticals, Inc. IPN10200 Trial Phase 3 — $2B Primary completion for IPN10200 trial (NCT06937931) in Cervical Dystonia
2027-03-28
in 9900 days 		PFE PFIZER PF-07275315 Trial Phase 2 — $20B Primary completion for PF-07275315 trial (NCT06977581) in Asthma
2027-03-30
in 9902 days 		RHHBY Roche Holding AG Emicizumab Trial Phase 3 — $5B Primary completion for Emicizumab trial (NCT06998524) in Von Willebrand Disease, Type 3
2027-03-31
in 9903 days 		AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL Olverembatinib Trial Phase 3 — $2B Primary completion for Olverembatinib trial (NCT06640361) in GIST
2027-03-31
in 9903 days 		RHHBY Roche Holding AG Atezolizumab Trial Phase 3 — $6B Primary completion for Atezolizumab trial (NCT04543617) in Esophageal Squamous Cell Carcin
2027-03-31
in 9903 days 		RHHBY Roche Holding AG Tiragolumab Trial Phase 3 — $4B Primary completion for Tiragolumab trial (NCT04543617) in Esophageal Squamous Cell Carcino
2027-03-31
in 9903 days 		NVSEF NOVARTIS AG CTL019 Trial Phase 3 — $2B Primary completion for CTL019 trial (NCT04094311) in B-cell Acute Lymphoblastic Leukemia
2027-03-31
in 9903 days 		ALT Altimmune, Inc. Pemvidutide Trial Phase 2 — $8B Primary completion for Pemvidutide trial (NCT07009860) in Alcohol Liver Disease
2027-03-31
in 9903 days 		TNGX Tango Therapeutics, Inc. TNG456 Trial Phase 2 — $15B Primary completion for TNG456 trial (NCT06810544) in Non Small Cell Lung Cancer
2027-03-31
in 9903 days 		ESALY Eisai Doxorubicin Trial Phase 2 — $4B Primary completion for E7386 trial (NCT04008797) in Endometrial Neoplasms
2027-03-31
in 9903 days 		MSCLF Satellos Bioscience Inc. SAT-3247 Trial Phase 2 — $1B Primary completion for SAT-3247 trial (NCT07287189) in Duchenne Muscular Dystrophy
2027-03-31
in 9903 days 		ESALY Eisai E7389-LF Trial Phase 2 — $3B Primary completion for E7389-LF trial (NCT04078295) in Solid Neoplasms
2027-03-31
in 9903 days 		CGON CG Oncology, Inc. Cretostimogene Grenadenorepvec Trial Phase 3 — $4B Primary completion for Cretostimogene Grenadenorepvec trial (NCT06567743) in High-Risk Non
2027-03-31
in 9903 days 		RHHBY Roche Holding AG Mosunetuzumab Trial Phase 3 — $9B Primary completion for Tocilizumab trial (NCT04077723) in Lymphoma, Non-Hodgkin
2027-03-31
in 9903 days 		INVA Vivus VI-0609 Trial Phase 2 — $15B Primary completion for VI-0609 trial (NCT06915246) in Lymphoma
2027-03-31
in 9903 days 		AZN AstraZeneca PLC AZD4360 Trial Phase 2 — $3B Primary completion for AZD4360 trial (NCT06921928) in Gastric Cancer
2027-03-31
in 9903 days 		RHHBY Roche Holding AG Englumafusp alfa Trial Phase 2 — $12B Primary completion for Englumafusp alfa trial (NCT04077723) in Lymphoma, Non-Hodgkin
2027-03-31
in 9903 days 		ESALY Eisai BB-1701 Trial Phase 2 — $18B Primary completion for BB-1701 trial (NCT06188559) in Breast Cancer
2027-04-01
in 9973 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR XLJDOD compound granule Trial Phase 3 — $5B Primary completion for XLJDOD compound granule trial (NCT05709249) in Colon Cancer
2027-04-04
in 9976 days 		CFOO China Foods Holdings Ltd. Trastuzumab Pamirtecan (T-Pam, DB-1303, BNT323) PDUFA NDA — $12B For Unresectable or Metastatic HER2-Positive Adult Breast Cancer. BLA accepted. AI-extract
2027-04-06
in 9978 days 		AZN AstraZeneca PLC Olaparib Trial Phase 3 — $12B Primary completion for Olaparib trial (NCT04421963) in Ovarian Cancer
2027-04-06
in 9978 days 		VRTX Vertex Pharmaceuticals Incorporated Suzetrigine Trial Phase 3 — $30B Primary completion for Suzetrigine trial (NCT07231419) in Diabetic Peripheral Neuropathic
2027-04-06
in 9978 days 		VRTX Vertex Pharmaceuticals Incorporated IVA Trial Phase 3 — $6B Primary completion for IVA trial (NCT05331183) in Cystic Fibrosis
2027-04-06
in 9978 days 		VRTX Vertex Pharmaceuticals Incorporated ELX/TEZ/IVA Trial Phase 3 — $6B Primary completion for ELX/TEZ/IVA trial (NCT05331183) in Cystic Fibrosis
2027-04-06
in 9978 days 		ESALY Eisai Perampanel Oral Suspension Trial Phase 2 — $1B Primary completion for Perampanel Oral Suspension trial (NCT04015141) in Pediatric Epilept
2027-04-10
in 9982 days 		NHPAP National Healthcare Properties, Inc. MAIWEIJIAN (Denosumab) PDUFA NDA — $4B sBLA accepted. AI-extracted from: Mabwell Announces Acceptance of Supplemental Biologics L
2027-04-12
in 9984 days 		NVSEF NOVARTIS AG Ianalumab Trial Phase 3 — $2B Primary completion for ianalumab trial (NCT05624749) in Systemic Lupus Erythematosus
2027-04-15
in 9987 days 		MRK MERCK Gefapixant 100 mg Trial Phase 2 — $2B Primary completion for Placebo trial (NCT06489028) in Venous Leg Ulcer
2027-04-15
in 9987 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 — $15B Primary completion for Lumateperone trial (NCT06372964) in Bipolar Depression
2027-04-15
in 9987 days 		MNOV MediciNova, Inc. MN-166 Trial Phase 3 — $2B Primary completion for MN-166 trial (NCT04057898) in Amyotrophic Lateral Sclerosis
2027-04-15
in 9987 days 		XENE Xenon Pharmaceuticals Inc. XEN1101 Trial Phase 3 — $4B Primary completion for XEN1101 trial (NCT05667142) in Primary Generalized Tonic-Clonic Sei
2027-04-15
in 9987 days 		CODX Co-Diagnostics, Inc. allo-APZ2-CVU Trial Phase 3 — $1B Primary completion for allo-APZ2-CVU trial (NCT06489028) in Venous Leg Ulcer
2027-04-15
in 9987 days 		WXI WUXI D3S-001 Trial Phase 2 — $4B Primary completion for D3S-001 trial (NCT05410145) in KRAS P.G12C
2027-04-15
in 9987 days 		NKTX Nkarta, Inc. NKX019 Trial Phase 2 — $1B Primary completion for NKX019 trial (NCT06557265) in Lupus Nephritis
2027-04-15
in 9987 days 		KYTX Kyverna Therapeutics, Inc. KYV-101 Trial Phase 3 — $1B Primary completion for KYV-101 trial (NCT06384976) in Multiple Sclerosis, Primary Progress
2027-04-15
in 9987 days 		LLY Eli Lilly and Company cetuximab Trial Phase 3 — $8B Primary completion for Cetuximab trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		KYTX Kyverna Therapeutics, Inc. Anti-CD20 mAB Trial Phase 2 — $5B Primary completion for Anti-CD20 mAB trial (NCT06384976) in Multiple Sclerosis, Primary Pr
2027-04-15
in 9987 days 		ABBV AbbVie Inc. ABBV-932 Trial Phase 2 — $8B Primary completion for ABBV-932 trial (NCT07220460) in Bipolar I or II Disorder
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Selinexor Trial Phase 3 — $8B Primary completion for Selinexor trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		HR Healthcare Realty Trust Inc MBK-01 Trial Phase 3 — $2B Primary completion for MBK-01 trial (NCT06687382) in Diverticulitis
2027-04-15
in 9987 days 		LLY Eli Lilly and Company LY3537982 Trial Phase 3 — $15B Primary completion for LY3537982 trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		CGTX COGNITION THERAPEUTICS INC CT1812 Trial Phase 2 — $9B Primary completion for CT1812 trial (NCT05531656) in Early Alzheimer's Disease
2027-04-15
in 9987 days 		LLY Eli Lilly and Company Pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		LLY Eli Lilly and Company pemetrexed Trial Phase 3 — $15B Primary completion for Pemetrexed trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		IPIX Innovation Pharmaceuticals Inc. S095018 Trial Phase 2 — $15B Primary completion for S095018 trial (NCT06162572) in Non-small Cell Lung Cancer (NSCLC)
2027-04-15
in 9987 days 		MIRM Mirum Pharmaceuticals, Inc. Volixibat Trial Phase 2 — $1B Primary completion for Volixibat trial (NCT05050136) in Primary Biliary Cholangitis
2027-04-15
in 9987 days 		RAPT RAPT Therapeutics, Inc. RPT904 Trial Phase 2 — $2B Primary completion for RPT904 trial (NCT07220811) in Ig-E Mediated Food Allergy
2027-04-15
in 9987 days 		LLY Eli Lilly and Company cisplatin Trial Phase 3 — $15B Primary completion for Cisplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Bortezomib Trial Phase 3 — $15B Primary completion for Bortezomib trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Dexamethasone Trial Phase 3 — $15B Primary completion for Dexamethasone trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Lenalidomide Trial Phase 2 — $15B Primary completion for Lenalidomide trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		LLY Eli Lilly and Company LY3016859 ISA Trial Phase 2 — $12B Primary completion for LY3016859 ISA trial (NCT05986292) in Osteoarthritis, Knee
2027-04-15
in 9987 days 		LLY Eli Lilly and Company carboplatin Trial Phase 3 — $18B Primary completion for Carboplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-16
in 9988 days 		SGIOY Shionogi S-531011 Trial Phase 2 — $1B Primary completion for S-531011 trial (NCT05101070) in Solid Tumors
2027-04-17
in 9989 days 		RHHBY Roche Holding AG Afimkibart Trial Phase 3 — $8B Primary completion for Afimkibart trial (NCT07137598) in Rheumatoid Arthritis
2027-04-20
in 9992 days 		PFE PFIZER Ritlecitinib higher dose Trial Phase 3 — $2B Primary completion for Ritlecitinib higher dose trial (NCT07029711) in Severe Alopecia Are
2027-04-20
in 9992 days 		AZNCF ASTRAZENECA PLC Camizestrant Trial Phase 3 — $8B Primary completion for Camizestrant trial (NCT05774951) in Breast Cancer, Early Breast Can
2027-04-20
in 9992 days 		AZNCF ASTRAZENECA PLC AZD5148 Trial Phase 2 — $2B Primary completion for AZD5148 trial (NCT07285213) in Clostridioides Difficile Infection
2027-04-21
in 9993 days 		SNY Sanofi Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate Trial Phase 2 — $1B Primary completion for Rotavirus vaccine trial (NCT06647407) in Meningococcal Immunization
2027-04-23
in 9995 days 		PFE PFIZER Ritlecitinib 100 mg Trial Phase 3 — $2B Primary completion for Ritlecitinib 100 mg trial (NCT06163326) in Vitiligo
2027-04-23
in 9995 days 		MRK MERCK Enfortumab Vedotin Trial Phase 3 — $3B Primary completion for Enfortumab Vedotin trial (NCT06305767) in Bladder Cancer
2027-04-23
in 9995 days 		GSK GSK plc RTS,S/AS01E vaccine Trial Phase 2 — $4B Primary completion for RTS,S/AS01E vaccine trial (NCT07036159) in Malaria
2027-04-23
in 9995 days 		MRK MERCK pembrolizumab Trial Phase 3 — $15B Primary completion for Pembrolizumab trial (NCT06305767) in Bladder Cancer
2027-04-23
in 9995 days 		MRK MERCK Intismeran autogene Trial Phase 3 — $4B Primary completion for Intismeran autogene trial (NCT06305767) in Bladder Cancer
2027-04-27
in 9999 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 — $80B Primary completion for Maridebart cafraglutide trial (NCT06987695) in Obesity Disease
2027-04-27
in 9999 days 		INCY Incyte Corporation INCB123667 Trial Phase 3 — $5B Primary completion for INCB123667 trial (NCT07023627) in Ovarian Cancer
2027-04-27
in 9999 days 		NVS Novartis AG GXV813 Trial Phase 2 — $12B Primary completion for GXV813 trial (NCT07467993) in Schizophrenia
2027-04-28
in 10000 days 		PFE PFIZER Tofacitinib Trial Phase 3 — $25B Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis
2027-04-28
in 10000 days 		SNY Sanofi Frexalimab Trial Phase 3 — $15B Primary completion for Frexalimab trial (NCT06111586) in Type 1 Diabetes Mellitus